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Cre   causes recombination, recombinase from phage PI 
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DTA   diphtheria toxin A 
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eGFP   enhanced green fluorescent protein 
ER   estrogen receptor 
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FACS   fluorescence assisted cell sorting 
FCS   fetal calf serum 
floxed   loxP sites flanked 
Flp   Flp recombinase from yeast 
FRT   Flp recognition target site 
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hER   human ER 
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1. INTRODUCTION 
 
The genomes of man (Lander et al., 2001), mouse (Waterston et al., 2002), 
Drosophila (Adams et al., 2000) and several other organisms have been completely 
sequenced in recent years. This progress tremendously facilitated the analysis of 
gene functions in vivo. Gene targeting by homologous recombination is a powerful 
technique to explore the function of genes in mice (for review, see e. g. Capecchi, 
1989). First described in 1987 by Thomas and Capecchi, it became a standard 
technique during the last years. The gene of interest is modified in embryonic stem 
cells (ES cells) by inserting a selection marker into the open reading frame (ORF) of 
the gene via homologous recombination (Thomas & Capecchi, 1987). The targeted 
pluripotent ES cells are kept in culture under non-differentiating conditions and are 
subsequently injected into donor blastocysts, which then become implanted into 
pseudo-pregnant foster mice. The resulting chimeric animal, consisting of wild type 
and gene targeted cells, is then backcrossed to wild type mice. If the chimeras 
contain germ cells originating from the gene targeted cells the genetic alteration can 
be transmitted through the germ line. This method allows the production of animals 
which carry the mutation of the gene in all cells of the body (for review, see e. g. 
Müller, 1999; Cohen-Tannoudji & Babinet, 1998). However, this technique has 
several inherent limitations such as embryonic lethality, compensatory effects by 
redundant genes, and side effects due to the leftover of the selection marker in the 
genome. These problems can be circumvented by more sophisticated methods of 
gene manipulation. The technology of conditional gene targeting allows for 
modification of genes in defined cell types, in spatially and temporally controlled 
manners (for review, see e. g. Rajewsky et al., 1996; Kühn & Schwenk, 1997).  Thus, 
the function of a given target gene can be studied in individual cell types at different 
developmental stages or after administration of specific inducers.  
  
1.1 Genetic engineering by sequence specific recombinases 
The field of gene targeting was revolutionized through the application of sequence 
specific recombinases as tools for genomic engineering. A number of bacterial and 
yeast recombinase enzymes are able to rearrange DNA at specific target sequences. 
This simple, but elegant reaction results in a precisely defined recombination event 
between two appropriate DNA target sequences. The hitherto available site specific 
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recombinase systems belong to two major groups: The resolvase/invertase family 
and the λ-integrase family. Members of the resolvase/invertase family comprise 
phiC31 integrase, β-recombinase, HK022 integrase or γδ-resolvase, which catalyse 
site specific DNA rearrangements via a conserved serine residue (for review, see e. 
g. Smith & Thorpe, 2002). The two most famous λ-integrase members are the Flp 
and Cre recombinases which use a tyrosine located in the C-terminal part of the 
respective enzyme as catalytic residue. Some of these recombinase systems have 
been found to be suited for genetic engineering in eukaryotic cells (for review, see e. 
g. Kilby et al., 1993).  
 
The complexity of these recombination systems considerably varies both in their 
requirement for cofactors or accessory molecules and in the size of the DNA target 
sites involved. However, λ-integrases such as Cre from bacteriophage PI and Flp 
from yeast catalyse recombinations between specific target sites of 34 bp without 
further need for cofactors. Since the only other requirement for the reaction is the 
expression of the appropriate recombinase enzyme, the concomitant presence of 
target sites and appropriate recombinase is sufficient for specific gene modification in 
many different species.  
 
The Cre/loxP system 
Gene modification employing site specific recombinases was pioneered using the 
Cre/loxP recombination technology (for review, see e. g. Rajewsky et al., 1996). The 
site specific DNA recombinase Cre (causes recombination) of the bacteriophage PI 
recognizes specifically 34 bp long sequences, called loxP (locus of X over in PI) 
(Sternberg & Hamilton, 1981; Sternberg et al., 1981). Cre excises DNA segments 
flanked by directly repeated loxP sites as a circular molecule, leaving a single loxP 
site in the genome (Sauer et al., 1988; Gu et al., 1993). When the loxP sites are 
arranged in opposite directions, Cre catalyses inversion of the intervening DNA 
(Kano et al., 1998; Lam & Rajewsky, 1998). Also, intramolecular recombinations can 
be performed, when the loxP sites are on different strands of DNA (van Deursen et 
al., 1995). Insertion of a DNA segment into a loxP site is also possible, though the 
excision reaction is favoured over the integration event (Fukushige & Sauer 1992). 
The usage of mutant loxP sites was shown to be useful in insertion strategies (Kolb, 
2001). Since Cre is one of the few recombinases which does not require cofactors or 
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accessory molecules in eukaryotic cells (Abremski & Hoess, 1984; Hoess et al., 
1990), Cre is the first choice for introducing gene modifications into the mouse 
genome. Modification of the ES cell genome by the Cre/loxP system is a two step 
process. The desired genetic modification including the loxP sites is introduced into 
the genome of ES cells via homologous recombination. Subsequently, the targeted 
allele is generated by site specific recombination of the loxP sites through expression 
of Cre by transient transfections of Cre-containing plasmids or other means. The 
removal of positive selection markers is one important application of Cre-mediated 
recombination in ES cells, since the presence of the selection marker gene can 
interfere with expression of the targeted gene or adjacent genes (Pham et al., 1996). 
Therefore, the selection marker is flanked by two loxP sites in the same orientation, 
which allows its deletion by Cre-mediated recombination leaving a single loxP site in 
the genome. Gene targeting provides the possibility to introduce deletions, point 
mutations, and insertions in ES cells. For instance, it has been used to delete a small 
region of the coding region of the Igα gene (Torres et al., 1996), to introduce specific 
point mutations into the cytoplasmic tail of the Igα gene (Kraus et al., 2001), and to 
insert rearranged variable regions into the Ig κ  locus (Pelanda et al., 1996) and Ig λ 
locus (Oberdoerffer et al., 2003). Large genomic deletions or inversions can be 
introduced into ES cells using the Cre/loxP technology. This requires two 
independent successive gene targetings, but due to the lower frequency of Cre-
mediated recombination at large distances between loxP sites, a positive selection 
strategy is recommended (Milstone et al., 1999). This approach has been used to 
generate deletions of several centimorgans (Ramirez-Solis et al., 1995). 
 
The Flp/FRT system 
Another system for the modification of genes was developed using the 
Saccharomyces cerevisiae derived 43 kDa Flp recombinase (for review, see e. g. 
Chen & Rice, 2003). The Flp recombinase is encoded by the 2µ circular plasmid of 
the budding yeast and mediates inversion between two 34 bp Flp recognition target 
(FRT) sites arranged in opposite direction, which are located on the same plasmid. 
Recombination between these FRT sites results in inversion of half of the 2µ plasmid 
with respect to the other and provides a mechanism for producing multiple plasmid 
copies from a single replication initiation by flipping the direction of the replication 
fork. Initial applications of the Flp/FRT recombination system at stably integrated 
chromosomal targets of eukaryotic cells displayed only low recombination 
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frequencies. Recently, the efficiency of this system has been considerably enhanced 
by specific modifications. The first improvement concerned the recognition sequence 
of Flp. The minimal 34 bp FRT site consists of two 13 bp inverted repeated binding 
sequences for Flp flanking the 8 bp asymmetric core region, which defines the 
directionality of the target site and which is the site of crossing over in the 
recombination event. In yeast, the 34 bp FRT recognition sequence is flanked by a 
third binding site for Flp in which a single nucleotide is exchanged resulting in a 48 bp 
wild type FRT site.  Two 48 bp FRT sites can be much more efficiently recombined 
than two minimal 34 bp recognition sequences. The second improvement was 
achieved through the generation of novel Flp recombinase variants with enhanced 
thermostability isolated by protein evolution. Three versions of Flp recombinase are 
available: Flp wild type (wt), Flp-L and Flpe. In Flp-L, a point mutation changes the 
encoded amino acid 70 from phenylalanine to leucine, which causes an enhanced 
thermostability of Flp-L at 37°C, but, coincidently, there is a loss of approximately 
80% activity in comparison to Flp-wt in vitro (Buchholz et al., 1996). Flpe harbours 
four amino acid exchanges (P2S, L33S, Y108N and S294P), which collectively 
improve the in vitro recombination activity 4-fold at 37°C and 10-fold at 40°C 
compared to Flp-wt (Buchholz et al., 1998). Mice expressing Flpe either in the germ 
line (Flp deleter) (Rodriguez et al., 2000) or constitutively in every organ (Flipper) 
(Farley et al., 2000) were shown to efficiently excise DNA segments between two 
head to tail arranged FRT sites. These mouse strains can be used to delete FRT site 
flanked positive selection marker required for gene targeting in vivo.        
 
The phiC31/att system  
At present, the Cre/loxP and the Flp/FRT recombination systems are most commonly 
used to manipulate the genomes of eukaryotes in heterologous environments in a 
site specific manner. However, additional recombinase systems have to be 
established in order to improve the technique of gene targeting for more 
sophisticated strategies. Recently, the Streptomyces phage derived phiC31 integrase 
has been described to mediate recombination efficiently in eukaryotic cells when a 
nuclear import signal (NLS) was located at the C-terminus of the enzyme (Andreas et 
al., 2002). The phiC31 system displayed deletion efficiencies of up to 50% at stably 
integrated chromosomal targets in a side by side comparison to the well defined 
Cre/loxP system. In contrast to the Cre and Flp systems, however, the phiC31 
integrase catalyses both integration and excision events irreversibly, since the sites 
generated by the recombination cannot serve as substrates for the enzyme (Belteki 
et al., 2003).  
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1.2 Conditional gene targeting 
Conditional gene targeting is defined as a gene modification, which is restricted to 
specific cell types and/or developmental stages of the mouse. The usage of the 
Cre/loxP system in conditional gene targeting requires both a mouse strain 
containing a loxP-flanked modification of the target gene and an additional mouse 
strain, which expresses the Cre recombinase in specific cell types. Crossing these 
two strains results in the generation of a conditional mouse mutant, which carries the 
mutation restricted to those cell types, in which the Cre recombinase is expressed. 
Such a conditional mouse mutant can be used to study the function of ubiquitously 
expressed genes in individual defined cell types and to circumvent lethality at early 
embryonic stages due to inactivation of a putative essential gene.  
 
Generation of loxP-flanked alleles 
For the removal of a gene segment by conditional gene targeting, the region of 
interest has to be flanked by loxP sites of the same orientation. This can be achieved 
by the ‘flox and delete’ approach, which requires construction of a gene targeting 
vector with three loxP sites pointing in the same orientation, two of which flank the 
positive selection marker and the third loxP site is placed within a homology arm 
(Fig.1). Transient expression of Cre in targeted ES cell clones results in two types of 
clones which have lost the selection marker. Recombination between the two 
external loxP sites leads to deletion of the selection marker and the gene segment 
whereas recombination between the loxP sites flanking the selection marker 
generates the loxP-flanked version of the gene (Fig.1). ES cell clones harbouring the 
loxP-flanked, or conditional, allele can be used to generate mice used in conditional 
gene targeting experiments. The positioning of the two remaining loxP sites within 
the locus of the target gene is critical for conditional gene targeting. They have to be 
placed in non-coding sequences around critical sequences such as exons so that 
gene expression is not disturbed by their presence. The desired deletion of the gene 
segment is achieved upon Cre-mediated recombination of the loxP-flanked region. 
This ‘flox and delete’ strategy was first demonstrated to function in an approach to 
conditionally inactivate the DNA polymerase β (Gu et al. 1994). The promoter and the 
first exon of the DNA polymerase β gene were flanked by loxP sites and the 
generated pol-β flox mouse strain was crossed with the lck-cre mouse strain (Orban 
et al., 1992), in which Cre is expressed only in thymocytes. The DNA polymerase 
was thus inactivated exclusively in T lineage cells circumventing the embryonic 
lethality caused by ablation of pol-β in the entire mouse by conventional knock-out.  
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Fig. 1 Generation of a loxP-flanked allele. 
The conditional targeting vector harbours a loxP (filled triangles) flanked neo cassette (neo) and a third loxP site which is 
inserted into intron 1. Homologous recombination (HR) in ES cells generates targeted clones which become subjected to 
transient Cre expression in a second transfection round. Two types of clones have lost the positive selection marker (neo) 
by this strategy. In one, recombination between the two external loxP sites leads to complete deletion of the selection 
marker and the gene segment, whereas the other recombination between the loxP sites flanking the selection marker 
generates the loxP-flanked allele (floxed allele).  
Cre transgenic mice 
At present, a large number of Cre transgenic mouse strains are available, enabling 
researchers to restrict conditional genetic modifications to B cells (Rickert et al., 
1997), to T cells (Lee et al., 2001), to different areas of the brain (Tsien et al., 1996; 
Casanova et al., 2001) and to various other tissues of the mouse (Tonks et al., 2003; 
Wen et al., 2003; Barlow et al., 1997; more Cre-transgenic mouse strains in Genesis 
2000, 26, 99-166 or under http://www.mshri.on.ca/nagy/cre-pub.html). Such Cre 
expressing mouse strains can be generated either by using conventional random 
transgenesis, or by targeted insertion into a gene (knock-in), or by using a bacterial 
artificial chromosome (BAC) strategy. In any case, the expression pattern of the 
promoter used to express Cre determines onset and cell type specificity of the Cre-
mediated gene modification. The technique of conventional random transgenesis has 
several disadvantages: the limited understanding of promoter regions used to 
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express the transgene, the potential unpredictable effects of enhancer/silencer 
elements present at the integration site on transgene expression and the necessity to 
analyze many different founder lines which may contain multiple copies, tandem 
repeats, broken and differently integrated transgenic constructs. The method of 
targeted insertion of Cre into a gene can be applied, when the inactivation of one 
allele of the endogenous gene can be tolerated. This has been shown to work by 
Rickert and coworkers, who generated a knock-in mouse strain by targeted insertion 
of the Cre gene into the second exon of the CD19 locus (Rickert et al., 1995). In this 
CD19-cre mouse strain, the Cre recombinase is exclusively expressed in B 
lymphocytes and mediates 75-80% excision of loxP-flanked targets in B cells in the 
bone marrow, whereas 90-95% deletion is observed in splenic B cells due to 
continuous expression of Cre (Rickert et al., 1997). Another technique, which is 
currently used to generate Cre expressing mouse strains, is the insertion of the Cre 
gene into bacterial artifical chromosomes (BAC) and the subsequent generation of 
BAC transgenic mice. BACs carry large genomic fragments from mouse or human of 
up to 400 kb and can be obtained commercially. The Cre gene can be introduced into 
defined genes encoded by the BAC via homologous recombination in bacteria (Testa 
et al., 2003). The large size of the BAC renders it likely that most if not all of the 
transcriptional control elements of the gene, into which Cre has been introduced, are 
present. This should result in a Cre expression pattern closely related to the 
expression of the endogenous gene. This strategy was successfully used by M. 
Alimzhanov (unpublished data) to express Cre solely in mature B cells by inserting 
the Cre gene in the CD21 gene of a 250 kb BAC.  
 
Indicators for Cre activity 
The success of Cre-mediated conditional gene targeting critically depends on 
stringent regulation of Cre expressing mouse strains, which have to be intercrossed 
with mice containing loxP-flanked target genes. If expressed from a transgenic 
construct, Cre-mediated deletion may occur in a mosaic or leaky fashion rendering 
excision of the loxP-flanked target alleles incomplete or unspecific, respectively. A 
general complication of Cre transgenes is due to the irreversibility of Cre-mediated 
deletion. Any transient expression of Cre during mouse development caused by the
control elements of the gene into which Cre has been inserted, or alternatively 
caused by artefacts of transgenesis, will lead to deletion of loxP-flanked targets in the 
cells expressing Cre. These cells and all cells arising from them through division will 
1. INTRODUCTION                                                                                                    8                    
A B
 
 
	 
		
	 
		

	

	 



	 



   
 
 
 
 
 
c
C
t
t
s
g
i
l
H
c
e
e
e
c
A
r
i
 Fig. 2 Indicator constructs for Cre activity. 
(A) Expression of the indicator gene is prevented by a transcriptional stop sequence (STOP) which is flanked by loxP sites
(closed triangles). Cre-mediated excision of the STOP results in expression of the indicator gene which can be monitored,
for example, by enzymatic reactions. 
(B) Shut down/activation indicator construct. The promoter expresses indicator 1, whereas expression of indicator 2 is
interrupted by the presence of the indicator 1 gene. Cre-mediated excision of the indicator 1 gene results in shut down of
indicator 1 expression and activation of indicator 2 expression.   ontain the modified alleles, regardless whether Cre expression is continued or not. 
re expressing mouse strains can be characterized with the help of reporter mice 
hat permit in vivo monitoring of Cre-mediated recombination events in diverse 
issues and at different developmental stages (Fig. 2A). For instance, a reporter 
train carrying a loxP-flanked stop sequence preceding the β-galactosidase (β-Gal) 
ene driven by the chicken β-actin promoter has been used to score excision events 
n mice (Tsien et al., 1996). Cre-mediated excision of the loxP-flanked stop sequence 
eads to β-Gal expression, which can be monitored by enzymatic reactions for β-Gal. 
owever, a limitation of this Cre reporter mouse strain became apparent, when 
haracterizing the expression pattern of the β-galactosidase gene upon Cre-mediated 
xcision of the loxP-flanked stop sequence in all tissues. The indicator gene was 
xpressed in a mosaic fashion in some organs such as brain. This mosaic 
xpression pattern of the β-galactosidase gene may result from artefacts of the 
onventional random transgenesis, which was used to generate this mouse strain. 
rtefacts of transgenesis can be caused by integration of multiple copies, tandem 
epeats, breakage of the indicator constructs, unknown multiple integration sites, 
nactivation of the indicator gene by methylation, influences of enhancers/silencers 
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present at the integration sites and insufficiently characterized promoter fragments 
used to express the transgene. 
 
A more convenient strategy for the generation of a Cre reporter strain would be to 
target a single reporter construct into a gene which is expressed ubiquitously 
throughout all developmental stages of the mouse. An excellent candidate for an 
appropriate locus is the ROSA26 locus, which was originally identified by gene trap 
(Zambrowicz et al., 1997). In the initially reported mouse line, retroviral sequences 
and a β-Gal neomycin resistance fusion gene (β-Geo) were integrated into the locus 
ROSA26. The wild type ROSA26 locus expresses two transcripts with no significant 
open reading frames (ORF) and a third in antisense orientation, which putatively 
encodes a protein, and which is not affected by the β-Geo insertion. Expression of 
the β-Geo gene is initiated from exon 1 of the ROSA26 allele and is ubiquitous during 
embryonic development and also in adult tissues. Mao and colleagues (1999) 
subsequently engineered the gene trapped proviral ROSA26 locus in ES cells by 
introducing a three loxP sites containing cassette, in which two loxP sites flanked the 
selection marker and one external loxP site flanking a transcriptional stop sequence 
to interrupt the expression of the β-Geo gene. This mouse strain expressed β-Gal 
only after Cre-mediated excision of the loxP-flanked region. This was verified by 
breeding the ROSA26 reporter strain to a Cre transgenic mouse strain which 
expresses Cre at early embryonic stages (Schwenk et al., 1995), i.e. Cre mediated 
excision was disseminated to all tissues of the adult mouse. Enzymatic reactions for 
β-Gal with the substrates X-Gal and fluoresceine-di-β-D-galactopyranoside (FDG) 
were carried out to detect expression of β-Gal at the single cell level. The expression 
of β-Gal upon Cre-mediated excision of the three loxP-flanked cassette in this mouse 
strain was shown to be ubiquitous (Wunderlich & Rajewsky, unpublished results).  
Later on, however, several limitations of this reporter strain became apparent. For 
instance, recombination between two adjacent loxP sites by partial Cre-mediated 
deletion results in retention of either the selection marker or the stop fragment in the 
locus, which therefore still lacks β-Geo gene expression despite Cre-mediated 
recombination. The excision event remains undetectable by X-Gal staining. In 
addition, loxP-flanked targets, which are integrated into the ROSA26 locus, were 
shown to be excised with low efficiency by inducible Cre constructs for reasons not 
yet understood (Voojis et al., 2001; Seibler et al., 2003). Therefore, mouse strains 
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carrying a reporter construct for Cre in the ROSA26 locus are not suited for the 
characterization of inducible Cre mouse strains. Moreover, until recently, enzymatic 
reactions had to be performed to detect β−galactosidase expression in Cre reporter 
mouse strains. Such enzymatic reactions are time consuming and difficult to perform 
in some organs. 
  
A more sophisticated reporter gene, which can be detected without any enzymatic 
reaction just by its presence, is the eGFP gene (enhanced Green Fluorescent 
Protein). The eGFP protein, originally derived from the jellyfish Aequorea victoria, can 
be visualized by its inherent fluorescence, even in living cells (for review, see e. g. 
Cubitt et al., 1995). EGFP owes its visible absorbance and fluorescence to a p-
hydroxybenzylideneimidazolinone chromophore formed by cyclisation of Thr65, 
Tyr66 and Gly67 and 1, 2-dehydrogenation of the tyrosine. Site directed mutagenesis 
of the amino acids forming the chromophore leads to versions of the fluorescent 
protein whose emission spectrum are shifted to yellow or blue such as eYFP (Yellow) 
and eCFP (Cyan). The only limitation of using these fluorescent proteins as reporter 
genes is the large amount of molecules (8x105), which have to be expressed in a 
single cell to detect fluorescence by fluorescence microscopy (Rizzuto et al., 1995). 
Therefore, strong promoters have to be used in order to generate a Cre reporter 
strain which expresses eGFP after Cre-mediated recombination. Another possibility 
is to use a loxP-flanked indicator 1 gene, which serves in a dual function to prevent 
expression of the indicator 2 gene before Cre-mediated deletion and, in addition, to 
control for expression from the reporter construct. In this case, Cre-mediated 
recombination leads to inactivation of indicator 1 gene and to expression of the 
indicator 2 gene. (Fig. 2B). This shut down/activation theme has been employed in 
the generation of the Z/EG and Z/AP Cre reporter strains, which switch their indicator 
genes either from lacZ to eGFP (Novak et al., 2000) or from lacZ to alkaline 
phosphatase (Lobe et al., 1999) upon Cre recombinase activity.  
 
1.3 Inducible gene targeting 
One step forward in techniques of conditional gene targeting is the temporally 
controlled expression of Cre, by which the onset of the conditional genetic alteration 
can be chosen at specific developmental stages (for review, see e. g. Lewandowski, 
2001). A pioneering breakthrough in this field was the generation of the Mx-Cre 
mouse strain (Kühn et al., 1995). Here, the Cre gene was placed under the control of 
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the interferon α/β inducible promotor of the Mx-1 gene. Application of interferon 
α/β leads to Cre expression and, thus, to highly efficient deletion of the loxP-flanked 
target genes such as the DNA pol-β gene segment (Gu et al., 1994) in a wide variety 
of tissues in mice. Deletion of loxP-flanked sequences using the Mx-Cre system is 
not restricted to lymphocytes only, since many cell types in the mouse are responsive 
to interferon. At present, Cre activity is tried to be more tightly regulated at both the 
transcriptional and the posttranslational level by inducible systems.  
 
1.3.1 Transcriptional control of Cre activity 
Cell type specific transcriptional control of Cre can be achieved by systems, in which 
the activity of almost silent minimal promoters can be enhanced manifold through 
binding of certain inducer proteins. These inducer proteins are in turn regulated by 
small molecules such as tetracycline (Gossen & Bujard, 1992), RU486 (Wang et al., 
1997a) or ecdysone (No et al., 1996). By placing the Cre expression under the 
control of a minimal promoter and directing the expression of the inducer protein 
(transactivator) to certain cell types, transcription of Cre in mice can be activated by 
administration of the above mentioned small molecules. A main disadvantage of 
these regulatory systems is the separate insertion of the gene encoding the 
transactivator and that of the controllable Cre into the genome leading to large 
numbers of transgenic mice, which have to be intercrossed and tested for the desired 
combination of the transgenes.      
 
The GLVP system 
In the GLVP system, the inducer protein consists of the Gal4 DNA binding motif, the 
Ligand binding domain (LBD) of the progesterone receptor and the VP16 
transactivation domain. This chimeric transactivating unit specifically binds to the 17-
mer Gal4 target sequence fused to a minimal promoter upon administration of RU486 
and activates expression of genes of interest placed under control of the 17-mer Gal4 
target sequence/minimal promoter hybrid (Wang et al., 1997a). Thereby, DNA 
specific binding to the 17-mer sequences is mediated by the GAL4 DNA binding 
motif, which in turn enables the transactivation domain of VP16 (Triezenberg et al., 
1988) to activate transcription from the minimal promoter only in the presence of 
RU486, since the LBD of the progesterone receptor regulates the temporal inducer 
dependent activity of the synthetic molecule. Tight regulation of gene expression by 
this system has been reported in tissue cultures (Burcin et al., 1998), but rare and 
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ineffective in vivo applications minimize the value for the temporal control of the Cre 
recombinase (Pierson et al., 2000; Chaisson et al., 2002). The main obstacle of this 
system seems to be the inefficient activation of the transactivator molecule by the 
steroid compound, since stably expressing cell types in mice mediate only a low 
extent of transcription upon induction from the minimal promoter.    
 
The ecdysone inducible system 
In an alternative approach for the inducible regulation of Cre, Cre could be placed 
under control of a system involving the insect molting hormone ecdysone as an 
inducer. The effect of ecdysone is mediated through the functional ecdysone 
receptor, which is a heterodimer of the ecdysone receptor and the gene product of 
the ultraspiracle gene. The functional ecdysone receptor binds to specific promoter 
elements of the target gene in order to activate transcription. Mutagenesis of the 
transactivation domain and the DNA binding domain of the natural occurring 
receptors resulted in a tightly controllable system in mice (No et al., 1996). However, 
the binary character of the heterodimeric receptor complicates the usage in vivo, 
since both partners must be present at equal amounts. Otherwise, homodimeric 
complexes are formed, which cannot activate the promoter and may function in a 
competitive way. Furthermore, the inducer ecdysone or its synthetic counterpart 
muristerone have to be available at non-physiological micromolar concentrations to 
sufficiently activate the ecdysone heterodimeric receptor complex (Saez et al., 2000). 
 
The tet-system  
Tetracycline controlled expression systems are widely used to regulate genes in cell 
lines (Resnitzky et al., 1994), plants (Weinmann et al., 1994), yeast (Nagahashi et 
al., 1997), Drosophila (Bello et al., 1998), and mice (Hasan et al., 2001; Schönig et 
al., 2003). Fig. 3 schematically outlines the function of the original tet-off system and 
the modified tet-on system. The tet-off system uses a synthetic transcription factor 
tTA (tetracycline controlled transcriptional activator), which is a fusion between a 
bacterial tet-repressor (tetR) and the transcriptional activating domain of VP16. tTA 
activates a minimal promoter which is fused downstream to an array of tet-operator 
(tetO) sequences (Gossen & Bujard, 1992), the cognate binding sites of tetR and, 
thus, of tTA. In the tet-off system, transcription is abrogated by administration of 
doxycycline, which upon binding to the tTA prevents binding of tTA to the tet-
responsive promoter. Despite of its extensive use, however, the tet-off system has 
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Fig. 3 Transcriptional regulation of gene expression by the tet-systems. 
The tet-off system. The promoter (P) drives the expression of the tet-transactivator (tTA), which binds in the absence of 
doxycycline (dox) to the tet-responsive promoter (tetO7) and activates expression of the gene of interest (X). Administration of 
dox causes dissocation of tTA from tetO7 and transcription is terminated. 
The tet-on system. Only in the presence of dox, the reverse tet-transactivator (rtTA) can bind to its promoter and activate 
expression of the gene of interest.   
 
some disadvantages for applications in mice. Doxycycline has to be continuously fed 
to prevent transcription of the target gene, until expression of the target gene can be 
initiated by removal of doxycyline (Kistner et al., 1996). Such long periods of 
doxycycline application results in storage of the antibiotic into cartilage and bones of 
mice (Bocker et al., 1984; Sande & Mandell, 1990). This may result in the slow 
release of doxycycline from its storage places after discontinuation of doxycycline 
administration and therefore may interfere with activation of the target genes by tTA. 
In the complementary tet-on system, transcription of the target gene will only be 
activated in the presence of doxycycline. This system is based on rtTA (reverse 
tetracycline controlled activator), which contains mutations in the tetR part resulting in 
requirement of doxycycline binding in order to bind to tetO (Gossen et al., 1995).  
However, the affinity of rtTA to doxycycline is three magnitudes lower than that of the 
tTA and, therefore, rtTA requires more inducer to become activated (Baron et al., 
1997). A recent report addressing this problem generated new rtTA mutants termed 
rtTA-M2 and rtTA-S2, which could already be activated by the low dose of 2 ng/ml 
doxycycline in tissue culture resulting in a 50-fold improved affinity of these new 
mutants to doxycycline (Urlinger et al., 2000). In both the tet-off and tet-on system, 
the genomic integration site of the tetO promoter driving the transgene of interest is 
critical. When endogenous enhancers are located in close environment to the tetO 
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promoter, the minimal promoter though silent in principle is activated, thus resulting 
in leaky expression of the transgene. A recently described integration site for the tetO 
promoter offers an alternative approach. A bidirectional tetO promoter (Baron et al., 
1995) in transgenic LC-1 mice (Schönig et al., 2003) drives the expression of Cre 
and luciferase, respectively, and can be tightly regulated by transactivating units of 
both the tet-on and tet-off system. Hitherto, a general disadvantage of both tet-
systems is their binary character with the consequence of large breeding effort to 
obtain the desired combination of the transgenes, which is time consuming and 
expensive. Recently, however, this problem was overcome by Utomo et al. (1999) 
who placed both the rtTA with its own promoter and the tetO driving expression of 
Cre on the same fragment of DNA.  
    
The lac system 
The lac system from E.coli can also be applied to regulate gene expression in an 
inducible manner in mice. The principle of the lac system constitutes of a tetrameric 
lac repressor complex, which binds to operator sequences in the lac promoter thus 
blocking the docking sites for the RNA polymerase in the absence of inducer. 
Administration of allolactose or isopropyl-beta-D-thiogalactopyranoside (IPTG) 
induces conformational changes of the lac repressor proteins, which subsequently 
dissociate from the promoter thus allowing for initiation of transcription of the desired 
gene. However, also the lac system has its problems. The major limitation is the 
positioning of the operator sequences into the eukaryotic promoter which should be 
regulated without disturbing its activity. Another limitation is the occurrence of CpG 
islands in the lac repressor gene which causes its silencing in mice. However, this 
limitation was recently overcome by eliminating the naturally occurring CpG islands 
and the mutation of cryptic splice sites in the lac repressor gene (Cronin et al., 2001). 
This modified lac gene was indeed suited for heterologous expression in mammals.      
 
1.3.2 Posttranslational control of Cre activity 
Steroid hormones such as estrogen, progesterone, androgen and glucocorticoid 
regulate gene expression directly through classical intracellular steroid hormone 
receptors and possibly indirectly through novel unconventional membrane bound 
receptors belonging to the G protein coupled receptor superfamily (for review, see e. 
g. Wehling, 1997; Picard, 1998). The intracellular steroid hormone receptors possess 
a well characterized ligand binding domain (LBD), which can be used for 
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posttranslational control of Cre activity. A fusion protein between Cre and the LBD 
can be expressed from any given cell type specific promoter. In the absence of 
steroid hormone, the LBDs are bound by heat shock proteins, which inactivate 
recombinase activity presumably by sterical hindrance. Only after addition of the 
steroid hormones as inducers, the fusion protein becomes activated and can mediate 
recombination of loxP sites flanked sequences in the nucleus (Fig. 4). This 
posttranslational inducible system was extensively used in exploring the regulation of 
transcription factors (Littlewood et al., 1995; Jackson et al., 1993).  
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Fig. 4 Posttranslational control of Cre activity. 
(A) Cre is fused to the ligand binding domain (LBD) of a steroid hormone receptor and kept as an inactive complex in the 
cytoplasm by bound heat shock proteins (hsp90). 
(B) The complex dissociates upon ligand binding and CreLBD translocates to the nucleus and mediates recombination. 
The family of intracellular steroid receptors share similarities in their structure, 
function and signal transduction capacity (reviewed in Beato et al., 1995). After 
binding the hormone, the receptors translocate from the cytoplasm to nucleus and 
activate or repress transcription of their target genes, which is mediated through 
binding to special palindromic HRE sequences (hormone responsive element) in the 
1. INTRODUCTION                                                                                                    16                  
promoter. Fig. 5 shows the functional domains of steroid hormone receptors: the non-
conserved transactivation domain (A/B), the DNA binding domain (C), the hinge 
domain (D) and the ligand binding domain (E/F) (reviewed in Evans, 1988).  
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In the absence of hormone, complexes of heatshock proteins retain the receptors in  
Fig. 5 Modular structure of steroid hormone receptors. 
All steroid hormone receptors consist of a non-conserved transactivation domain (A/B), a DNA binding domain (C), a hinge 
domain (D) and a ligand binding domain (E/F). Numbers indicate the position of amino acids in the human progesterone 
receptor (PR) and the human estrogen receptor (ER), respectively. Ligand binding domains (LBD) which are marked were 
used by the cited groups to inducible regulate fusion proteins at the posttranslational level.  
the cytoplasm (Passinen et al., 1999). Binding of hsp90 and other factors like the 
immunophilins hsp56 and hsp70 to the LBD maintain the receptors in an inactive but 
ligand-friendly conformation. Hormone binding causes dissociation of this large 
multiprotein complex and subsequent import of the receptors into the nucleus. The 
nuclear import is achieved by specific amino acid sequences termed NLS (nuclear 
localisation signal) which are masked by the binding of the hsp chaperones in the 
cytoplasm (Guiochon-Mantel et al., 1989; Tyagi et al., 1998). Once in the nucleus, 
the steroid receptors dimerize, bind as homodimers to specific HRE in the promoter 
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of their target genes and change thereby expression levels of the latter by either 
activating or repressing transcription. 
 
The LBDs of steroid hormone receptors contain (i) the binding pocket for the 
hormone, (ii) the internal NLS, (iii) the hsp90-binding sites and, (iv) the domains 
necessary for dimerization of the monomeric receptors (for review, see e. g. Moras & 
Gronemeyer, 1998). The LBDs of all steroid hormone receptors exhibit a common 
structural feature. They consist of 12 α-helices which form an antiparallel sandwich 
(Williams & Sigler, 1998; Brzozowski et al., 1997). Ligand binding causes sequential 
conformational changes of helices H11, H10, H3 and H12, whereas H12 functions as 
a lid of the binding core. These conformational changes lead to dissocation of hsp 
from the receptor and to its translocation into the nucleus (Allan et al., 1992a).  
 
Until recently, posttranslationally inducible recombinase systems used wild type 
LBDs of steroid hormone receptors fused to Flp or Cre (Logie & Stewart, 1995; 
Metzger et al., 1995). However, these chimeric recombinases are activated by 
endogenous steroids of the LBD and are therefore of limited use for applications in 
mice. Consequently, mutations were introduced into the LBDs of chimeric Cre 
recombinases, that abolish the activation by natural ligands while retaining the ability 
to be activated by synthetic hormone antagonists (Fig. 5). Mutated LBDs of the 
glucocorticoid receptor (Brocard et al., 1998), the androgen receptor (Kaczmarczyk & 
Green, 2003), the progesterone receptor (Kellendonk et al., 1999) and the estrogen 
receptor (Schwenk et al., 1998) have been used to regulate Cre activity at the 
posttranslational level. Fig. 4 shows a general scheme for the regulation of Cre 
through LBDs. The fusion protein between Cre and the LBD is kept as an inactive 
complex in the cytoplasm by the bound hsp90 proteins. Ligand binding causes 
dissociation of this complex and the CreLBD fusion protein enters the nucleus and 
mediates recombination of loxP-flanked targets (for review, see e. g. Picard, 1994). 
Several limitations of this system became evident in initial experiments, and the 
system has to be further optimized to control Cre activity. For instance, there is still 
significant background recombination in the absence of inducer. Several reasons 
may contribute to the background activity of the fusion protein. First, the addition of 
strong NLS domains as that from the SV40 large T antigen to the fusion protein 
results in a higher background activity. Second, the hinge domain between Cre and 
the LBD could be cleaved by intracellular proteases resulting in uncontrolled Cre 
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recombinase activity. Third, unexpected processing of CreLBD mRNAs, as e.g. by 
cryptic splicing, could also result in background activity.  
 
An additional limitation of the system is the lower deletion efficiencies obtained with 
CreLBD fusion proteins in comparison to Cre (Kellendonk et al., 1996, Zhang et al., 
1996). This results in only partial deletion of loxP-flanked targets after ligand 
administration in most of the available CreLBD transgenic mouse strains (Schwenk et 
al., 1998). The lower efficiencies can be explained by the insufficient availability of 
the inducer, i.e. the inducer concentration is not sufficient in certain organs to activate 
CreLBD. Alternatively, Cre-mediated catalysis could be impaired by sterical 
hindrance of the fused LBD. In addition, recombinase activity could be impeded by 
unfavourable chromatin configurations of the loxP-flanked DNA segment at the time 
period of nuclear localisation of the fusion protein. 
 
Fusions between Cre and the LBD of the estrogen receptor 
In order to generate a posttranslational system of Cre fused to the LBD of the 
estrogen receptor (ER), single amino acid substitutions have to be introduced in the 
ER-LBD to prevent its activation by the endogenous hormone 17 β−estradiol (E2) but, 
coincidently, to maintain its binding capacities for synthetic steroids. In 1989, a 
natural ER mutant was isolated from chicken, which exhibited diminished affinity for 
E2 due to an amino acid exchange from glycine to valine at position 400 (G400V) 
(Tora et al., 1989). Another ER mutant was described for the murine ER (mER) with 
a glycine for arginine substitution at position 525 (G525R), which displayed only 
1/1000 of the affinity for E2 of the WT-ER (Danielian et al., 1993). However, this 
G525R mutant could be still activated by the antiestrogen 4-hydroxy-tamoxifen (4-
OHT) at the physiological concentration of 200 nM as well as by the ER-antagonists 
raloxifene and ICI 182,780 (Van Den Bemd et al., 1999). These ER-antagonists are 
known to bind at the same binding pocket of the ER as E2, but they induce different 
conformational changes in the LBD (Brzozowski et al., 1997). However, these 
conformational changes still induce translocation of the ER to the nucleus, but once 
inside the nucleus, the antagonist-ER complex induces a completely different 
activation and suppression pattern of genes in comparison to the E2-ER complex. 
Besides the LBD of the mutant mER, LBDs of the mutant human ER (hER) have also 
been used in posttranslational inducible systems. In particular, the mutant human ER 
(G521R) (Feil et al., 1996), harbouring a homologous mutation to the mER (G525R), 
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was fused to Cre and expressed under a ubiquitously active promoter in transgenic 
mice. This mouse strain was shown to regulate Cre activity in every organ, except the 
thymus, in a tamoxifen dependent manner (Brocard et al., 1997; Metzger & 
Chambon, 2001). Tamoxifen injections led to heterogenous excision efficiencies of 
loxP-flanked target genes with highest efficiencies of approximately 40-50% in tail, 
skin, kidney and spleen. Schwenk et al. (1998) have described a similar CreER 
construct expressed exclusively in B cells since the transgene was controlled by the 
heavy chain enhancer combined with the SV40 minimal promoter. Intra-peritoneal 
injections of 8 mg 4-OHT in mice carrying both the B lymphocyte restricted CreER 
allele and the loxP-flanked region of the DNA pol-β gene caused up to 65% excision 
of the loxP-flanked gene segment solely in B cells.  
The homologous mutations G521R (hER) and G525R (mER) possess not only 
reduced affinity to E2, but also to 4-OHT. In consequence, nearly lethal doses of 4-
OHT have to be injected to achieve activation of the CreER fusion protein (Danielian 
et al., 1998).  
Feil et al. (1997) significantly improved the affinity of the hER LBD to synthetic 
ligands. They developed two different mutant hER LBDs, termed ERT1 and ERT2, 
each containing three different amino acid substitutions, which result in 
unresponsiveness to E2 but in a 10-fold higher affinity to synthetic ligands as 
compared to the former single mutants of the ER-LBD (mERG525R and hERG521R, 
respectively). A fusion protein between Cre and the triple mutant ERT1 with the 
mutations G400V, L539A and L540A is activated at nanomolar concentrations of ICI 
182,780 in tissue culture. Also, a chimeric molecule between Cre and the triple 
mutant ERT2 (G400V, M543A, L544A) can be activated by 10 nM 4-OHT. The 
activation characteristics of the CreERT2 in vivo were confirmed by recent 
publications. A transgenic mouse strain with CreERT2 expression restricted to 
keratinocytes (K14 CreERT2) requires 10-times lower doses of tamoxifen in order to 
activate Cre activity in comparison with a mouse strain, which expresses the CreERT 
(G525R) single mutant controlled by the same promoter (Indra et al., 1999; 
Vasioukhin et al., 1999). During the last years, numerous CreERT2 transgenic 
mouse strains were generated, which express the fusion protein ubiquitously (Seibler 
et al., 2003), or restricted to muscle (Kühbandner et al., 2002), to brain (Casanova et 
al., 2002), and to several other tissues (Forde et al., 2002; Leone et al., 2003). In 
most of these strains, highly efficient deletion of loxP-flanked targets can be induced 
by oral application or i. p. injection of tamoxifen in the range of 2-5 mg daily for 5 
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days. The reduced doses of tamoxifen, which have to be injected and subsequently 
block endogenous estrogen receptor mediated signalling, do not interfere with most 
experimental applications. Coincidently, the background activity of the CreERT2 
fusion protein in the absence of inducer is ranging at tolerable levels between 3-10% 
in mice. A disadvantage of tamoxifen inducible systems is that they cannot be 
applied in the brain, since the hormone does not pass the blood brain barrier at 
sufficient concentrations to activate CreERT2 fusion proteins. Seibler et al. (2003) 
generated a ubiquitously expressed CreERT2 mouse strain by knock-in into the 
ROSA26 locus, which yielded almost complete deletion of a loxP-flanked gene 
segment of the ect2 gene in all tissues upon tamoxifen injection, except in the brain, 
though the CreERT2 protein was expressed in the brain as revealed by Western 
blotting.  
 
Fusions between Cre and the LBD of the progesterone receptor 
Posttranslational control of Cre activity has also been achieved by chimeric 
molecules between Cre and the LBD of the progesterone receptor (PR), which are 
expressed under a constitutive active cell type specific promoter. Mutants of the LBD 
of the CrePR fusion protein result in a CrePR that is unresponsive to progesterone, 
but can still be activated by synthetic derivatives of progesterone. These mutations 
are located at the C-terminus of the PR, which is known to undergo conformational 
changes upon binding of progesterone (Allan et al., 1992b). Indeed, C-terminal 
truncations of the PR-LBD are sufficient to mediate unresponsiveness to 
progesterone, but not to the antiprogesterone RU486 (Vegeto et al., 1992; Xu et al., 
1996). Two carboxy-terminal truncations are presently in usage, a 42 amino acid 
truncation (PR891) and a 19 amino acid truncation (PR914). The latter keeps a 
higher affinity to RU486 and is activated at nanomolar concentrations of RU486 
(Wang et al., 1997b). Kellendonk et al. (1996) demonstrated for the first time that Cre 
activity of CrePR fusion proteins is dependent on the presence of RU486 in tissue 
culture. These authors reported that expansion of the hinge domain between Cre and 
PR enhanced the maximal activity of CrePR in the presence of RU486. However, 
expansion of the hinge domain is also accompanied with a progressive increase of 
background activity.  A fusion between Cre and the PR-LBD ranging from amino acid 
641-891 (CrePR1) displayed the best properties in their assay and had therefore 
been tested in mice by either targeted or random transgenesis. Usage of cell type 
specific promoters restricted CrePR1 expression to different areas of the brain 
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(Kellendonk et al., 1999; Kitayama et al., 2001; Tsujita et al., 1999), to the heart 
(Minamino et al., 2001), and to the skin (Zhou et al., 2002; Cao et al., 2001).  A 
common feature of all these CrePR1 mouse strains was the appearance of the 
background activity with prolonged age of the mice, whereas RU486 administration 
led to high extents of inducible Cre mediated recombination. 
 
1.5 Objectives 
The aim of this study is to generate novel mouse strains allowing the inducible 
expression of Cre and, therefore, the inducible modification of genes by the Cre/loxP-
technology. I chose two methods to achieve this aim, an inducible CrePR system and 
a tet-on system for control of Cre-expression. These systems were first tested in vitro 
and the most promising constructs were subsequently transmitted into the mouse 
germ line to investigate their performance in vivo. As a first step, a reporter construct 
allowing for quantitative monitoring of Cre activity was introduced into the ROSA26 
locus by homologous recombination in HM-1 ES cells. This Cre reporter consists of a 
loxP-flanked DsRed gene followed downstream by an eGFP gene. Cre-mediated 
excision of DsRed turns on the eGFP gene which can be visualized by a change of 
fluorescence from red to green. Second, various inducible Cre constructs were tested 
in these Cre reporter containing ES cells. In order to avoid differences caused by 
genomic integration site and variations in copy numbers of the transgene, these 
constructs were targeted by knock-in into two defined genomic loci: the HPRT locus 
and the ROSA26 locus. ES cell clones displaying favourable characteristics, i.e. high 
inducibility of Cre paired with low background activity can be immediately injected 
into blastocysts for the generation of chimeras. The in vivo characteristics of the 
respective inducible Cre system can immediately be tested in vivo in chimeras, since 
ES cell derived cells of the chimeras contain both the Cre reporter and the inducible 
Cre construct. This test can yield quantitative results due to the nature of the Cre 
reporter, which allows to distinguish between ES cell derived tissues in which Cre-
mediated recombination occurs (eGFP positive), and those in which no 
recombination occurred (DsRed positive). This experimental set-up allows for the 
rapid screening of inducible Cre systems in ES cells and in chimeras and 
subsequently for the immediate generation of mouse strains from constructs 
displaying favourable characteristics. In addition, I generated a posttranslational 
inducible CrePR system restricted to B cells by targeted insertion into the CD19 
locus.  
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2. MATERIALS AND METHODS 
 
2.1 Chemicals and antibodies 
All chemicals were obtained from Sigma (Steinheim, Germany) or Merck (Darmstadt, 
Germany), if not otherwise stated. Enzymes were delivered from the following 
companies: Boehringer (Mannheim, Germany), Gibco (Karlsruhe, Germany), NEB 
(Schwalbach, Germany), Stratagene (Heidelberg, Germany), and Takara (over 
Boehringer, Ingelheim, Germany). Size markers for agarose gel electrophoresis were 
provided from Gibco (1 kb marker, λ-HindIII Marker, 100 bp ladder). 
 
Table1. List of antibodies
Specificity Clone Reference Supplier 
B220/CD45R RA3-6B2 Coffman et al., 1982 Home made/ 
Pharmingen 
CD4 GK.1.5/4 Dialynas et al., 1983 Pharmingen 
CD5 53-7.3 Ledbetter & Herzenberg, 1979 Pharmingen 
CD8 53-6.7 Ledbetter & Herzenberg, 1979 Pharmingen 
CD19 1D3 Krop et al., 1996 Pharmingen 
Cre Polyclonal 
serum 
Kellendonk et al., 1996 Babco 
Cre Polyclonal 
serum 
 Novagen 
Actin AC-15  Sigma 
GFP Polyclonal 
serum 
 Clontech 
TCR-β H57-597 Kubo et al., 1989 Pharmingen 
 
 
2.2 Molecular biology 
Standard methods of molecular biology were performed - if not otherwise stated - 
according to protocols described in Sambrook et al. (1989). 
 
2.2.1 Competent E.coli and isolation of plasmid DNA 
Competent Escherichia coli DH5α cells or Stbl-2 cells were prepared according to the 
protocol of Inoue et al. (1990) and used in heat shock transformations of plasmid 
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DNA. Ligation was performed with NEB T4-ligase according to the manufacturer’s 
instructions. 
Plasmid DNA was isolated from transformed E. coli DH5α with an alkaline lysis 
method (QIAGEN, Hilden, Germany) according to the protocol of Zhou et al. (1990). 
Plasmid DNA of a higher purity was obtained using QIAGEN columns (QIAGEN, 
Hilden, Germany) following the supplier’s instructions. 
 
2.2.2 Constructions of expression plasmids and targeting vectors 
Primers for the amplification of cDNAs used in plasmid constructions are depicted in 
Table 2. Schematic overviews of the generated expression plasmids and targeting 
vectors together with major restriction sites are shown in Fig. 6-9. All constructs used 
for plasmid generation were confirmed by sequencing. Sequences of the generated 
plasmids and targeting vectors are available in chapter 10 supplementary data as pdf 
formats. 
 
 
Table 2. Primers used for cloning 
Sequences of oligonucleotides are shown in 5’ to 3’ direction. Explanation indicates the usage of the primer in a PCR reaction.  
 
Name of primer Sequence Explanation 
5PR650 TTTAAGGATCCACCATGGGCGCCCTGGATGCTGTT
GCTC 
Used for amplification of coding 
regions of PR650-914 and PR650-
891 with 3PR914 and 3PR891. 
5PR676 TTTAAGGATCCACCATGGGCGCCTCACCAGGTCAA
GACATACA 
Used for amplification of coding 
regions of PR676-914 and PR676-
891 with 3PR914 and 3PR891. 
5PR678 TTTAAGGCGCCGGCGGCGGTCAAGACATACAGTTG
ATT 
Used for amplification of coding 
region of PR678-914 with 3PR914. 
3PR891 AAATTGATATCTATCCGTACGCATGCATAGCAGTAC
AGATGAAGTTGTTT 
Used for amplification of coding 
region of PR650-914 and PR676-
914 with 5PR650 and 5PR676. 
3PR914 AAATTGATATCTATCCGTACGCATGCATAGCAATAA
CTTCAGACATCATTT 
Used for amplification of coding 
region of PR678-914, PR650-914 
and PR676-914 with 5PR678, 
5PR650 and 5PR676. 
5Cre19 TTTAAGGCGCCACGAGTGATGAGGTTCGCA Used for amplification of coding 
region of phage Cre19 with 
3Cre343. 
3Cre343 AAATTGGCGCCATCGCCATCTTCCAGCAGG Used for amplification of coding 
region of phage Cre19 with 
5Cre19. 
5hCre2 GGGGGATCCACCATGGGTGCCTCCAACCTGCTGAC
TGTG 
Used for amplification of coding 
region of hCre2 with 3hCre343. 
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5hCre19 TTTAAGGATCCACCATGGGTGCCACGAGTGATGAG
GTTCGCA 
Used for amplification of coding 
region of hCre19 and Cre* with 
3hCre343 and 3hCreV336A. 
3hCre343 CCCTTGGCGCCGTCCCCATCCTCGAGCAG Used for amplification of coding 
region of hCre2 and hCre19 with 
5hCre2 and 5hCre19. 
3hCreV336A AAATTGGCGCCGTCCCCATCCTCGAGCAGCCTCGC
CATGGCCCC 
Used for amplification of coding 
region of Cre* with 5hCre19. 
3PacloxBNco CACCATGGTGGATCCATAACTTCGTATAATGTATGC
TATACGAAGTTATTTAATTAACCACTGGAAAGACCG
CGAA 
Cloning of RRDR 
3loxAscEVEINheMsc TTTTGGCCAGCTAGCGAATTCGATATCGGCGCGCC
GATAACTTCGTATAATGTATGCTATACGAAGTTATAA
GCTTACTTACCATGTCAGAT 
Cloning of RRDR 
3BstEIIRFP TTTGGTCACCTTCAGCTTCACGG Cloning of RRDR 
3EGFP TTTGATATCTAAGATACATTGATGAGTTTGGA Cloning of RRDR 
3NotBambPA TTTGCGGCCGCGGATCCCCCCAGCTGGTTCTTTC Cloning of RRDR 
3XhoFRTneo TTTCTCGAGGAAGTTCCTATACTTTCTAGAGAATAG
GAACTTCGGAATAGGAACTTCCCCCAGCTGGTTCTT
TC 
Cloning of RRDR 
3RedStu TTTTAGGCCTCCCAGCCCATCGTCTTCTTCTGCATT
ACGGGGCCGTCGGAGGGGAAGTTCACGCCGATGA
ACTTCACCTTGTAGATGAAGCAGCCGTCTTGCAGTG
ACGAGTCTTGGGTCACAGTCACGAC 
Cloning of RRDR 
3SacIIROSA TTTCCGCGGCCGCCGGATCCCCGCAAACGCACCAA
GC 
Cloning of pROSA26w/oATG 
5BstEIIROSA AAAGGTGACCCTTCTTTCCCCC Cloning of pROSA26w/oATG 
5RedBstEII AAAAGGTGACCAAGGGCGGCCCCCTGCCCTTCGC
CTGGGACATACTGTCGCCGCAATTCCAATAC 
Cloning of RRDR 
5PacloxRFP AAATTAATTAAATAACTTCGTATAGCATACATTATAC
GAAGTTATCTGCAGGGATCCACCATGGGCAAGAAG
AAGAGGAAGGTGGCCTCCTCCGAGAACGTCATCAC
C 
Cloning of RRDR 
5SalWSS AAAGTCGACTCGGGGACACCAAATATGGC Cloning of RRDR 
5EGFP AAAGATATCTCCACCATGGTGAGCAAGGGCGAGG Cloning of RRDR 
5NotbPA AAAGCGGCCGCGGGGATCAATTCTCTAGAGC Cloning of RRDR 
5SalFRTneo AAAGTCGACGAAGTTCCTATTCCGAAGTTCCTATTC
TCTAGAAAGTATAGGAACTTCTACCGGGTAGGGGA
GGCG 
Cloning of RRDR 
XbaNheSA AAATCTAGAGCCTCGCTAGCATCTGTAGGGCGCAG
TAGTC 
Cloning of RRDR 
3AscWSS AAAGCGGCCGCGGCGCGCCGATATCCTGCAGACTT
ACCTTCCATGTCAGATCCAGACATGATAAG 
Cloning of RRDR 
3BamCAGGS TTTGGATCCGAATTCACGCGTGTTTAAACTTGCCCA
GGAGCTGTAGGAA 
Cloning of pExChange 
3BamSV40 TTTGGATCCTACCACATTTGTAGAGGTTTTAC Cloning of pExChange 
3EFPme TTTGTTTAAACCACGACACCTGAAATGGAAGAAAAA
AAC 
Cloning of pExChange 
5BamWSSmod AAAGGATCCTCGGGGACACCAAATATGGC Cloning of pExChange 
5BglIISV40 AAAAGATCTCAGACATGATAAGATACATTGA Cloning of pExChange 
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5PmeEF AAAGTTTAAACAAAGCTAACTGTAGGACTGAGT Cloning of pExChange 
5SpeCAGGS AAAACTAGTGGCGCGCCGTTTAAACTATTAATAGTA
ATCAATTACGGG 
Cloning of pExChange 
3BamEx1 TTTGGATCCGGTAGCCAGGCTCCCTGGG Cloning of pCD19 
3PacEx11 TTTTTAATTAACAGCTGTGGAAGAGAGAGC G Cloning of pCD19 
3probeB GGATCCCTCTCATATCTTCATA Amplification of probe B for CD19 
3XbaEx2 TTTTCTAGATTAATTAAGCTAGCACTAGTGGGGAGC
CCCAGCCCCTCT 
Cloning of pCD19 
5NheLA AAAGCTAGCCCTCCCGGACTCCTCACCT Cloning of pCD19 
5NotEX1e AAAGCGGCCGCATTTAAATCTAAGCTAGAATGAAAC
CTA 
Cloning of pCD19 
5BamEx1 AAAGGATCCATCTCCTCTCCCTGTCTC Cloning of pCD19 
5probeB CAGCTGAGTCTTATGAAAATGCA Amplification of probe B for CD19 
 
 
2.2.2.1 CrePR expression plasmids 
PCR was applied to amplify the coding regions of the LBD of the progesterone 
receptor PR650-891 and 650-914 (Misrahi et al., 1987) from the template 
pPAPGLVP (Wang et al., 1997b) using the 5'-primer 5PR650 with the 3'-primers 
3PR891 and 3PR914, respectively. The PR coding regions were cloned into the 
BamHI- and EcoRV-sites of the pNN265E-bpA vector containing a CMV promoter, a 
synthetic intron and a bovine polyadenylation signal (R. Kühn, Artemis 
Pharmaceuticals, Cologne, Germany). Fig. 6 shows pNN265E-bpA and constructs 
cloned into this plasmid. For amplification of PR676-891 and PR676-914, the primer 
5PR676 was used in combination with 3PR891 and 3PR914. In these new PR-LBD 
containing vectors, the phage Cre gene starting from amino acid 19 was cloned into 
the SfoI site after amplification using pPGK-Cre-bpA (Fellenberg, 1997) as template 
and 5cre19 and 3cre343 as primers. Constructs containing the humanized version of 
Cre, hCre2 and hCre19 were amplified from pBluehCre (Shimshek et al., 2002) by 
using the primers 5hCre2 and 5hCre19 together with 3hCre343 and then cloned into 
the BamHI/SfoI-sites of the pNNPR676-914. The mutant humanized CreV336A 
(Cre*) was amplified using the primers 5hCre19 and 3hCreV336A and then cloned as 
described above into pNNPR676-914 and pNNPR650-914. Coding region of PR678-
914 was amplified by PCR from template pPAPGLVP (Wang et al., 1997b) using the 
5'-primer 5PR678 with 3'-primer 3PR914 and cloned in pNNCre19PR650-914, which 
was BsiWI digested and then partially digested with SfoI to generate 
pNNCre19PR678-914. This vector was digested with BamHI/SfoI to cut out the 
phage Cre, which was subsequently replaced by BamHI/SfoI digested Cre* from 
pNNCre*PR650. The resulting vector was termed pNNCre*PR.  
2. MATERIAL AND METHODS                                                                                  26                  
	


	





	
 
    
!
"#
$
	
  "#
$ "# "#$
%%



 
	
 

	
 

	
 

	
 

	
 

	
 

	 
 	 

	 

	 

 	
 	

! !
 
 

 &
"#"#
	

 	

	




	



	 
 



 ' 
	

!

 	 	 
 
	 

 





 !
 	   	
 
Fig. 6 Maps of expression vectors. 
Parts of the plasmids with major restriction sites constructed for expression in mammalian cells. pNN265bPAE- was kindly 
provided by R. Kühn and contains a CMV enhancer/promoter (CMV), a multiple cloning site (MCS) and a bovine pA (bPA). 
In the BamHI/EcoRV sites, I have cloned the Cre19PR constructs consisting of a 18 aa truncated Cre gene from PI fused 
to different LBDs of the PR with the indicated aa, the hCrePR constructs derived from a humanized Cre gene and the 
Cre*PR constructs with the humanized Cre* gene containing mutation V336A. pTriEX1 was obtained from Novagen and 
contains the CAGGS promoter (CMV enhancer; chicken β−actin promoter) and a synthetic intron ranging from SD (splice 
donor) to SA (splice acceptor). The neomycin resistance gene is driven by the pGK promoter (neo) and is flanked by FRT 
sites (closed ellipses). pBS KSII was obtained from Stratagene. The EF1α promoter was amplified as described in 
Materials and Methods under 2.2.2.5. The CreERT2 from pTECreERT2 contains the full length NLS Cre gene fused to the 
ERT2 LBD from aa 282 to 594 containing aa substitutions G400V, M543A and L544A. The construction of pTE RFP/GFP 
is described in detail in 2.2.2.2. The plasmid contains two loxP sites (filled triangles), the DsRed gene, a FRT site flanked 
neo, the Westphal stop sequence (WSS) and the eGFP gene. pEXChange contains the rtTA-M2, two polyadenylation 
signals from SV40 (SV40pA), the WSS and the tetO7 (CMV minimal promoter fused to 7 x tet responsive elements) Cre 
cassette. 
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2.2.2.2 ROSA26 Cre indicator targeting vector 
In order to generate a new indicator mouse for Cre, the pRRDR targeting vector was 
constructed to introduce the Cre indicator into the ROSA26 locus of embryonic stem 
cells. The RRDR targeting vector is shown in Fig. 7 and consists of a 2.5 kb SAH to 
ROSA26, a strong adenoviral splice acceptor, a loxP site, a slightly modified DsRed 
gene, a FRT site flanked neo gene, the WSS, a loxP site, an eGFP gene, a 4.2 kb 
LAH to ROSA26 and the diphtheria toxin gene. The pRRDR was constructed in nine 
cloning steps. An 800 bp NcoI/ NotI fragment from pDsRed1 (Clontech, Germany) 
containing the ORF of DsRed was cloned into pTriEx1 (Novagen, Darmstadt, 
Germany). This vector was digested with XbaI/NcoI and ligated to an 170 bp PCR 
fragment generated with the primers XbaNheSA and 3PacloxBNco from pSAβ-Geo 
(Friedrich & Soriano, 1991). The PCR product consists of a splice acceptor from 
adenovirus and a loxP site from phage PI. Silent mutation of two cryptic splice 
acceptors in DsRed ORF (Baird et al., 2000) was performed by PCR directed 
mutagenesis with the primers 5RedBstEII and 3RedStu. The resulting PCR fragment 
was digested with BstEII/StuI and inserted into the vector described above. The neo 
cassette flanked by FRT sites was amplified from pgkSSneo (Christ et al., 2002) with 
the primers 5SalFRTNeo and 3XhoFRTNeo and cloned into XhoI of the plasmid 
generated before. The PCR fragment of the WSS (Lakso et al., 1992) generated from 
pBS302 (Gibco, Karlsruhe, Germany) with the primers 5SalWSS and 
3loxAscEVEINheMsc was ligated into the XhoI/SwaI opened vector. It contains the 
WSS and the second loxP site. To produce a functional DsRed gene, the bPA PCR 
product generated with primers 5NotbPA and 3NotBambPA was cloned into the NotI 
site. The NLS sequence and the two mutations K5E and K9T were inserted at the N-
terminus of DsRed to prevent aggregation in transfected cells (Bevis et al., 2002). 
PCR was performed with the primers 5PacloxRFP and 3BstEIIRFP and the resulting 
PCR fragment was digested with PacI/BstEII and ligated with PacI/BstEII digested 
vector. The pTE RFP/GFP expression vector was generated by ligating the ORF of 
eGFP (Yang et al., 1996; Baird et al., 1996) into the EcoRV site (Fig. 6). The eGFP 
was amplified with the primers 5EGFP and 3EGFP from a MCS lacking pEGFP-CI 
plasmid (Clontech, Germany). Removal of the MCS of pEGFP-CI was performed by 
BglII/BamHI digestion and self ligation. 
The Cre indicator construct was cut out with NheI and cloned into pROSA26w/oATG 
opened by XbaI to produce the final targeting vector pRRDR. pROSA26w/oATG was 
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generated by inserting an SacI/SacII 1.6 kb fragment from A-04 (Mao et al., 1999). 
The 1.6 kb fragment was modified before by replacing the BstEII/SacII fragment of 
ROSA26 genomic DNA by a PCR product generated with the primers 5BstEIIROSA 
and 3SacIIROSA, in which the endogenous start codon was mutated by inserting a 
BamHI site (Fig. 7). 
 
2.2.2.3 ROSA26 Cre*PR targeting vector 
Ubiquitous expression of the posttranslational inducible Cre*PR can be achieved by 
targeted insertion in the ROSA26 locus (Fig. 7). The targeting vector pRRCP 
generated consists of 1 kb SAH to ROSA26, a strong adenoviral splice acceptor, the 
Cre*PR gene, a FRT site flanked neo gene, 4.2 kb LAH and the diphtheria toxin gene 
as negative selection marker. A schematically map of pRRCP is represented in Fig. 
7. The targeting vector was constructed by NheI digestion of a transition plasmid 
pTECre*PR (Fig. 6), which results in a fragment of the splice acceptor, the Cre*PR 
gene and the FRT flanked neo, which was subsequently ligated to the pROSA26-1 
targeting vector, which was digested with XbaI. To produce pTECre*PR (Fig. 6), the 
Cre*PR678-914 fusion protein ORF was digested with BglII, blunted and then 
digested with NotI from pNNCre*PR (Fig. 6). This fragment was cloned into a 
modified version of pTE RFP/GFP (Fig. 6) lacking loxP sites, DsRed, WSS and 
eGFP.  
The SA Cre*PR FRT neo cassette was cut out from the pTECre*PR plasmid with 
NheI (Fig. 6) and cloned into XbaI of pROSA26-1 (Soriano, 1999) to generate 
pRRCP (Fig. 7). 
 
2.2.2.4 HPRT CAGGS Cre*PR targeting vector  
In order to generate ubiquitously expressed Cre*PR in mice, a CAGGS promoter 
driven Cre*PR gene was inserted into the HPRT targeting vector pMP10 (Fig. 8). A 
MluI/AscI fragment from pTECre*PR (Fig. 6), containing the sequences of the 
CAGGS promoter (Niwa et al., 1991), a synthetic intron (Choi et al., 1991), the 
Cre*PR678-914 and the bPA, was cloned into AscI digested pMP10 (S. Casola, 
unpublished) to generate pMP10 CCP (Fig. 8). pMP10 is a derivative from pMP8 
(Reid et al., 1991) and contains an AscI and PmeI site to insert the transgene of 
interest upstream of the HPRT promoter. In addition, pMP10 contains SbfI, SwaI and 
SgrAI sites to linearize the targeting vector (Fig. 8).    
2. MATERIAL AND METHODS                                                                                  29                  













	




	




 
'
 

$
	







	






 









	



'
"


 
'
 









	



'
"









	




	




	




 
'
 


	




	






















 
&


	







	




 
!
"
#
$
%





!
"
#
$
%








	



'
"

&







!
"
#
$
%
 
!
"
#
$
%
&




!
"

$
%
 
!
"
#
$
%
&



	













Sc
he
ma
tica
l d
raw
ing
s o
f th
e g
en
era
ted
 RO
SA
26
 ta
rge
ting
 ve
cto
rs 
wit
h m
ajo
r re
str
icti
on
 sit
es.
 AT
G, 
de
str
oye
d s
tar
t c
od
on
; D
TA
, d
iph
the
ria
 to
xin
 A 
ge
ne
 dr
ive
n b
y t
he
 pG
K p
rom
ote
r; S
AH
, 
sho
rt a
rm
 of
 ho
mo
log
y; 
LA
H, 
lon
g a
rm
 of
 ho
mo
log
y; 
SA
, a
de
no
vira
l sp
lice
 ac
cep
tor
; fi
lled
 tri
an
gle
s, 
lox
P s
ites
; D
sR
ed
, D
sR
ed
 ge
ne
; c
los
ed
 el
lips
es,
 FR
T s
ites
; N
eo
, n
eo
my
cin
e r
esi
sta
nc
e 
ge
ne
 dr
ive
n b
y t
he
 pG
K p
rom
ote
r; W
SS
, W
est
ph
al 
sto
p s
eq
ue
nce
; e
GF
P, 
eG
FP
 ge
ne
; C
re*
, a
 18
 aa
 tru
nca
ted
 hu
ma
niz
ed
 C
re 
ge
ne
 co
nta
inin
g m
uta
tion
 V3
36
A; 
PR
67
8-9
14
, L
BD
 of
 th
e 
pro
ge
ste
ron
e r
ece
pto
r ra
ng
ing
 fro
m 
aa
 67
8-9
14
; b
PA
, b
ovi
ne
 po
lya
de
nyl
atio
n s
ign
al. 
  
 Fi
g. 
7 M
ap
s o
f R
OS
A2
6 t
arg
etin
g v
ect
ors
.  
2. MATERIAL AND METHODS                                                                                  30                  
2.2.2.5 HPRT EF1αCre*PR targeting vector  
The human EF1α promoter (Kim et al., 1990; Wakabayashi-ito et al., 1994) was 
amplified from BAC RP11-206H23 (a gift from J. Seibler, Artemis Pharmaceuticals, 
Cologne, Germany) with the primers 5PmeEF and 3PmeEF and cloned into the 
EcoRV of pBS KSII (Stratagene, Heidelberg, Germany). This plasmid was digested 
with BamHI/ NotI and ligated with the BamHI/NotI 1.8 kb fragment from pNNCre*PR 
containing the Cre*PR and the bPA to generate pBS EF1αCre*PR (Fig. 6). The 4.3 
kb MluI fragment of pBS EF1αCre*PR was cloned into pMP10 (S. Casola, 
unpublished) to produce pMP10 EF1αCre*PR (Fig. 8). 
 
2.2.2.6 HPRT CAGGS tet-on targeting vector  
In order to establish a tet-on inducible system for Cre, the pEXchange plasmid was 
constructed in which the rtTA-M2 transactivator (Urlinger et al., 2000) with its own 
promoter and the tetO7 Cre cassette are located on one DNA fragment (Fig. 6). Cell 
type specific expression of the rtTA-M2 can be achieved by exchanging the promoter 
region. AscI digestion releases the tet-on cassette consisting of the promoter, the 
rtTA-M2, two SV40 pAs and a WSS (Lakso et al., 1992), followed by the tet-
responsive cassette which consists of the tetO7 promoter, a synthetic intron and the 
Cre ORF. The AscI fragment was cloned into the HPRT targeting vector pMP10 (Fig. 
8). The 1.1 kb WSS fragment produced by PCR with the primers 5BamWSSmod and 
3AscWSS from pBS302 was ligated into BamHI/AscI digested pTriEx1 (Novagen, 
Darmstadt, Germany). In the resulting vector, a non-functional CAGGS promoter 
fragment was cloned in XbaI/BamHI amplified from pCAGGS Flpe (Schaft et al., 
2001) with the primers 5SpeCAGGS and 3BamCAGGS. Between the promoter and 
the WSS, the rtTA-M2 followed by two SV40pA from pUHrT 62-1+SV40 (a derivative 
of pUHrT 62-1, in which an additional SV40pA was inserted) was cloned with 
EcoRI/BamHI. This plasmid was digested with PstI/AscI and a 2.1 kb PstI/AscI 
fragment from ptetO7-I-Cre-pA was inserted, which contained the tetO7 promoter, a 
synthetic intron, the Cre ORF and a pA (gift from F. Schwenk, Artemis 
Pharmaceuticals, Cologne, Germany). In the final pEXchange, the promoter can be 
exchanged by a single digest (PmeI) to get different cell type specificities (Fig. 6). For 
strong ubiquitous expression of the rtTA-M2, a HincII CAGGS fragment from 
pTECre*PR was inserted into PmeI. The tet-inducible cassette was cut out with AscI 
and ligated to pMP10 (S. Casola, unpublished) to generate pMP10 Ctet-on (Fig. 8). 
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  	Fig. 8 Maps of HPRT targeting vectors. 
Schematical drawings of the generated HPRT targeting vectors. Abbreviations used are as in Fig. 7. CAGGS, CMV 
enhancer combined with the chicken β−actin promoter; SD, splice donor; EF1α, promoter of the EF1α gene; rtTA-M2, 
reverse tetracycline controlled transactivator M2; SV40pA, polyadenylation signal from SV40; tetO7, CMV minimal 
promoter fused to 7 x tet-responsive elements. 
2. MATERIAL AND METHODS                                                                                  32                  
2.2.2.7 HPRT EF1αtet-on targeting vector  
The pEXchange plasmid described in Materials and Methods under 2.2.2.6 was 
digested with PmeI to release the CAGGS promoter region and ligated to the PCR 
fragment containing the EF1α promoter, which was described in Materials and 
Methods under 2.2.2.5. The same cloning strategy was used as for construction of 
pMP10 Ctet-on described in Materials and Methods under 2.2.2.6 to produce pMP10 
EF1αtet-on (Fig. 8). 
 
2.2.2.8 CD19 Cre*PR targeting vector  
In order to achieve B cell specific expression of transgenes, a targeting vector for 
CD19 was constructed (pCD19), in which the transgene of interest can be inserted 
into the NheI site in the second exon of the CD19 gene (Fig. 9). The SAH of the 
mCD19 gene was generated in two steps. First, a 900 bp fragment, amplified with the 
primers 5NotEx1e and 3BamEx1 from genomic 129/ola DNA containing part of the 
promoter and part of exon 1, was used for ligation with pBS TK, which contains the 
TK gene for negative selection with GANC. Second, a BamHI/XbaI digested 420 bp 
PCR product generated with the primers 5BamEx1 and 3XbaEx2 consisting of the 
destroyed, endogenous start AUG of CD19, which was replaced by a BamHI site and 
the first intron, was introduced into the plasmid pBS TK containing the 900 bp 
fragment described above. The LAH containing exons 2-11 of mCD19 was amplified 
from genomic 129/ola DNA with the primers 5NheLA and 3PacEx11 and ligated into 
the plasmid with the SAH. The single NheI site in exon 2 can be used to introduce 
the transgene of interest. 
The SA Cre*PR FRT neo cassette was cut out from pTECre*PR (Fig. 6) with NheI 
and was cloned into the NheI site to generate the CD19 Cre*PR targeting vector 
pCD19Cre*PR (Fig. 9). 
 
2.2.2.9 CD19 CreERT2 targeting vector  
The transitional vector pTECreERT2 (Fig. 6) was generated, which consists of the 
CAGGS promotor, a synthetic intron, the CreERT2 and a FRT flanked neo cassette. 
It was produced by a 2 kb HincII/AscI fragment of pCAGGSCreER (Seibler et al., 
2003) consisting of the CreERT2 ORF cloned into BamHI blunted/AscI digested 
pTECre*PR. From the resulting plasmid, the CreERT2 FRT flanked neo cassette was 
cut out with NheI and inserted into pCD19, which results in pCD19CreERT2 (Fig. 9). 
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2.2.3 Isolation of genomic DNA  
Cells were incubated overnight at 56°C in lysis buffer (10 mM Tris-HCl, pH 8; 10 mM 
EDTA; 150 mM NaCl; 0.2% SDS; 400 mg/ml proteinase K). DNA was precipitated by 
adding an equal volume of isopropanol, pelleted by centrifugation, washed in 70% 
EtOH, and resuspended in TE-buffer (10 mM Tris-HCl, pH 8; 1 mM EDTA) plus 
RNAseI (50µg/ml). DNA from ES cell clones grown in 96-well tissue culture dishes 
was extracted and prepared according to the protocol of Pasparakis and Kollias 
(1995). For the preparation of DNA from mouse tissue, the latter was incubated 
overnight at 56°C in tissue lysis buffer (0.1 M Tris-HCl, pH 8.5; 5 mM EDTA; 0.2% 
SDS; 0.2 M NaCl; 600 mg/ml proteinase K). Debris were pelleted and the 
supernatant was mixed with an equal volume of isopropanol and the precipitated 
DNA was washed in 70% EtOH, dried and resuspended in TE-buffer. 
 
2.2.4 RT-PCR 
The mRNA from mouse organs was prepared using the RNeasy mini kit (QIAGEN, 
Hilden, Germany) according to the manufacture’s protocol. DNA was removed by 
DNaseI digestion (Promega, Mannheim, Germany). cDNA synthesis of 5 µg total 
RNA was done as described in superscript II protocol (Gibco, Karlsruhe, Germany). 
 
Table 3. Oligonucleotides used for amplification of specific cDNAs from ROSA26 and CD19 locus. 
 
Name of primer Sequence Explanation 
ROSAG CGCCGTAGGTCAGGGTGGT Used with ROSA512 to amplify GFP 
cDNA from RRDR. 
ROSA512 GCCGTTCTGTGAGACAG Used in combination with ROSAG, 
ROSAR1 and ROSA31 for amplification 
of cDNAs from ROSA locus. 
ROSAR1 CGCCCTCGATCTCGAACT C Used with ROSA512 to amplify DsRed 
cDNA from RRDR. 
ROSA31 AAATGTTCTGGACAAACACTTC Used with ROSA512 to amplify 
transcript 1 from ROSA locus. 
5EGFP AAAGATATCTCCACCATGGTGAGC
AAGGGCGAGG 
Used with ROSAG for amplification of 
GFP cDNA. 
5BamEx1 AAAGGATCCATCTCCTCTCCCTGTC
TC 
Used to amplify Cre*PR transcript from 
CD19 locus of CD19CP with hCreintrev. 
hCreintrev ACCAGGGACACAGCATTGG Used to amplify Cre*PR transcript from 
CD19 locus of CD19CP mice with 
5BamEx1. 
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2.2.5 DNA electrophoresis 
Separation of DNA fragments by size was achieved by electrophoresis in agarose 
gels (0.7% - 2%; 1 x TAE; 0.5 mg/ml ethidiumbromide (Sambrook et al., 1989)). DNA 
fragments were extracted from agarose gel slices with either the QIAEX II or the 
QIAquick Gel Extraction Kit (QIAGEN, Hilden, Germany) following the manufacturer's 
protocols. 
 
2.2.6 DNA sequencing 
DNA was sequenced using the 'Big Dye termination Cycle Sequencing Kit' (Applied 
Biosystems, Foster City, USA), which is a PCR-based modification of the original 
Sanger protocol (Sanger et al., 1977). The fluorescently labelled DNA fragments 
were separated and analysed with the ABI373A and ABI377 systems (Applied 
Biosystems, Foster City, USA). 
 
2.2.7 Quantification of DNA and RNA 
The concentration of nucleic acids was determined by measuring the absorption of 
the sample at 260 nm and 280 nm in a spectrophotometer. An OD260 of 1 
corresponds to approximately 50 µg/ml for double stranded DNA or 40 µg/ml for RNA 
and single stranded DNA. Purity of nucleic acids can be estimated by the ratio 
OD260/OD280 with 1.8 and 2.0 for DNA and RNA, respectively. Alternatively, the DNA 
was electrophoresed in an agarose gel, and the concentration was approximated 
from the band intensity in comparison with a standard. 
 
2.2.8 PCR 
PCR (Mullis and Faloona, 1987; Saiki et al., 1985) was used to screen mice and ES 
cells for the presence of targeted alleles or transgenes and to amplify fragments for 
sequencing (primers shown in Table 4). Reactions were performed in either Hybaid 
machines (MWG-Biotech, Ebersberg, Germany) or Triothermocyclers (Biometra, 
Göttingen, Germany). Genotyping of mice and ES cells was generally performed in a 
total volume of 50 µl in the following reaction mix: 50 pmol of each primer, 1.5 U of 
Thermus aquaticus (Taq) DNA polymerase (homemade), 250 µM dNTPs, 10 mM 
Tris-HCl pH 8.3, 50 mM KCl, 2.5 mM MgCl2, 100 ng template DNA. Amplification 
started with denaturation for 4 min at 94 °C followed by 30-35 cycles of 94 °C for 30 
sec, 52-60 °C for 30 sec, 72 °C for 30 sec and a final extension step at 72 °C for 10 
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min. To amplify cDNA fragments for cloning or sequencing, the High Fidelity Kit with 
proofreading activity was used (Roche, Mannheim, Germany) with the primers shown 
in Table 2. 
 
Table 4. Mouse typing by PCR 
Sequences of oligonucleaotides are shown in 5’-3’ direction. Explanation indicates the usage of the primer in standard PCR 
reactions. PCR of transgenic Cre lines was performed as published. 
 
Name of primer Sequence Explanation 
ROSA1 CAGGGTTTCCTTGATGATGTCA Typing of RRDR-DsRed and 
RRDR-eGFP with ROSAG and 
ROSAR; Typing of RCP with 
hcreintrev. 
ROSAG CGCCGTAGGTCAGGGTGGT Typing of RRDR-eGFP with 
ROSA1. 
ROSAR AGCTTCACGGTGTTGTGGCC Typing of RRDR-DsRed with 
ROSA1. 
hCreintrev ACCAGGGACACAGCATTGG Typing of RCP with ROSA1; CCP 
with 5Cre*; CD19CP with 
5BamEx1. 
5Cre* TCCACCATGGGTGCCACCTC Typing of CCP with hcreintrev. 
5BamEx1 AAAGGATCCATCTCCTCTCCCTGTCTC Typing of CD19CP with hcreintrev. 
 
2.2.9 Southern blot analysis 
Digestion of 5-15 µg DNA was performed overnight with 50 - 100 U of the appropriate 
restriction enzyme. Subsequently, the DNA fragments were separated by agarose 
gel electrophoresis and transferred onto HybondTM-N+ (Amersham, Illinois, USA) or 
GeneScreenPlus (Dupont, Wilmington, USA) nylon membranes by an alkaline 
capillary transfer according to the method of Chomczynski and Qasba (1984). 
Membranes were baked at 80°C for 20 min to fix the DNA equilibrated in 2x SSC 
(Sambrook et al., 1989) and then prehybridized at 65°C for 4 h in hybridization 
solution (1M NaCl, 1% SDS, 10% dextran sulfate, 50 mM Tris-HCl pH 7.5, 250 µg/ml 
sonicated salmon sperm DNA). The radioactively labelled probe was added to the 
hybridization solution and allowed to hybridize at 65°C for 10 h in a rotating cylinder. 
 
The following probes were used: 
 
(i) For the ROSA26 locus: 
800 bp EcoRI/PacI fragment from A-04 (Mao et al., 1999). 
1000 bp SacII/XbaI fragment from pROSA26-1 (Soriano, 1999). 
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(ii) For the HPRT locus: 
300 bp RsaI probe (Reid et al., 1991). 
1000 bp Cre* probe digested with BamHI/XhoI from pNNCre*PR650-914         
(Wunderlich et al., 2001). 
1000 bp Cre probe digested with XhoI/SpeI from pGKCrebPA (Fellenberg, 1997). 
 
(iii) For mCD19 locus: 
900 bp PCR fragment amplified with 5NotEx1e and 3BamEx2 and subcloned into 
pGemTeasy (Promega, Mannheim, Germany). 
1000 bp PCR fragment amplified with 5ProbeB and 3ProbeB and subcloned into 
pGemTeasy (Promega, Mannheim, Germany). 
 
(iv) For the neomycin resistance gene: 
400 bp BamHI fragment from pBSNeoprobe (N.Uyttersprot, unpublished) 
 
(v) For the eGFP gene: 
800 bp GFP ORF from an EcoRV digest of pTE RFP/GFP. 
 
(vi) For the pol-β locus: 
900 bp fragment of BamHI/HindIII digested pPolbeta (Gu et al., 1994). 
 
Aliquots of 50 ng DNA of the above probes were radioactively labeled with 2.5 mCi 
[α32P]dATP (Amersham, Braunschweig) using the LaddermanTM Labeling Kit (Takara, 
Japan) based on the principle of random primed oligolabeling (Feinberg and 
Vogelstein, 1984). Unincorporated radiolabeled nucleotides were removed with 
MicroSpinTM S-200HR columns to reduce background during hybridization 
(Pharmacia, Freiburg, Germany). The probe was denatured at 100°C for 5 min and 
then cooled on ice, before it was added to the hybridization solution. After 
hybridization, stringent washes were initially performed twice in 2 x SSC/0.1 % SDS 
and then followed by washes in 1 x SSC/0.1 % SDS and 0.5 x SSC/0.1 % SDS, if 
necessary. All washes were performed at 65°C under gentle shaking for 30 min. After 
each wash, the filter was monitored with a Geiger-counter and the washes were 
stopped when specific signals reached 20 to 100 cps. Then, the filter was sealed in a 
plastic bag and exposed to X-ray film (Kodak XAR-5 or BioMAX MS; Eastman 
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Kodak) at -80°C. Films were developed in an automatic developer or, alternatively, 
filters were exposed to a phosphoimager screen (Fuji, Fuji, Japan) and analyzed on a 
Bio-Imaging Analyser (Fuji Bias 1000; Fuji, Japan). 
 
2.3 Cell biology 
 
2.3.1 Fibroblast cell culture 
CV1-5B cells originally obtained from Kellendonk et al. (1996) or murine embryonic 
fibroblasts (MEF) were cultured in DMEM supplemented with 10% FCS, 100U/ml 
penicillin and 0.1 mg/ml streptomycin. Aliquots of 8 x104 cells were plated on a 6 
well-plate, grown for 24h and then transfected with CrePR plasmid DNAs using 
Fugene6 according to manufacturer’s protocol (Roche, Mannheim, Germany). To 
determine transfection efficiencies, the plasmid pHD2-AP encoding the alkaline 
phosphatase was cotransfected. Twelve hours after transfection, cells were 
trypsinized and split into 2 wells of a 12 well-plate containing medium with or without 
RU486 and, 60 hours later, cells were fixed in 4% formaldehyde in PBS and stained 
overnight with X-Gal staining solution as described (Kellendonk et al., 1996). After 
heat inactivation of endogenous alkaline phosphatases (AP) at 65°C for 30 min, cells 
were stained for the cotransfected AP activity using fast red tablets (Roche, 
Mannheim, Germany). In each well, blue and red cells in three different areas were 
counted. The ratios of blue to red cells were determined and the value obtained with 
authentic Cre was set to 100%. Each experiment was performed at least in triplicate. 
In dose response assays, 8x105 CV1-5B cells were plated on 9 cm dishes, grown for 
24 h and then transfected with 5 µg of the test plasmids. Twelve hours after 
transfection, cells were trypsinized and split into seven wells of 6 well-plates 
containing increasing concentrations of RU486. Seventy two hours after transfection, 
cells were fixed and stained for β-galactosidase activity as described above.  Relative 
β-galactosidase activity was expressed as the percentage of the maximal activity 
after substraction of the activity obtained in the absence of ligand. Each experiment 
was performed in duplicate.  
 
2.3.2 Embryonic stem cell culture 
All targetings were performed in HM-1 ES cells (Magin et al., 1992). Culturing and 
transfection of ES cells was performed according to published protocols (Pasparakis 
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and Kollias, 1995; Torres and Kühn, 1997). To maintain the pluripotency of the ES 
cells, the latter were cultured in the presence of leukaemia inhibiting factor (LIF) 
containing ES cell medium on a layer of embryonic feeder (EF) cells. The ES cell 
medium (DMEM, 15 % FCS, 1 mM sodium pyruvate, 2 mM L-glutamine, 1 x non 
essential amino acids, 1:1000 diluted LIF supernatant, 0.1 mM 2-β-mercaptoethanol) 
contained FCS, which had been priorly tested to promote ES cell growth and to 
prevent in vitro differentiation (Gibco, Karlsruhe, Germany). ES and EF cells were 
grown in tissue culture dishes (Falcon, Bedford, USA) and kept at 37°C under humid 
atmosphere with 10% CO2. EF cells in DMEM supplemented with 10% FCS, 1 mM 
sodium pyruvate, 2 mM L-glutamine were never passaged more than three times and 
mitotically inactivated by mitomycin-C treatment (10 µg/ml for 2 h) before seeding 
with ES cells. ES cell colony growth was stopped before they became confluent. 
Colonies were washed twice with PBS and then treated shortly with trypsin (0.05 % 
trypsin, 0.02 % EDTA in PBS; Gibco, Karlsruhe, Germany) at 37°C, until the cells 
detached from the dish. The cell suspension was then used for passaging, 
transfection, or freezing. ES cells were frozen in 90% FCS, 10 % DMSO at -80°C and 
later transferred into liquid nitrogen for long term storage. For transfection, 1 x 107 ES 
cells were mixed with 30 to 40 µg DNA in 800 µl transfection buffer (RPMI w/o phenol 
red, Gibco, Karlsruhe, Germany) and electroporated at 23°C (500mF, 240V). After 5 
min. incubation, ES cells were transferred onto an embryonic feeder layer and 48 
hours later placed under G418 (300 µg/ml, 71% active) or HAT selection (120 µM 
hypoxanthine, 0.4 µM aminopterin, 20 µM thymidine). If necessary, selection against 
HSV-tk containing random integrants started at day five after transfection by 
supplementing the medium with 2 mM gancyclovir (Cymeven, Syntex). On 
approximately day 9 after transfection, double resistant colonies were picked and 
split into EF-containing 96-well tissue culture dishes for expansion. In HPRT 
targetings, picked HAT resistant clones were maintained in HT medium (120 µM 
hypoxanthine, 20 µM thymidine) for five days to dilute out the toxin aminoptherin (A) 
and then switched to normal ES medium.  
 
2.3.3 Culture of ex vivo splenocytes 
The spleens were aseptically removed from mice and then pressed through a sterile 
sieve. Erythrocytes were lysed for 2 min by NH4Cl (140 mM NH4Cl, 17 mM Tris-HCl 
pH 7. 65). Splenocytes were kept in DMEM supplemented with 10 % FCS, 1 mM 
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sodium pyruvate, 2 mM L-glutamine, 1x non essential amino acids, 0.1 mM 2-β-
mercaptoethanol supplemented with various activation compounds (LPS; ConA; 
PMA; BAFF) for not longer than three days. In experiments, in which Cre activity 
should be induced, the cells were treated once with various amounts of inducer 
(RU486, Org31710, 4-OHT, 1mM stocks in ethanol). 
 
2.3.4 HTNC treatment 
Various cell types were treated by His-TAT-NLS-Cre (HTNC) (Peitz et al., 2002) to 
delete loxP-flanked gene segments as follows. 
ES cells: 
2x105 ES cells were plated in a well of a 6 well culture dish with feeders, 5 h prior to 
HTNC treatment. The medium was removed and replaced with DMEM w/o FCS/PBS, 
1:1, 4-0.25 µM HTNC from a 50% glycerol stock solution of 180 µM HTNC for 20 h 
(Peitz et al., 2002; M. Peitz, unpublished). Thereafter, the cells were cultured as 
described before. The deletion efficiency at 2 µM HTNC was usually 97% (T. 
Wunderlich, N. Hövelmeyer, C. Merkwirth, unpublished results). 
Ex vivo splenocytes: 
3x106 ex vivo splenocytes were treated with 2-0.5 µM HTNC in DMEM w/o FCS/PBS, 
1:1 or 10 µM HTNC in medium for 20 h. Subsequently, cells were centrifuged and 
cultured in the presence of LPS (10 µg/ml). After three days, cells were surface 
stained and FACS analysed or lysed for preparation of DNA and/or RNA. 
Fibroblasts: 
3x105 CV1-5B or RRDR/RRDR or RRDR∆neo/RRDR∆neo fibroblasts were treated 
for 20 h with 2-0.25 µM HTNC in DMEM w/o FCS/PBS, 1:1. 
 
2.3.5 Induction of Cre activity by ligand addition 
Induction by hormone: 
2x105 double targeted ES cells (RRDR-DsRed/+; CCP or EF1αCP) were treated with 
various amounts of either RU486 or Org31710 (Organon, Oss, The Netherlands) for 
4-21 days. The medium was changed every day and ligand was added freshly. 
Induction by doxycycline: 
2x105 double targeted ES cells (RRDR/+; Ctet-on or EF1αtet-on) were treated for 4 -
10 days with doxycycline 1µg/ml in medium. Medium was freshly prepared and 
exchanged every day. 
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2.3.6 Preparation of cells from lymphoid organs 
Thymus, spleen and lymph nodes were squashed between two frosted sides of a 
microscope slide to obtain single cell suspensions. Bones were flushed with medium 
(DMEM, 10% FCS, 2 mM L-glutamine) to extract bone marrow cells. Erythrocytes 
were lysed from spleen and bone marrow preparations in 140 mM NH4Cl, 17 mM 
Tris-HCl pH 7.65 for 2 min. Blood from the tail vein was collected in a tube with 
heparin (Liquemin, Roche, Mannheim, Germany) and then layered on top of 7% 
Ficoll 400 (Pharmacia, Freiburg, Germany). After 1350 g centrifugation at 23°C for 15 
min., lymphocytes were recovered from the interphase of the gradients and 
resuspended in DMEM, 10% FCS, 2 mM L-glutamine and kept on ice. 
 
2.3.7 Flow cytometry 
Cells (106 per sample) were surface stained in 30 µl PBS, 0.1 % BSA, 0.01 % NaN3 
with combinations of fluoresceine isothiocyanate (FITC), phycoerythrine (PE) and Cy-
ChromeTM (Cyc) conjugated mAbs for 20 min on ice. After staining, the samples were 
washed and resuspended in the above medium. Stained cells were analyzed on a 
FACSCalibur and data were evaluated using CellQuest software (Becton Dickinson, 
Mountain View, USA). Dead cells were labelled with Topro-3 for exclusion from the 
analysis. Monoclonal antibodies, listed in Table 1, were either homemade (C.Uthoff-
Hachenberg, B. Hampel) or purchased from Pharmingen (San Diego, USA). 
 
2.4 Biochemistry 
 
2.4.1 Protein extracts preparations 
Lysates from mouse organs were prepared either freshly or from frozen tissue. 
Tissue was diced into small pieces using a clean razor blade. Then, RIPA buffer 
(1xPBS, 1% NP-40) was added at 3 ml/g tissue supplemented with various protease 
inhibitors. Samples were centrifuged at 13,000 rpm for 5 min to separate 
supernatants from debris. Supernatants were transferred to a fresh tube and protein 
concentrations were determined in a photometer according to the Warburg formula. 
Protein extracts were diluted with RIPA buffer to 15 mg/ml before adding running 
buffer (3xSDS sample buffer, NEB, Schwalbach, Germany) and DTT (30xDTT, NEB, 
Schwalbach, Germany) to 200 µg of protein extracts. To separate the cytoplasmic 
protein fractions from the nuclear extracts, MEFs were resuspended at 106/15 µl cells 
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in hypotonic solution (10 mM Hepes [pH 7.9], 10 mM KCl, 2 mM MgCl2, 0.5 mM DTT, 
0.1 mM EDTA, supplemented with various protein inhibitors) and incubated at 4°C for 
10 min. Then NP-40 was added to 1 % and the cells were centrifuged at 13,000 rpm 
for 1 min. The supernatant containing the cytoplasmic fraction was recovered from 
the nuclear pellet and the nuclear pellet was resuspended in 106/10 µl cells of high 
salt buffer (20 mM Hepes [pH 7.9], 420 mM NaCl, 1.5 mM MgCl2, 0.5 mM DTT, 0.2 
mM EDTA and 10 % glycerol) and incubated on ice for 30 min. Nuclear extracts were 
recovered after centrifugation at 10,000 rpm for 10 min at 4°C and stored at  – 80 °C. 
. 
2.4.2 Western blot 
Protein extracts were electrophoresed by SDS-PAGE (10-15 %) (Laemmli, 1970) and 
transferred to immobilon-NC membranes (Millipore, Bedford, USA). The membranes 
were blocked with 5 % NF-milk/PBS or 5 % BSA/PBS for 1 h and probed using either 
one of two polyclonal antisera against Cre or anti-actin as primary antibodies. 
Membranes were then incubated with goat anti-rabbit IgG-horseradish peroxidase 
(HRP) conjugates (Vector, Burlingame, USA) as secondary antibody and developed 
using the ECL or ECL+ kit. 
 
2.5 Mouse experiments 
Vasectomy of male mice, tail bleeding as well as breeding of foster mothers and the 
general handling of mice were performed according to Hogan (Hogan et al., 1987) 
and Silver (Silver, 1995). 
 
2.5.1 Mice 
C57BL/6, C57BL/6 x Balb/c, 129/Sv and CD1 mice were obtained from Bomholtgard, 
Charles River, Harlan Winkelmann or Jackson Laboratories. CB20 mice were taken 
from breedings in our animal facility. CD19-cre mice (Rickert et al., 1997), deleter 
mice (Schwenk et al., 1995), RAGE-EG mice (Constien et al., 2001), Flp deleter 
(Rodriguez et al., 2000) and pol-β flox/flox (Gu et al., 1994) mice were intercrossed 
with the newly generated RRDR strain, the ROSACre*PR strain, the CAGGS Cre*PR 
strain and the CD19Cre*PR strain in conventional facilities. 
 
2.5.2 Activation of CrePR 
100 mg RU486 were dissolved in 50 µl DMSO and vortexed. Then, 1.95 ml of either
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 trioctanoin (Acros, Geel, Belgium) or sesame oil was added and sonicated for 1-2 
min. Aliquots of the emulsions were frozen at -20°C and sonicated again after 
thawing. The emulsions were either fed or i.p. injected into mice. Feeding and i.p. 
procedures were done as described (Seibler et al., 2003). The Org31710 was 
obtained at a 400 mg/ml EtOH solution from Organon (Oss, The Netherlands). Seven 
ml of trioctanoin were added to 1 ml of the solution and vortexed. Administration and 
further handling of Org31710 was performed as described above. 
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3. RESULTS 
 
3.1 A strategy for rapid screening of inducible Cre constructs 
In order to test efficiency and potential background activity of newly generated 
inducible Cre constructs first in ES cells and then in chimeric mice, I followed the 
strategy shown in Fig. 10. Knock-in procedures were preferred over the generation of 
classical transgenic mice to produce defined conditions and to circumvent tandem 
repeats, multiple integration sites and breakage of the construct that can affect 
expression of the transgene. The karyotypic male HM-1 ES cell line (Magin et al., 
1992) was used, which harbours a spontaneous deletion of the promoter and the first 
two exons of the single X-linked hypoxanthine-phospho-ribosyl-transferase (HPRT) 
gene. The HPRT gene was chosen, since it is a housekeeping gene, so that any 
promoter inserted is not restricted in its expression by unfavourable chromatin 
configurations (Bronson et al., 1996; Vivian et al., 1999; Hatada et al., 1999; 
Cvetkovic et al., 2000; Evans et al., 2000; Guillot et al., 2000). It is also of advantage 
that the targeting vector pMP10 is available, which mediates a highly efficient, 
directly selectable homologous recombination event at the HPRT locus in HM-1 ES 
cells (Reid et al., 1991). This targeting vector pMP10 is arranged such that 
recombination between the targeting vector and the homologous genomic sequences 
inserts the missing HPRT promoter and exons into the HM-1 genome. Upstream of 
the HPRT promoter in the pMP10 targeting vector, the inducible Cre transgene is 
inserted, which is driven by its own promoter (Fig. 10A). A successful gene targeting 
creates an intact HPRT gene and restores HPRT activity. Homologous recombined 
ES cell clones can be efficiently enriched by HAT selection for the presence of the 
HPRT gene product.  
 
To have a quantifiable readout of Cre action, a special indicator consisting of DsRed 
and eGFP was inserted into the ubiquitously expressed ROSA26 locus of HM-1 ES 
cells (Fig. 10B). This locus was originally identified by Friedrich & Soriano (1991) in a 
gene trap in embryonic stem cells and was shown to be expressed in all cells of the 
adult mouse. The introduced Cre reporter expresses the DsRed gene flanked by loxP 
sites. Upon Cre-mediated excision of the DsRed gene, the eGFP gene is turned on, 
which should be visualized by a change of cell fluorescence from red to green. The 
inducible Cre construct can therefore be analyzed in doubly targeted ES cells only 
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when the promoter of the Cre transgene is active in ES cells. The presence of the 
DsRed/eGFP Cre indicator in the ROSA26 locus allows quantitative analysis of the 
inducible Cre construct, which is inserted into the HPRT locus in chimeras, since 
DsRed expression identifies ES cell-derived cells and tissues within the chimeras. All 
ES cell-derived cells should be red before Cre-mediated recombination and green 
thereafter.    
 
3.2 An attempt to generate an improved Cre indicator mouse strain 
In order to test the DsRed/eGFP Cre indicator RRDR (RRosa Double Reporter) in 
transient transfection experiments, it was cloned into the expression vector pTriEX1 
containing the CAGGS promoter and a downstream splice donor as shown in Fig. 11. 
The resulting plasmid was termed pTE RFP/GFP and consists of a strong adenoviral 
splice acceptor inserted in front of a loxP site, followed by a DsRed gene which was 
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Fig. 10  Rapid screening for inducible Cre constructs. 
(A) The X-linked HPRT locus of HM-1 ES cells harbours a spontaneous deletion of 50 kb including the promoter and the 
first two exons. This deletion of the HPRT locus is complemented by the HPRT targeting vector, together with the inducible 
Cre construct driven by its own promoter. The inducible Cre construct is inserted 5’ of the HPRT promoter. Selection 
procedure for homologous recombination will be done in HAT medium, for the presence of the HPRT gene product. 
Southern blot is performed for determination of homologous recombinant clones by a StuI digest. 
(B) A special Cre indicator (RRDR) was inserted before the HPRT targeting into the ubiquitously expressed ROSA26 locus. 
Before Cre-mediated recombination, the loxP-flanked DsRed gene is expressed. After deletion, the eGFP gene is turned 
on and the cell switches its fluorescence from red to green. 
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modified by introducing silent mutations and thereby inactivating two strong cryptic 
splice acceptors and by fusing a NLS to the N-terminus. Downstream is a neo gene 
flanked by two FRT sites, followed by the Westphal stop sequence (WSS) (Lakso et 
al., 1992), a second loxP site, and the eGFP gene. The FRT sites flanking the 
positive selection marker neo provide the possibility to remove neo by Flp 
transfection, since it was shown to negatively influence the expression of 
neighbouring genes (Pham et al., 1996). The WSS was introduced to prevent 
transcriptional read-through of the pA of the DsRed, which would lead to eGFP 
expression simultaneously to DsRed expression. For further reference, RRDR 
containing the loxP-flanked DsRed-stop cassette is termed RRDR-DsRed and the 
RRDR, from which this cassette has been excised, is termed RRDR-eGFP.   
 
Transient transfections of the RRDR into fibroblasts 
Transiently transfected fibroblasts of pTE RFP/GFP revealed strong fluorescence of 
the DsRed protein restricted to the nuclei of transfected cells (Fig. 11B). When a Cre 
coding plasmid was cotransfected, nearly all transfected cells exhibited green 
fluorescence in the cytoplasm (Fig. 11C), demonstrating that the DsRed/eGFP Cre 
indicator system works well in transient transfections.  
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Fig. 11  Transient transfection of the Cre indicator into fibroblasts. 
(A) Location of the Cre indicator after targeting into the ROSA26 locus. 
(B) 8x104 CV1-5B cells were transiently transfected with 1 µg pTE RFP/GFP or (C) with 1 µg pTE RFP/GFP together with 1 
µg pGKCre in a 6 well-plate. After two days, DsRed is expressed in the nucleus of CV1-5B fibroblasts and eGFP in nucleus 
and cytoplasm. 
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Knock-in of the RRDR indicator into the ROSA26 locus of HM-1 ES cells 
When the project was started, the ROSA26 locus was considered to be the best 
locus for the insertion of a Cre indicator construct. This locus was identified in a gene 
trap by Friedrich & Soriano (1991). Fig. 12 shows that the ROSA26 locus expresses 
two transcripts (transcripts 1 and 2) with no significant ORF and a third transcript in 
antisense orientation (transcript AS) which putatively encodes a protein. In the 
ROSA26 gene trap line, the adenoviral β−Geo gene trap construct was inserted into 
the first intron of ROSA26, disrupting transcripts 1 and 2 (Fig. 12). The transcript AS 
in antisense orientation was not affected by the gene trap insertion (Zambrowicz et 
al., 1997). The strong adenoviral splice acceptor (SA) in front of the β−Geo gene 
directed splicing from exon 1 of transcript 1 and 2 of ROSA26 to the SA of the β−Geo 
gene, which was then expressed by the endogenous ROSA26 promoter preceding 
exon 1. Transgenic mice harbouring the ROSA26 β−Geo insertion express β-
galactosidase in all cells at early developmental stages of mouse embryos and in all 
tissues of young mice. The targeting strategy used here resembles the integration of 
the adenoviral β−Geo vector into the first intron of the ROSA26 locus (Soriano, 
1999). Since it is now known that the expression level of the gene is relatively low 
(Mao et al., 2001), I modified the original strategy, i.e. the putative endogenous start
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Fig. 12 Transcripts of the ROSA26 locus. 
Major restriction sites of the genomic ROSA26 region are indicated together with the integration site of the β-Geo gene trap 
construct and the endogenous ROSA26 transcripts. Note that transcript 2 and transcript AS share homology. The asteriks 
at the end of transcript 2 indicates that its 3’ end is not yet determined. The figure is adapted from Zambrowicz et al., 1997. 
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codon in the first exon of transcripts 1 and 2 was replaced by a BamHI site in order to 
achieve higher expression levels of transgenes which are inserted into this locus. 
Independent targeting experiments with the ROSA26 targeting vector pRRDR 
containing the DsRed/eGFP Cre indicator (Fig. 13A) in HM-1 ES cells resulted in 
homologous recombination frequencies ranging from 1 in 5 to 1 in 10 as described 
previously (Soriano, 1999). ES cell clones harbouring homologous recombination 
events were identified by Southern blot: Homologous recombination leads to the 
appearance of a novel 7.2 kb band in addition to the 16 kb wild type band (Fig. 13B) 
in EcoRI digested DNA using Eco/Pac probe A (Fig. 13C). The cointegration of the 
BamHI site replacing the start codon (AUG) was detected by probing BamHI digested 
DNA with Xba/Sac probe B using Southern blot analysis (Fig. 13D). A band of 1.5 kb 
identifies clones in which the endogenous start codon was replaced by the BamHI 
site of the targeting vector, whereas clones retaining the start codon were identified 
by a 2.5 kb band. None of the homologous recombinant ES cell clones revealed 
DsRed expression using fluorescence microscopy (data not shown). Nevertheless 
clone D2 contained the correct integration of the Cre indicator, as verified by 
Southern blot and by sequencing the DNA of the Cre indicator from targeted ES 
cells. Subsequently, D2 ES cells were injected into blastocysts of C57BL/6 or CB20 
mice. This resulted in five chimeric mice, all of which transmitted the Cre indicator 
transgene through the germ line after backcrosses to C57BL/6 or CB20 mice. Germ 
line transmission was first identified by coat colour and then verified by Southern 
blotting and/or PCR using the primers ROSA-1 with ROSA-R and ROSA-G.  
 
Deletion of the DsRed-stop cassette in ES cells by HTNC treatment 
His-TAT-NLS-Cre (HTNC) can be used to efficiently mediate recombination of loxP-
flanked alleles in tissue culture (Peitz et al., 2002). HTNC is a highly purified Cre 
protein which is modified by fusing the TAT domain and a NLS sequence to the N-
terminus of Cre. These two domains enable the Cre protein to cross cell membranes 
and to mediate recombination. In order to test whether excision of the DsRed-stop 
cassette of the RRDR indicator leads to eGFP expression in D2 ES cells carrying the 
RRDR indicator insertion in the ROSA26 locus (Fig. 14A), 2x105 of these ES cells 
were plated on 6 well-plates for 5 h, 1 day or 3 days prior to HTNC treatment (Fig. 
14B). Subsequently, the cells were incubated with HTNC for 20 h, and the extent of 
excision of the loxP-flanked DsRed-stop cassette and eGFP expression was
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Fig. 13  Targeting of the Cre indicator RRDR into ROSA26. 
(A) RRDR targeting vector with major restriction sites. Short arm of homology (SAH) is elongated to 2.5 kb in comparison to 
the original pROSA26-1 targeting vector. The endogenous ROSA26 start codon is replaced by a BamHI site. The long arm of 
homology (LAH) is 4.2 kb with downstream negative selection marker diphtheria toxin A (DTA). The Cre indicator was 
inserted into the original XbaI* site resulting in its disappearance. 
(B) The ROSA26 genomic locus diplays bands in EcoRI and BamHI digested DNA of 16 kb and 5.8 kb, respectively. 
(C) After homologous recombination, Southern blot analysis of EcoRI digested genomic DNA with external probe A resulted 
in a 7.2 kb band (floxed) besides the 16 kb wild type band (WT). 
(D) In Southern blot analysis using internal probe B on BamHI digested genomic DNA, clones with the destroyed start codon 
displayed a 1.5 kb band (ATG), besides the 5.8 kb wild type band (WT).  
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determined by Southern blot and by fluorescence microscopy, respectively. Probing 
EcoRI digested DNA with probe A in Southern blot analysis showed 97% deletion in 
samples treated with 10 µM HTNC in medium containing FCS and 2 µM HTNC in 
medium without FCS for 5 h after plating, respectively. Excision of the DsRed-stop 
cassette became progressively less efficient the later HTNC was administered after 
plating of the ES cells (Fig. 14C). Therefore, it seems that HTNC works best on small 
ES cell colonies. Fig. 14D shows ES cell colonies with 50% deletion from sample 5, 
which were incubated with 2 µM HTNC w/o FCS at 3 days old colonies (Fig. 14C). 
The DsRed-stop cassette of the colony on the right of Fig. 14D was excised by HTNC 
as indicated by its green fluorescence, whereas HTNC failed to excise the loxP-
flanked target in the colony on the left. 
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Fig. 14 Deletion of the DsRed-stop cassette in RRDR ES cells by HTNC treatment. 
(A) Southern blot screening strategy for deletion of the DsRed-stop cassette. EcoRI digested DNA reveals a 16 kb wild type 
band (WT), a 7.2 kb RRDR-DsRed band and a 5.7 kb RRDR-eGFP band using probe A.   
(B) The His-TAT-NLS-Cre protein (HTNC) was highly purified by Ni-NTA column chromatography. The minimal TAT domain 
and the NLS sequence enable the native protein to cross membranes and to mediate recombination of floxed targets to a 
high extent. 
(C) Southern blot of ES cells incubated for 20 h with HTNC at indicated concentrations with or without (w/o) FCS.  
(D) RRDR ES cells (3 days old colonies) were incubated with 2 µM HTNC for 20 h resulting in 50% deletion. Upper part 
reveals two ES cell colonies and lower part the corresponding fluorescence photograph. 
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Fig. 15  PCR analysis of organs of chimeric mice generated from HTNC treated ES cells. 
(A) PCR screening to distinguish between RRDR-DsRed and RRDR-eGFP. Using a three primer approach, RRDR-DsRed 
is indicated by a 300 bp band generated by ROSA-1 and ROSA-R, whereas the RRDR-eGFP appears as a 340 bp band 
generated by ROSA-1 and ROSA-G.  
PCR analysis of genomic DNA from different organs removed from (B) chimera # 61, D2∆10 generated from RRDR-DsRed 
ES cells treated with 10 µM HTNC in 15% FCS and (C) chimera # 62, D2∆2, or (D) chimera # 63, D2∆2, or (E) chimera # 
64, D2∆2, all generated from RRDR-DsRed ES cells treated with 2 µM HTNC w/o FCS. 
 
HTNC treatment of ES cells could be a fast and useful technique for removing loxP-
flanked target sequences in vitro. Every chimera generated from the parental clone 
D2 transmitted the inserted transgene through the germ line. Therefore, ES cells 
from samples 1 (D2∆10) and 3 (D2∆2) of the previous experiment were injected into 
blastocysts to evaluate whether HTNC treatment affects the pluripotency of ES cells, 
i.e. the ability to give rise to germ cells in chimeric animals. Three chimeras were 
generated from both D2∆10 (#59, #60, #61) and D2∆2 (#62, #63, #64).Two chimeras 
generated from the former died before reaching breeding age. The remaining 4 
chimeras were bred to CB20. One animal of D2∆2 (#63) was sterile; the other three 
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did not transmit the transgene through the germ line in 10 litters. To determine 
whether parts of the organs of the chimeric mice were derived from ES cells, 
chimeras were sacrificed, DNA was prepared and analyzed by PCR. Since the ES 
cell preparations D2∆10 and D2∆2 both contained ES cells, in which HTNC treatment 
resulted in excision of the loxP-flanked DsRed-stop cassette (RRDR-eGFP), and ES 
cells where this did not occur (RRDR-DsRed), a PCR was designed to detect both 
versions of the RRDR indicator. Fig. 15A shows the PCR strategy used to distinguish 
between RRDR-DsRed and RRDR-eGFP. In this PCR, three primers were used in a 
single reaction. Amplification by the primers ROSA-1 and ROSA-R results in a 
product of 300 bp and indicates the presence of RRDR-DsRed. In the case of the 
RRDR-eGFP allele only the ROSA-1 and ROSA-G primers can anneal to DNA and 
will amplify a 340 bp PCR product. Fig. 15B, C, D and E display the results of PCR 
reactions performed on DNA isolated from the indicated organs of chimeras #61, 
#62, #63 and #64. All organs of chimera #61 showed the band amplified from RRDR-
eGFP except in thymus and testis. All organs of chimera #62 and #63 were positive 
for the RRDR-eGFP by PCR depicted in Fig. 15C and D. Fig. 15E displays PCR 
reactions performed on DNA isolated from organs of chimera #64. Except the liver, 
all organs of chimera #64 were partly derived from ES cells.  
 
In toto, this experiment indicates that ES cells which have been transduced by HTNC 
are able to give rise to all tissues of the mouse including testis and ovary. However, 
the chimeric mice consisting of wild type and transgenic cells failed to transmit the 
RRDR-eGFP allele to the offspring. This might be due to the fact that the germ cells 
were not derived from the transduced ES cells or that germ cells derived from HTNC- 
treated ES cells were not able to give rise to fertility. 
Fig. 16  Flow cytometry of 
RRDR splenocytes to detect 
DsRed. 
Splenocytes isolated from wild type 
(WT), RRDR/+, RRDR∆neo/+ and 
RRDR/RRDR homozygote mice 
were labelled with CD19 FITC. 
RRDR∆neo/+ are mice in which the 
neo gene of the DsRed-stop 
cassette was deleted by the Flpe 
deleter. Dead cells were excluded 
from analysis by TOPRO-3. 
DsRed
WT
RRDR/+ RRDR∆neo/+ RRDR/RRDR
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Detection of DsRed in mice with the RRDR indicator 
To explore DsRed expression in RRDR/+ mice, in RRDR/RRDR mice and in 
RRDR∆neo/+ mice, all major organs were removed and analyzed by fluorescence 
microscopy. None of the organs revealed any red fluorescence (data not shown). 
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Fig. 17  Transduction of HTNC into RRDR splenocytes activated ex vivo by LPS. 
(A) Southern blot screening strategy for deletion of the DsRed-stop cassette. Probe B detects the 11.5 kb WT band of 
EcoRV digested DNA, the RRDR-DsRed band of 7 kb and the RRDR-eGFP band of 2.5 kb, respectively.  
(B) The HTNC protein was highly purified by Ni-NTA column chromatography. The minimal TAT domain and the NLS 
sequence make HTNC permeable to membranes. 
(C) Southern blots of ex vivo RRDR and (D) RAGE-EG splenocytes treated for 20 h with 10 µM HTNC in 15% FCS (lane 
1), 2 µM HTNC w/o FCS (lane 2) and control (lane 3). Deletion efficiencies are indicated as percent. Southern blot 
screening strategy for Cre-mediated excision of the RAGE-EG indicator is shown in Fig.24A. 
(E) LPS activated splenocytes were labelled with CD19PE and eGFP expression was analyzed by flow cytometry.  
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Splenocytes isolated from these mice were stained with CD19 FITC and CD5 Cyc 
and analyzed by FACS. TOPRO-3 was used to exclude dead cells from the analysis. 
No DsRed expression was observed in either T cells (CD5 positive, data not shown) 
or B cells (CD19 positive, (Fig. 16)). Fig. 16 shows the FACS analysis of the 
splenocytes isolated from the above mentioned mice. Cells shifted in the red channel 
of the dot blot are either contaminating erythrocytes or dead cells. 
:"  -&.()
 (
.
"(  
:(",-&.>)

 .
-&."(
,
,
	
)


,
,
	
)



B
	


(



)




 
(
@

?

!
B
)

:  ,-&./0)

	
 .
-&./"(

,,
,,
,,
 
 
 
 
 A 
 
 
 
 
 
 
B 
 
 
 
 C 
 
 
 
 
 
 
 
 
 
Fig. 18  RT-PCR of HTNC transduced RRDR/+ splenocytes. 
(A)  Detection of endogenous ROSA26 transcript 1. cDNA from wild type (lane 1), non-transduced (lane 2) and 2 µM HTNC 
treated (lane 3) RRDR/+ splenocytes is used in PCR with primers R512 and R31. The correctly spliced transcript 1 
appears as a 533 bp band in all samples. 
(B) Detection of the DsRed transcript. PCR is carried out using primers R512 and ROSA-R1. The correctly spliced DsRed 
transcript is 250 bp. 
(C) Detection of the eGFP transcript. PCR reaction was performed using primers R512 and ROSA-G. The correctly spliced 
eGFP transcript PCR product has a size of 330 bp. 
All bands were isolated from the gel, cloned in pGEM Teasy and confirmed by sequencing. 
Deletion of the DsRed-stop cassette by HTNC in LPS activated splenocytes 
In order to test whether eGFP is expressed from the ROSA26 locus, I isolated 
splenocytes from either RRDR/+ mice (Fig. 17A) or RAGE-EG/+ mice (Constien et 
al., 2001) and incubated them with 2 µM HTNC (Fig. 17B) in DMEM w/o FCS in order 
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to delete the loxP-flanked DsRed-stop cassette. After 20h, an excess of B cell 
medium, supplemented with 20 µg/ml LPS was added and cells were kept in culture 
for further three days. Deletion efficiencies of the loxP-flanked regions of RRDR/+ 
and RAGE-EG/+ were determined by Southern blotting and were about 80% in both 
cases (Fig. 17C and D). No difference could be observed between HTNC transduced 
and non-transduced splenocytes in terms of cell number and expression of eGFP 
determined by FACS (Fig. 17E). From these cells, mRNA was isolated and subjected 
to RT-PCR using primers for amplification of transcripts of the endogenous transcript 
1 of ROSA26, DsRed and eGFP (Fig. 18). All samples contained the correctly spliced 
transcript 1 as indicated by a band of 533 bp (Fig. 18A). Non-transduced splenocytes 
of RRDR/+ mice only show the DsRed transcript detected with the primers R512 and 
ROSA-R1 by PCR (Fig. 18B), whereas the eGFP transcript is only present in 
splenocytes transduced by HTNC, indicating the presence of a functional RRDR-
eGFP allele (Fig. 18C). In addition, transduced splenocytes contained less DsRed 
mRNA compared to non-transduced splenocytes. 
 
The residual DsRed mRNA present in RNA preparations of HTNC-treated RRDR 
splenocytes is presumably due to the remaining 20% cells retaining the RRDR-
DsRed allele, in which Cre-mediated excision did not take place (Fig. 17C). All PCR 
products had the expected sizes and subsequent sequencing of the fragments 
confirmed their identity as properly spliced transcripts. In DsRed and eGFP 
transcripts, the start AUGs on the mRNA were those, which had been introduced.  
 
Deletion of the DsRed-stop cassette in vivo by the Cre expressing mouse 
strains CD19-cre and deleter 
RRDR-DsRed/+ mice were crossed to CD19-cre mice (Rickert et al., 1997) and 
deleter mice (Schwenk et al., 1995) in order to delete the loxP-flanked DsRed-stop 
cassette from RRDR-DsRed specifically in B lymphocytes or ubiquitously in all cells 
of the mouse, respectively. FACS analysis of splenocytes and fluorescence 
microscopy of all major organs revealed no difference between CD19-cre/+; RRDR/+ 
or deleter; RRDR-eGFP/+ and control mice (Fig. 19A and data not shown). Western 
blot analysis of lysates from all major organs using antibodies against eGFP did not 
reveal any significant eGFP expression (Fig. 19B). Only in lysates prepared from 
offspring of RAGE-EG/+ mice intercrossed with the deleter (RAGE∆/+),  which were 
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shown to express eGFP at high levels (Constien et al., 2001) and which were used 
as positive controls, the eGFP protein was detected by FACS (Fig. 19A) and Western 
blot (Fig. 19B), respectively. Nevertheless, eGFP mRNA could be detected by RT-
PCR performed with RNA isolated from spleens of CD19-cre/+; RRDR/+ mice, 
deleter; RRDR-eGFP/+ mice and deleter; RAGE∆/+ mice (Fig. 20). 
The fact that eGFP mRNA, but not protein could be detected in spleens of CD19-
cre/+; RRDR/+ and deleter-cre; RRDR-eGFP/+ could mean that the mRNA 
expressed from the RRDR-eGFP allele is not translated efficiently. Alternatively, 
eGFP protein is not expressed by the RRDR-eGFP allele at levels sufficient for 
detection in FACS and Western blot. Ultimately, this suggests that, although the 
DsRed/eGFP indicator construct is functional in principle, fluorescent proteins are not 
expressed, or not at sufficient levels to be used as a convenient indicator for Cre-
mediated recombination.     
A 
Fig. 19 Detection of eGFP in 
mice. 
(A) FACS analysis of splenocytes 
isolated from the indicated mice. Cells 
were labelled with CD19 PE.  
(B) Western blots of various organs of 
the indicated mice using α-eGFP 
antibody.   
B 
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Fig. 20  mRNA expression of DsRed and eGFP in splenocytes. 
Using RNeasy mini kit, mRNA from 106 splenocytes of different mice was prepared. RT reaction was carried out to produce 
cDNA, which was subsequently amplified in PCR with the primers indicated in (A) for ROSA26 transcript 1, in (B) for 
ROSA26 DsRed, in (C) for ROSA26 eGFP and in (D) for general eGFP.    
 
3.3 The inducible Cre*PR system 
 
Activity of various inducible Cre constructs 
Cre activity of CrePR fusion proteins can be controlled by the synthetic steroid 
RU486 (Kellendonk et al., 1996). A fusion of NLS Cre (Cre containing the nuclear 
localisation signal NLS) to the ligand binding domain (LBD) of the progesterone 
receptor (PR) ranging from amino acid 641 to 891 has been used to achieve 
inducible recombination in brain (Kitayama et al., 2001) and heart (Minamino et al., 
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2001). However, background activity in the absence of inducer occurs and 
administration of inducer leads only to incomplete recombination. The C-terminal 
deletion mutant PR891 (Fig. 5) is insensitive to the natural ligand progesterone, but it 
still has high affinity for the synthetic ligand RU486 (Kellendonk et al., 1996).  
In order to improve the inducibility of the system, new constructs were generated. 
Besides PR891 deletion mutants, I also cloned C-terminally extended versions 
ending with amino acid 914 of the PR, since previous reports suggested that PR914 
mutants have a higher sensitivity to RU486 (Wang et al., 1997b; Xu et al., 1996). At 
the N-terminus of the PR-LBD, I introduced new truncations resulting in constructs 
starting with amino acids 650 and 676, respectively. These modifications are 
expected to decrease accessibility of the CrePR to proteases due to the shorter 
linker between Cre and PR (Fig. 6). Activity assays and dose response experiments 
were performed with constructs containing the new LBDs in combination with Cre 
lacking the first 18 amino acids, which were suggested to be devoid of structural and 
catalytic functions (Guo et al., 1997; Wierzbicki et al., 1987). Each construct was 
cloned into the same expression vector, pNN265E-bPA, containing a CMV promoter, 
a synthetic intron, and a bovine polyadenylation signal (Fig. 6). In activity assays, 
8x104 CV1-5B cells were plated on a 6 well 24 h prior to transfection and then 
transfected with 1 µg of test plasmids together with 1 µg of pHD2-AP encoding 
alkaline phosphatase in order to determine transfection efficiencies. After 12 h, cells 
were split into two wells of a 12 well-plate and medium was supplemented either with 
100 nM RU486 or with control medium. Three days later, cells were fixed and stained 
first for β-galactosidase activity.   
β-galactosidase is expressed upon Cre-mediated excision of the loxP-flanked stop 
cassette of the reporter construct, which is stably integrated into the CV1-5B 
genome. Subsequently, cells were stained for alkaline phosphatase to monitor 
transfection efficiencies. In each well, blue (indicating β-galactosidase activity) and 
red (indicating alkaline phosphate activity) cells were counted in three different areas. 
The ratio of blue to red cells was determined and the ratio obtained with unmodified 
Cre was set to 100%. Each experiment was conducted at least in triplicate. Fig. 21 
compares the activities of the CrePR constructs with different lengths of the LBDs. 
Constructs encoding LBDs PR676-914 or PR 676-891 fused to Cre show the lowest 
maximal activity in the presence of inducer, but also the lowest background activity. 
The Cre19PR650-891 and Cre19PR650-914 exhibit the same maximal activity of 
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about 40% of authentic Cre and background activities of about 10% in the absence of 
RU486. The resulting ‘induction factors’ are shown in Fig. 21A. The term ‘inducibility’ 
will be used to describe the fold increase of Cre activity after addition of inducer 
relative to the background activity in the absence of inducer.  
 
Dose response assays demonstrated that the two PR914 versions retain a higher 
affinity to the inducer. In these experiments, 5 µg of pNNCre19PR676-914, 
pNNCre19PR676-891, pNNCre19PR650-914 and pNNCre19PR650-891 were 
transfected in 8x105 CV1-5B fibroblasts plated on a 9 cm dish. After 12 h, cells were 
trypsinized and split into seven wells in a 6 well-plate format, containing different 
concentrations of RU486. Seventy two hours after transfection, cells were stained for 
A B
Fig. 21  Quantitative analysis of recombinase 
activities of various CrePR fusion proteins. C (A) Reporter cells were transfected with different Cre19PR 
expression vectors and cultured in the presence (+) or absence (-) 
of 100 nM RU486. Three days later, the relative β-galactosidase 
activity was determined as described in Materials and Methods. 
The columns show mean values of at least three different 
transfections with standard deviations indicated by vertical lines. 
(B) Dose response analysis of different Cre19PR fusions. Reporter 
cells were transfected with the indicated constructs and cultured in 
the presence of various concentrations of RU486. No β-
galactosidase activity was detected in the presence of 1 µM 
progesterone. (C) Comparisons of activities of different Cre fused 
to PR676-914. The mean value from six different transfections are 
depicted with standard deviations indicated by vertical lines. 
Cre19, truncated Cre lacking the first 18 amino acids; hCre, 
humanized Cre; Cre2, full length Cre. 
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β-galactosidase and counted as described above. For each CrePR construct the β-
galactosidase activity obtained with the maximal concentration of inducer (1 µM) 
minus the background activity obtained in the absence of inducer was set to 100%. β-
galactosidase activities obtained with lower RU486 concentrations were expressed 
as proportion (percent) of this maximal activity for each individual construct. Each 
experiment was performed in duplicate and mean values are given in Fig. 21B. The 
CreLBD construct with PR676-914 has a half maximal activity (C50 value) of 0.04 nM, 
whereas the other constructs used in this analysis display C50 values that are at least 
one order of magnitude lower.  
 
Based on these results, further investigations concentrated on the construct 
displaying the lowest C50 value (concentration of half maximal activity) and the 
highest inducibility, namely Cre19PR676-914. This construct contains a truncated 
Cre recombinase lacking the first 18 amino acids at the N-terminus. In order to 
investigate the influence of both N-terminal truncation and optimization of codon 
usage for Cre, PR676-914 was fused to a Cre encoding cDNA which codon usage 
was improved for the expression in mammalian cells (Shimshek et al., 2002), 
designated hCre below, encoding either full length (hCre2) or a truncated Cre lacking 
the first 18 aa (hCre19). A comparison of the recombinase activities of these 
constructs with the corresponding truncated phage CrePR fusion (Cre19PR676-914) 
relative to unmodified Cre shows that both truncated Cre19PR variants containing 
either hCre or phage Cre display higher recombinase activity (26% of Cre) than the 
full length hCre (16%) in the presence of inducer (Fig. 21C). The background activity 
is slightly higher in case of the hCre constructs (5%) as compared to the construct 
originating from phage Cre (3%).    
 
Analysis of aberrant splice events 
Since the CrePR system is intended to be used as a genetic switch in mice, it has to 
be taken into account, that aberrant splicing of the CrePR-encoding mRNA may 
occur depending on the sequence context of the integrated construct. In order to 
check the presence of cryptic splice sites in the CrePR constructs, computer aided 
analysis of different CrePR mRNAs was performed using the programs GeneFinder 
and Splice Site Score Calculation. According to this analysis, wild type Cre contains 
four distinct sites displaying similarity to the consensus sequence of splice donors 
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(Fig. 22). Two of these cryptic splice donors are located at the 3’ end of the Cre 
gene. The PR-LBD fusion partner contains at least three sequences within the region 
coding for PR650-914 that show high similarity to the splice acceptor (SA) consensus 
sequence. SA (8.3) and SA (11.2) were shown to be used in alternatively spliced 
isoforms of the PR (Balleine et al., 1999; Leygue et al., 1996). In RT-PCR 
experiments, a cryptic spliced CrePR product could be isolated, in which splicing 
occurred from SD (5.8) to SA (11.2) (Fig. 22) (Wunderlich, 1999). This cryptically 
spliced mRNA can result in a C-terminally truncated translation product because of a 
premature stop codon.  
A 
&.;#9=
&>;"9 = &>;"9#=

&.;!9 =
&>;"9=
&>;%9=
&.;(9#=
%

",%!&&
&.;$9 =
&.;!9#= &.;"9 = &.;!9 =
&>;$9%=
:%

",%!
&.;$9 =&.;(9#=
&>;%9=
&&
%
B
 
Fig. 22 Map of cryptic splice sites within mRNAs of (A) Cre19PR650-914 and (B) hCre19PR650-
914. 
Potential splice donors (SD) and acceptors (SA) are shown together with calculated scores in parentheses, which express 
how well the splice sites fit to the consensus sequence. Cryptic splice sites were identified by using the program 
GeneFinder (http://dot.imgen.bcm.tmc.edu:9331/gene-finder/gf.html). The corresponding scores were calculated by the
program splice site score calculation (http://www2.imcb.osaka-u.ac.jp/splice/score.html). For example, a 100% match to 
the mammalian 3’ splice site corresponds to a score of 14.2. A perfect 5’ splice site would have a score of 12.6. The mean 
scores of the 5’ and 3’ splice sites in constitutive exons were 8.1 and 7.9, respectively. Sites that proved to function in a 
physiological context are shown in bold. SS, splice substrate.  
 
I wanted to prevent that unwanted splicing which could result in truncated, 
constitutively active forms of CrePR due to a partial loss of the PR-LBD. Three of the 
potential splice donor sites in the hCre gene had been eliminated by introducing 
mammalian codon usage (Shimshek et al., 2002). However, one cryptic donor site 
was still present in the hCre gene (SD (8.9) in Fig. 22B). Since a silent mutation is 
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insufficient to unambiguously suppress the risk of splicing at this position, an amino 
acid substitution was introduced at the codon 336 of hCre by mutation of GTG (Val) 
to GCG (Ala) (Fig. 22). This mutation is expected to completely prevent splicing at 
this position, since the indispensable GT for splice donors is abolished (Fig. 23). 
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Fig. 23 Alignment of codons 335-337 of phage Cre, humanized Cre and its V336A mutant
compared to the consensus sequence of splice donor sites. 
The boxed GT indicate those nucleotides which are critical for splicing. Bases in bold indicate identity to the consensus 
sequence. 
Activity of the Cre*PR constructs 
The hCreV336A, designated Cre* below, was fused to either the LBD of PR676-914 
or the LBD of PR650-914 and the inducibilities were compared in activity tests to the 
corresponding phage Cre constructs consisting of Cre19PR676-914 and 
Cre19PR650-914. Unmutated CrePR676-914 displays a recombinase activity of 
2.5% in the absence of RU486, whereas the mutant Cre*PR676-914 exhibits at least 
a 10-fold decreased background activity of 0.2% (Fig. 24), close to the detection limit.  
No significant difference was observed with respect to the maximal activity of both 
PR676-914 constructs (26%), irrespective of the mutation. Due to the reduced 
background activity of Cre*PR676-914, it has an inducibility of 128-fold, compared to 
10-fold for CrePR676-914. 
 
As demonstrated in Fig. 21A, the maximal activity of the Cre19PR650-914 construct 
is significantly higher than that of the N-terminally truncated Cre19PR676-914 
version, but this is accompanied with a higher background activity. However, by 
introducing the V336A mutation into Cre*PR650-914 construct, the background 
activity was reduced at least 25-fold to a negligible level. The maximal activity of the 
Cre*PR650-914 fusion protein in the presence of RU486 was 40% of that of 
authentic Cre, enhancing the inducibility to 200-fold (Fig. 24) (Wunderlich et al., 
2001).  
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 Fig. 24 Recombinase activities of various CrePR 
fusion proteins containing a V336A mutation 
within Cre in comparison to corresponding 
unmutated constructs. 
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White columns correspond to unmutated phage Cre and 
black columns represent mutated CreV336A. CV1-5B 
reporter cells were transfected with different Cre19PR 
expression vectors and cultured in the presence (+) or 
absence (-) of 100 nM RU486. Three days later the relative β-
galactosidase activity was determined as described in 
Materials and Methods. The columns show mean values of 
three different transfections with standard deviations indicated 
by vertical lines.
 
 
 
 
 
 
 
In order to compare the previously described CrePR1 system (Kellendonk et al., 
1996) with the newly generated Cre*PR system, the CrePR1 open reading frame 
was cloned into the pNN265E-bpA vector. A side by side comparison of the two 
systems is shown in Fig. 25. Cre*PR exhibits a dramatically reduced background 
activity as compared to CrePR1, whereas both constructs show the same maximal 
activities of 50% in the presence of RU486 (Fig. 25A). Dose response analysis 
revealed the increased sensitivity of PR650-914 to RU486, due to the elongation of 
the C-terminus of PR-LBD. The C50 value of Cre*PR is at least 10 times lower than 
that of CrePR1 (Fig. 25B).  
 
Fig. 25 Comparative analysis of inducible Cre recombinase activities of the improved Cre*PR 
system and the previously published CrePR1 system. 
(Α) CV1-5B reporter cells were transfected with the different CrePR1 or Cre*PR650-914 expression vectors and cultured in 
the presence (+) or absence (-) of 100 nM RU486. Three days later the relative β-galactosidase activity was determined as 
described in Materials and Methods. The columns show mean values of three different transfections with standard 
deviations indicated by vertical lines. (B) Dose response analysis of CrePR1 and Cre*PR650-914. Reporter cells were 
transfected with the indicated constructs and cultured in the presence of various concentrations of RU486. 
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Before using the Cre*PR system for the generation of inducible mouse strains, I 
attempted to completely prevent cryptic splicing of Cre* to PR-LBD. In order to 
achieve this, a version of the PR-LBD beginning with amino acid 678 was designed 
in which the amino acids S676 and P677 were mutated to glycines. Thereby, the SA 
(11.2) of the PR shown in Fig. 22 is mutated such, that it does not exhibit any 
similarity to the consensus of splice acceptors any more. Comparisons of 
Cre*PR676-914, Cre*PR650-914 and Cre*PR678-914 with the corresponding phage 
Cre constructs in activity assays are shown in Fig. 26. The data obtained with 
Cre*PR676-914 and Cre*PR650-914 shown in Fig. 24 were confirmed, whereas the 
newly generated Cre*PR678-914 shows the same properties as Cre*PR650-914: A 
dramatically reduced activity in the absence of inducer and a similar activity in the 
presence of RU486. Accordingly, the Cre*PR678-914, designated Cre*PR below, 
was used to establish the Cre*PR system in mice. 
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Fig. 26 Comparison of recombinase activities of different Cre*PR fusion proteins with unmutated 
constructs. 
White columns correspond to unmutated phage Cre, black columns represent mutated Cre*PR constructs. CV1-5B 
reporter cells were transfected with different Cre19PR expression vectors and cultured in the presence (+) or absence (-) 
of 100 nM RU486. Three days later the relative β−galactosidase activity was determined as described in Materials and 
Methods. The columns show mean values of three different transfections with standard deviations indicated by vertical 
lines. 
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3.4 Targeted insertion of Cre*PR into ubiquitously expressed loci 
In order to achieve ubiquitous, RU486 dependent deletion of loxP-flanked target 
genes in mice, three different approaches were followed: Cre*PR was inserted into 
the HPRT locus under the control of either the CAGGS or the EF1α promoter, or into 
the ROSA26 locus under the control of the endogenous ROSA26 promoter.     
 
3.4.1 Knock-in of CAGGS- and EF1α-driven Cre*PR into the HPRT locus of 
RRDR ES cells 
Since Cre*PR678-914 (designated Cre*PR) showed the best properties in in vitro 
experiments, it was used for generating constructs allowing the introduction of the 
transgene into defined loci of the mouse genome. According to the original strategy 
depicted in Fig. 10, Cre*PR constructs expressed under the control of the CAGGS or 
the EF1α promoter were targeted into the HPRT locus of RRDR ES cells. 
Successfully targeted ES cells were identified on day 9 of HAT selection and picked 
as single clones. Subsequently, HT medium was applied for the next 5 days to dilute 
out aminophterin, since it is thought to interfere with proper blastocyst development. 
Subsequently, the cells were cultured in normal ES cell medium. Southern blot 
analysis of StuI digested genomic DNA using an internal probe against the Cre* part 
of Cre*PR revealed correctly targeted clones and excluded random integration sites 
of the transgene (Fig. 27). Targeting frequencies were always 100%, i.e. each 
surviving ES cell colony arose from a homologous recombinant. When 107 ES cells 
were transfected with 30 µg of the targeting vector, usually 20 to 30 colonies were 
observed after selection. The same proportion was obtained, when 10 times less 
cells were transfected with 10 times less DNA, resulting in 2 to 3 colonies per 
transfection. 
 
Analysis of CAGGS- and EF1α-driven Cre*PR in RRDR ES cells 
In order to test RU486 inducible recombinase activity in RRDR ES cells, ES cell 
clones containing homologous integrations of the RRDR-DsRed allele and CAGGS 
Cre*PR or EF1α Cre*PR were treated with 100 nM RU486 for 16 days as detailed in 
Fig. 28. Southern blotting using a probe to detect the RRDR indicator showed RU486 
inducible Cre activity in the CAGGS Cre*PR clone, but not in that clone in which 
Cre*PR was expressed from the EF1α promoter (Fig. 28B, C). No recombination was 
observed in both cases in the absence of inducer. To detect the Cre*PR protein in 
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ES cells, Western blot analysis was performed with whole ES cell lysates using a 
polyclonal anti-Cre rabbit serum. In lane 1 of Fig.28 D, the lysates from clone 9 of the 
CAGGS Cre*PR were loaded and a specific band of 67 kDa was observed, whereas 
no significant signal was detected in EF1α Cre*PR lysates (lane 2).  
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In order to examine whether high degrees of recombination of the DsRed-stop 
cassette can be achieved with the CAGGS Cre*PR, RRDR-DsRed/CAGGS Cre*PR 
ES cells were treated with 100 nM RU486 for 22 days. Cells were trypsinized every 
second day to keep the cells undifferentiated and to synchronize the cell cycle. 
Southern blot analysis revealed absence of Cre-mediated recombination in samples 
without RU486, but up to 81% deletion of the RRDR indicator after 22 days (Fig. 
29C). 
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Fig. 27 Knock-in of CAGGS Cre*PR and EF1αCre*PR into HPRT locus of RRDR ES cells. 
The HPRT locus of HM-1 ES cells contains a spontaneous deletion of 50 kb including the promoter and the first two exons 
of the HPRT gene. With the targeting vector (pMP10) the HPRT gene is complemented. This targeting event can be 
selected with HAT medium. Upstream of the HPRT promoter, the Cre*PR either driven by the CAGGS or the EF1α
promoter was inserted. Homologous recombination can be confirmed in Southern blots of StuI digests. A probe against 
Cre* was used and in correctly targeted clones appeared a 8.5 kb band. Since StuI cuts only once in the construct, also 
random integrants can be excluded from analysis. Size marker was the λ-Hind from Gibco.  
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Fig. 28 Cre*PR in RRDR ES cells. 
(A) Knock-in constructs in the HPRT locus of RRDR ES cells. Cre*PR is either expressed from EF1α or CAGGS promoter. 
(B) Knock-in construct of the RRDR Cre indicator in the ROSA26 locus. The locus is shown before (RRDR-DsRed) and 
after Cre-mediated excision of the DsRed-stop cassette (RRDR-eGFP) with indicated sizes of DNA fragments.  
(C) 2x105 twice targeted ES cells of EF1α Cre*PR and CAGGS Cre*PR were treated with 100 nM RU486 for the indicated 
days. Genomic DNA of samples were digested with EcoRV and used in Southern blot against the indicator as shown in B. 
(D) Western blot of cell lysates from ES cells of CAGGS Cre*PR (1), EF1αCre*PR (2), wild type (3), ROSACre*PR (4) and 
spleen of CD19-cre-/+ (5). Sizes of proteins were estimated by comparison to a standard protein marker from NEB.  
A 
Fig. 29D shows an experiment, which should address the question, whether there is 
a difference in deletion efficiency when adding the inducer only once or four times. 
RU486 at a concentration of 1000 and 100 nM, respectively, was added only once or 
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four times to the cells by daily exchanging the medium and cells were kept in culture 
for the period of four days. Southern blotting using a probe to detect the Cre indicator 
revealed that Cre-mediated excision was influenced in a dose dependent manner of 
RU486. Also, Cre*PR activity was increased when the inducer was added four times 
with 1000 nM and 100 nM, respectively (Fig. 29D).   
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Fig. 29 Kinetics of CAGGS Cre*PR in RRDR ES cells
ES cells were targeted twice into the ROSA26 locus (A) and the H
the WT, RRDR-DsRed and RRDR-eGFP alleles in Southern blots. 
targeted ES cells were treated with 100 nM RU486 for the indicated
(D) Dose dependence of Cre*PR on RU486. 2x105 cells were trea
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structure and pharmacokinetics (Kloosterboer et al., 1994). Also, Org31710 is much 
better soluble in the vehicles trioctanoin and sesame oil, which have to be used for 
the applications in mice. 2x105 twice targeted ES cells of clone K9 (CAGGS Cre*PR 
in HPRT, RRDR in ROSA26) were plated on 12 wells and inducer (RU486 or 
Org31710) was applied once at the indicated concentrations (Fig. 30B, C). Cells 
were grown for three days without changing the medium, then harvested and 
analyzed by Southern blot for the RRDR Cre indicator using a probe to detect eGFP 
on EcoRI digested DNA. In this case, the smaller 2.2 kb band indicates the loxP-
flanked Cre indicator RRDR-DsRed, whereas the appearance of the bigger 5.4 kb 
band shows deletion of the DsRed-stop cassette indicating the RRDR-eGFP (Fig. 
30A). In this experiment, RU486 could induce higher Cre*PR activity than Org31710, 
as assessed by excision of the loxP-flanked DsRed-stop cassette from the RRDR-
DsRed indicator in inducer-treated ES cells. In order to test the activity of RU486 in 
vivo, 8 week old mice were i.p. injected once with 2.5 mg RU486 either resuspended 
in trioctanoin or sesame oil. One and four hours after injection, blood was taken from 
the tail vein and serum was prepared. A 1/50 dilution of the sera was applied to 
RRDR/CAGGS Cre*PR ES cells and maintained on the cells for three days. 
Subsequently, cells were harvested and genomic DNA was prepared and analyzed 
by Southern blot as described above. Excision efficiencies of the RRDR indicator are 
shown in Fig. 30C. The sera taken from mice after 1 h induce Cre*PR activity 
corresponding to 1 µM of RU486. Sera taken 4 h after injection contained less, but 
still considerable RU486 activity (Fig. 30B, C).  
 
Since the CAGGS Cre*PR construct worked in ES cells, two clones (K1 and K9) 
were chosen for injection into C57BL/6 blastocysts. Clone K1 gave 11 chimeras with 
20 to 80% chimerism, clone 9 gave two female chimeras with 30% and 50% 
chimerism, respectively, as indicated by coat colour. Chimeras generated from clone 
K1 did not transmit the transgene through the germ line at all, whereas both chimeras 
generated from clone K9 did. All male progenies from this breeding with the right coat 
colour (in total four animals) carried the transgene as determined by Southern blot 
and/or PCR. None of the female offspring carried the transgene. Since the CAGGS 
Cre*PR construct was inserted into the X-linked HPRT locus, the male transgenic 
offspring had to be backcrossed again two times to obtain experimental male mice 
with the desired genotype.  
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Fig. 30 Dose response assays of CAGGS Cre*PR in RRDR ES cells. 
(A) Southern blot screening strategy to distinguish between RRDR-DsRed and the excised RRDR-eGFP allele. Using a 
probe against eGFP, the 2.2 kb band indicates the RRDR-DsRed and the 5.4 kb band the RRDR-eGFP allele.  
(B) Southern blot of twice targeted ES cells (CAGGSCre*PR in HPRT locus; RRDR in ROSA26 locus) treated with 
increasing doses of RU486 and Org31710. The four lanes on the right are from sera of mice injected i.p. with 2.5 mg 
RU486 dissolved in trioctanoin or sesame oil. Sera were taken at 1 h and 4 h after injection and applied to twice targeted 
ES cells for three days. Size marker belongs to the λ-Hind from Gibco. 
(C) Quantification of excision efficiencies was performed with Fuji Bias reader. Black bars correspond to samples treated 
with RU486; white bars show Cre*PR activities in the presence of Org31710. Dark grey bars indicate recombination 
efficiencies achieved with serum of mice injected with 2.5 mg RU486 in trioctanoin and light grey bars correspond to serum 
of mice injected with 2.5 mg RU486 in sesame oil.     
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3.4.1.1 Analysis of chimeras generated from RRDR/CAGGS Cre*PR ES cells 
Chimeras were generated from ES cell clones K1 and K9, which were targeted first in 
the ROSA26 locus with the DsRed/eGFP Cre indicator and then in the HPRT locus 
with the inducible Cre*PR (Fig. 31A and B). This allows to test the ubiquitously 
expressed Cre*PR driven by the CAGGS promoter in vivo. Chimeras showing the 
highest degree of coat colour chimerism were fed for 5 consecutive days with 5 mg 
RU486 dissolved in trioctanoin, or injected i.p. with 5 mg RU486, and subsequently 
kept under standard conditions for 5 additional days. Mice were sacrificed and DNA 
was prepared from all major organs indicated in Fig. 31C. 
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sFig. 31 Analysis of chimeras generated from RRDR/CAGGS Cre*PR ES cells. 
ES cells were targeted twice with the constructs shown in (A) and (B). Subsequently, they were injected into C57BL/6 
blastocyst and chimeric mice were generated. (B) PCR screening strategy to distinguish between RRDR-DsRed (300 bp) 
and excised RRDR-eGFP (340 bp) alleles. (C) Chimeras were either fed or injected i.p. with 5 mg RU486 in trioctanoin for 
5 consecutive days. Five days later, mice were sacrificed and genomic DNA was prepared from indicated organs and used 
in PCR experiments. (D) The sensitivity of the PCR screening was determined by dilutions of RRDR-eGFP (EG) DNA with 
RRDR-DsRed (Ds) DNA at indicated concentrations.  
outhern blotting to detect recombination events at the Cre indicator was not 
uccessful, even when a probe against the internal eGFP was used (data not 
hown). This indicates that the proportion of ES cell-derived cells in the chimeras was 
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not as high as expected from the coat colour observation. Therefore, deletion 
efficiencies were analyzed by a PCR approach, which was designed to detect the 
loxP-flanked RRDR-DsRed allele and the RRDR-eGFP allele of the indicator (Fig. 
31B). When using a three primer approach with the primer ROSA-1 in combination 
with the primers ROSA-R and ROSA-G (Table 4 under 2.2.8), it is possible to 
distinguish between the RRDR-DsRed (300 bp) and the excised RRDR-eGFP (340 
bp) alleles of the indicator on agarose gels. A band representing the RRDR-eGFP 
allele, resulting from Cre-mediated excision of the loxP-flanked DsRed-stop cassette 
from RRDR-DsRed, could only be amplified from mice which had been treated with 
the inducer, while untreated mice showed only the band amplified from the loxP-
flanked RRDR-DsRed allele (Fig. 31C). In order to test the sensitivity of this PCR 
approach, DNA of tails from RRDR-eGFP/+ and RRDR-DsRed/+ mice was prepared, 
and DNA from both preparations was mixed in various ratios. Decreasing dilutions of 
RRDR-eGFP/+ with RRDR-DsRed/+ DNA were used in PCR experiments to 
determine the detection limit of the RRDR-eGFP. One RRDR-eGFP allele can be 
detected in thousand RRDR-DsRed alleles in this three primer PCR. Therefore, the 
absence of the PCR product of the RRDR-eGFP allele from PCR reactions of 
RRDR/CAGGS Cre*PR chimeras which were not treated with inducers indicates the 
absence of background recombination, i.e. the ‘tightness’ of the Cre*PR system in 
this experiment (Fig. 31D).    
 
3.4.1.2 Analysis of the CAGGS Cre*PR system in vivo 
In order to further determine the in vivo inducibility of the CAGGS Cre*PR strain with 
a different indicator mouse strain, female CAGGS Cre*PR/+ mice were intercrossed 
with male mice of the genotype RAGE-EG-/- containing an eGFP indicator construct 
for Cre in the RAGE locus (Constien et al., 2001) (Fig. 32A). Since the CAGGS 
Cre*PR transgene is located on the X-chromosome, only male offspring were 
analyzed by PCR for the presence of the CAGGS Cre*PR transgene and used for 
further experiments. Four week old double transgenic males were i.p. injected with 
2.5 mg RU486 or 2.5 mg Org31710 daily for five days. Five days after the last 
injection, mice were sacrificed and organs were analyzed by fluorescence 
microscopy and flow cytometry. Only in positive controls (RAGE∆/+; deleter) 
widespread GFP expression could be observed (data not shown). To exclude the 
possibility that, in injected mice, Cre*PR induced recombination took place without 
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inducing GFP expression from the RAGE locus, DNA isolated from organs of these 
mice was analyzed by Southern blot using a probe to detect GFP. In KspAI digested 
DNA, the RAGE allele that underwent Cre-mediated recombination can be 
distinguished from the loxP-flanked allele as shown in Fig. 32A. A low degree of Cre-
mediated excision of exons II-VII could be observed in liver, kidney and brain of 
RU486 injected mice (~13%), whereas in Org31710 treated mice, excision took place 
only in liver (Fig. 32B). No Cre activity was observed in mice that were not injected 
with synthetic hormones. Since no recombination of the loxP-flanked target was
A 
B 
C D
Fig. 32 CAGGS Cre*PR in mice 
Female mice of the CAGGS Cre*PR strain were intercrossed with RAGE-EG-/- males to obtain male experimental mice. 
(A) Screening strategy for the deletion of the conditional RAGE-EG allele according to Constien et al. (2001).  
(B) Southern blot against GFP of KspAI digested DNA from organs of mice which were i p. injected with 2.5 mg of RU486 
and Org31710 daily for five days, respectively.  
.
(C) Southern blot of ex vivo splenocytes, which were kept in medium supplemented with LPS and increasing amounts of 
RU486 and Org31710.  
(D) Western blot against Cre of lysates from organs of the indicated mice.    
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observed in spleen, splenocytes were cultured in the presence of LPS and increasing 
doses of either RU486 or Org31710 in order to determine whether Cre activity could 
be induced in vitro. Three days later, these splenocytes were analyzed by flow 
cytometry. No GFP expression could be detected by FACS (data not shown). In 
accordance, Southern blot analysis of the DNA purified from these splenocytes did 
not reveal any recombination of the RAGE-EG reporter (Fig. 32C). Western blot 
analysis of CAGGS Cre*PR mice revealed, however, that Cre*PR was expressed in 
various organs (Fig. 32D).  
These data could indicate that the inducible Cre*PR system can only mediate 
recombination of loxP-flanked gene segments in vivo, when the Cre*PR fusion 
protein is highly expressed. This view is supported by the fact that the highest 
expression level of Cre*PR protein is detected in liver, as indicated by Western blot, 
and that Cre*PR mediates recombination in this organ in vivo upon injection of either 
RU486 or Org31710. The excision of the RAGE-EG reporter in kidney and brain of 
RU486 injected mice could be explained by high expression of the Cre*PR in defined 
subpopulations of cells in these organs, since Western blot analysis of lysates 
prepared from these organs revealed only intermediate (kidney) to low (brain) 
expression levels of Cre*PR.   
 
3.4.2 Knock-in of Cre*PR into the ROSA26 locus 
Knock-in strategies into the ROSA26 have been described to confer ubiquitous 
expression of transgenes in mice (Mao et al., 2001; Srinivas et al., 2001). In order to 
achieve ubiquitous expression of Cre*PR, the original strategy of Soriano (1999) was 
applied to insert the Cre*PR into this locus. After the initiation of this project, two 
publications appeared, in which the authors reported the knock-in of Cre fusion 
proteins in combination with the estrogen ligand binding domains into the ROSA26 
locus (Voojis et al., 2001; Seibler et al., 2003). Especially, the improved CreERT2 
version showed a high degree of inducible recombination after administration of the 
synthetic ligand tamoxifen to transgenic mice. The unwanted background activity in 
the absence of inducer appeared only when short loxP-flanked gene segments as 
that from the conditional allele of the retinoblastoma gene were crossed to the 
respective transgenes (Voojis et al., 2001; F.Schwenk, personal communication).  
The knock-in strategy of Cre*PR into the ROSA26 locus is shown in Fig. 33A. 
Southern blot revealed the 16 kb wild type band of EcoRI digested DNA probed with 
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the external Eco/Pac probe A and an additional 6.8 kb band in correctly targeted ES 
cell clones (Fig. 33B). ES cells from U.Strobel, which were previously targeted with a 
conditional allele for an artificial LMP1-CD40 construct into HPRT locus, were used 
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Fig. 33 Knock-in of Cre*PR into the ROSA26 locus. 
(A) Knock-in strategy of Cre*PR in ROSA26. In Southern blots of EcoRI digested DNA using probe A, the 16 kb wild type 
(WT) band appeared and a 6.8 kb band in correctly targeted clones. 
(B) Southern blot of homologous recombinant clones. Size marker is the λ-Hind from Gibco. 
(C) ES cells used for the knock-in of ROSACre*PR were targeted previously with a conditional LMP1-CD40 allele into the 
HPRT locus (Strobel & Rajewsky, unpublished). In Southern blots against LMP1 on SacI digested DNA, the floxed band 
appears at 5.3 kb, whereas a 3.9 kb band arises after Cre-mediated deletion of the WSS. Southern blot of twice targeted 
ES cells (F10) induced for the indicated days with 100nM RU486. Size marker is the λ-Hind from Gibco. 
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for the targeting of Cre*PR into the ROSA26 locus. This allows to test the efficiency 
of ROSACre*PR in ES cells (Fig. 33C). The targeting frequencies were 1 in 8 in this 
experiment and the two ES clones F10 and B11 were chosen for further experiments. 
Induction of Cre activity was achieved by supplementing the medium with 100 nM 
RU486 for 16 days. In order to test the extent of excision, genomic DNA was 
digested with SacI and probed with an internal LMP1 probe, which should detect the 
loxP-flanked LMP1-CD40 allele as a 5.3 kb band, whereas the allele from which the 
loxP-flanked stop cassette had been excised should display a band of 3.9 kb (Fig. 
33C). However, no recombination was observed in this experiment, even when ES 
cells were treated with HTNC, which has been shown to delete loxP-flanked DNA 
segments with high efficiency in ES cells. Expression of Cre*PR was shown in 
Western blot analysis, in which a band of 67 kDa appeared after incubation of 
membranes onto which protein extracts from ROSACre*PR ES cells had been 
blotted with the polyclonal Cre antiserum (Fig. 28D, lane 4). Correct integration and 
integrity of the inserted transgenic sequences into the genome of ES clones F10 and 
B11 was confirmed by sequencing. To this end, a 3.3 kb PCR product amplified from 
F10 and B11 DNA with the primers 5BstEIIROSA and 3PR914 containing the first 
exon of ROSA26, intronic sequences, and the Cre*PR ORF was sequenced. F10 
and B11 were then injected into C57/BL6 blastocysts. Chimeras from clone B11 
failed in germ line transmission, whereas a chimera of clone F10 (90% chimerism by 
coat colour) transmitted the transgene to its offspring at a high extent. Mice carrying 
the ROSA26Cre*PR insertion were further intercrossed to RAGE-EG-/- mice, pol-β 
flox/flox mice and RRDR/RRDR mice in order to test its applicability in vivo.   
  
3.4.2.1 Analysis of the ROSACre*PR system in vivo 
In order to test deletion efficiencies of ROSACre*PR in vivo, ROSACre*PR mice were 
intercrossed with conditional alleles for the DNA polymerase-β gene (Gu et al., 1994), 
the RAGE-EG gene (Constien et al., 2001) and the RRDR indicator.  
 
Double transgenic offspring carrying ROSACre*PR and pol-β flox/+ were either i.p. 
injected or orally fed with 5 mg RU486 for five days. Afterwards, mice were further 
kept for five days, before they were sacrificed. Several organs were isolated and 
genomic DNA was prepared for analysis by Southern blot. DNA isolated from organs 
of ROSACre*PR-/+; pol-β flox/+ was digested with BamHI and probed with the 900 
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bp pol-β probe to detect the wild type (10 kb), the loxP-flanked (4.5 kb) and the 
deleted (3 kb) alleles of pol-β (Fig. 34A). Fig. 34B shows that no inducible 
recombination of the loxP-flanked pol-β allele could be detected in any organ in the 
presence and absence of RU486. Also, in ex vivo splenocytes of these mice, which 
were isolated and kept in culture in the presence of 1 µM RU486, Cre*PR failed to 
excise the loxP-flanked allele (data not shown). In order to confirm that Cre*PR is 
expressed in vivo, cell lysates of all major organs were analyzed by Western blot 
(data not shown). This experiment revealed that Cre*PR is expressed in all the 
organs that were analyzed, but at various levels. Similar results were obtained with 
experimental mice of the genotype ROSACre*PR-/+; RAGE-EG-/+ (data not shown). 
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Fig. 34 ROSACre*PR in mice 
ROSACre*PR mice were intercrossed with pol-β flox/flox mice (Gu et al., 1994) to obtain experimental mice. (A) Screening 
strategy for the deletion of the conditional pol-β allele adapted from Gu et al. (1994). (B) Southern blot against the pol-β  
gene of organs from mice which were either i p. injected or orally fed with 5 mg RU486 daily for five days. Size marker was 
the λ-Hind from Gibco. 
.
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3.4.2.2 Analysis of ROSACre*PR in mouse embryonic fibroblasts 
Mouse embryonic fibroblasts (MEFs) of embryos of ROSACre*PR/RRDR-DsRed and 
RRDR-DsRed/+ were generated in order to test the functionality of ROSACre*PR in 
vitro. In addition, experiments with MEFs should address the question, whether the 
Cre*PR protein translocates to the nucleus upon binding of RU486 (Fig. 35A, C). In 
order to induce Cre*PR activity in these cells, 100 nM RU486 was added to 106 
MEFs. Two days later, cells were harvested and separated in two samples for the 
analysis by Southern and Western blots. No recombination of the DsRed-stop 
cassette was observed in the presence or absence of inducer (Fig. 35B). To test
Fig. 35 Cre*PR translocates to the nucleus 
upon binding of RU486, but does not 
recombine the DsRed-stop cassette in 
ROSACre*PR/RRDR-DsRed MEFs.
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106 MEFs of embryos with the genotype ROSACre*PR/RRDR-DsRed were seeded on 6 cm plates and induced with 100 
nM RU486. Two days later, cells were harvested analyzed by Western blot (A) and by Southern blot (B). (C) Schematical 
outline of the function of CrePR. (D) Sizes of DNA fragments obtained from these MEFs after EcoRV digest and probing 
with probe B in Southern blot analysis.  
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 whether the Cre*PR protein translocates to the nucleus upon RU486 treatment (Fig. 
35C), cytoplasmic and nuclear protein extracts were prepared from the MEFs by NP-
40 lysis and the cytoplasmic fractions were subsequently analyzed by Western blot. 
Complete MEF cell lysates served as controls (Fig. 35A). In the cytoplasmic fraction 
isolated from RU486 treated ROSACre*PR/RRDR-DsRed MEFs, nearly no Cre*PR 
protein could be detected, whereas a specific band for Cre*PR is present in non-
induced samples. To exclude the proteolytical degradation of the Cre*PR upon ligand 
binding, complete protein lysates of induced and non-induced MEFs were loaded as 
controls. In both samples, Cre*PR protein is present at equal amounts. These data 
suggest that indeed the Cre*PR protein translocates to the nucleus upon RU486 
binding as demonstrated by the disappearance of the Cre*PR protein from 
cytoplasmic fractions of induced MEFs, whereas the Cre*PR protein is present in the 
cytoplasm of non-induced cells. However, once in the nucleus, the Cre*PR does not 
recombine the DsRed-stop cassette of the RRDR indicator as shown by Southern 
blot (Fig. 35B). A possible explanation could be that the Cre*PR protein sticks at the 
nuclear pores and is not imported in the nucleus. However, this appears rather 
unlikely, since lysis of MEFs with 1% NP-40 to obtain the cytoplasmic fraction also 
solubilizes the nuclear envelope including the nuclear pore complexes (Wunderlich et 
al., 1976). By this method, the solubilized compartment of the nuclear envelope is 
therefore in the cytosolic fraction.      
 
3.5 B lymphocyte restricted expression of Cre*PR  
One step forward in inducible gene targeting is to restrict the inducible Cre system to 
certain cell types by the usage of cell type specific promoters. In order to achieve a B 
cell restricted expression of transgenes, the B cell specific CD19 locus was shown to 
be an excellent candidate for integration of transgenes (Zhou et al., 1992). CD19 is a 
B lymphocyte cell surface marker that is expressed early during pre-B cell 
differentiation and its expression persists until terminal differentiation into plasma B 
cells (for review, see e. g. Fearon, 1993). The murine CD19 gene (mCD19) is 
composed of 15 exons and is a member of the Ig gene superfamily. CD19 contains 
two extracellular Ig-like domains separated by a non Ig-like domain with a 
hydrophobic membrane-spanning domain and an extensive cytoplasmic domain. 
When Cre recombinase was knocked-in into the mCD19 locus, its expression yielded 
very efficient Cre-mediated excision of loxP-flanked target sequences in B 
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lymphocytes (Rickert et al., 1995). In this knock-in strategy, the ORF of the Cre was 
inserted into the second exon of the CD19 gene and it was attempted to mutate the 
endogenous start AUG of CD19. The targeting was successful, but replacement of 
the endogenous AUG codon could not be achieved (J. Roes, personal 
communication). A possible reason is that, in the CD19 targeting vector used, the 
short arm of homology was not long enough. Nevertheless, the CD19-cre mouse is 
an extremely useful tool for conditional gene targeting in B cells (Rickert et al., 1997).  
 
However, the original CD19-cre targeting vector has the disadvantage that it cannot 
be used for insertion of other transgenes. Therefore, I constructed a general CD19 
targeting vector termed pCD19, into which the gene of interest can be inserted with a 
single cloning step to achieve B cell specific expression (Fig. 9). In addition, the short 
arm of homology was elongated to increase the chances for cointegration of the 
mutated endogenous translation start of CD19 in comparison to the former strategy. 
Because of its importance for immunological experiments, I generated not only 
CD19Cre*PR (Fig. 36), but also CD19CreERT2 constructs (Fig. 9). At the time when 
the project was started, I had only access to sequence information of the 129 ola 
mouse strain and therefore amplified the homology arms of pCD19 from 129 ola 
genomic DNA. Nevertheless, targetings were not only performed in isogenic ES cells, 
but also in C57BL/6 derived ES cells (Kontgen et al., 1993), since the B6 genetic 
background is particularly well analyzed in the context of immunological experiments. 
These two ES cell lines do not differ with respect to restriction site polymorphisms in 
Southern blot analysis using at least seven different restriction enzymes in the 
mCD19 gene (data not shown).  
 
Targeting experiments were performed in HM-1 ES cells (Magin et al., 1992) and 
Bruce-4 ES cells (Kontgen et al., 1993), as already described. From each 
transfection, 130 G418 and GANC resistant ES cell colonies were isolated as single 
clones and their genomic DNAs were analyzed by Southern blot. The identification of 
a 9.4 kb band besides the 28 kb wild type band by probing SpeI digested DNA with 
the CD19 probe B indicates correctly targeted clones (Fig. 36A, B). From 130 HM-1 
clones only a single clone, C9, showed the additional band (Fig. 36). The targeting of 
Bruce-4 cells was not successful. A second digest of DNA isolated from clone C9 
with BamHI revealed the cointegration of the mutated start AUG in a Southern blot
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using CD19 probe A (Fig. 36C). Sequencing of a PCR fragment amplified with the 
primers 5NotEx1e and 3PR914 from the CD19 locus of clone C9 confirmed the 
expected sequences and clone C9 was therefore used for injection into blastocysts of 
CB20 or C57BL/6 donors. Backcrosses of the resulting chimeric mice led to germ line 
transmission and CD19Cre*PR mice were intercrossed with mice carrying the RRDR 
indicator and with a mouse strain which carries a conditional allele for the insulin 
receptor (Brüning et al., 1998).  
 
In order to examine the B cell specific expression of Cre*PR in CD19Cre*PR mice, I 
performed RT-PCR, Western blot analysis and flow cytometry (Fig. 37). B cells and T 
cells of the spleen were labelled with anti-B220 FITC and anti-TCR-β PE, 
respectively, and separated by FACS sorting. The purity of B cells and T cells was 
more than 95% after FACS sorting. Subsequently, mRNA of the purified lymphocytes 
from wild type mice and CD19Cre*PR-/+ mice were isolated and subjected to cDNA 
synthesis. The specific cDNA of Cre*PR expressed from the CD19 promoter was 
amplified with the primers 5BamEx1 and hCreintrev yielding a 440bp PCR product, 
when splicing from CD19 exon 1 is directed to the splice acceptor of Cre*PR (Fig. 
37B). The 440bp product appears only in splenic B cells of CD19Cre*PR mice, but 
not in splenic T cells (Fig. 37B). Sequencing of the PCR product verified the 
expected sequences and confirmed the correct splice junctions. In order to detect the 
Cre*PR protein, Western blot of 3x106 splenocytes from wild type mice, CD19-cre-/+ 
mice and CD19Cre*PR-/+ mice were performed with the polyclonal Cre anti-serum 
(Fig. 37C). The Cre*PR protein was detectable in lysates of spleen cells of 
CD19Cre*PR mice.  
 
Correct integration of Cre*PR into the CD19 locus was confirmed by flow cytometry 
of blood lymphocytes. Peripheral blood mononuclear cells (PBMCs) were isolated 
from the blood of CD19Cre*PR mice by Ficoll gradient centrifugation and stained with 
CD19 FITC to identify B lymphocytes (Fig. 37C). Both B cells from heterozygotes 
CD19-cre-/+ mice and those from CD19Cre*PR-/+ mice expressed only half of the 
CD19 molecules on their surface in comparison to wild type mice, whereas no CD19 
expression was observed on the surface of B cells from homozygotes CD19-cre-/- 
mice (Fig. 37C). Obviously, the Cre*PR is correctly integrated into the second exon of 
the CD19 gene.  
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A 
B 
C D
Fig. 37 B cell specific expression of CD19Cre*PR. 
(A) Insertion of Cre*PR in the CD19 locus. 
(B) RT-PCR of cDNAs from 106 sorted splenic T cells and B cells of wild type (WT) and CD19Cre*PR-/+ mice. Primers 
5BamEx1 and hCreintrev were used to amplify the correctly spliced 440bp product of Cre*PR expressed from CD19. 
(C) Western blot of 3x106 splenocytes from the indicated mice using a polyclonal Cre anti serum. 
(D) Blood lymphocytes were isolated by Ficoll gradient centrifugation and stained with CD19 FITC. Dot blots and 
corresponding histograms of the indicated mice are shown.  
 
In order to determine the inducibility of Cre*PR in B cells in vivo, CD19Cre*PR mice 
were intercrossed with the RRDR indicator mouse strain. Subsequently, mice 
carrying the CD19Cre*PR and RRDR-DsRed alleles were i.p. injected with 2.5 mg 
RU486 daily for five days, before sacrificing the mice and preparing single cell 
suspensions from bone marrow and spleen. Pro/pre B cells were purified as B220+, 
IgM- fraction by FACS sorting from bone marrow cells labelled with anti-B220 FITC 
and anti-IgM PE. Splenic B220+ cells were separated from splenic TCR-β+ cells by 
FACS sorting. DNA was prepared from 106 cells in order to detect the loxP-flanked
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Fig. 38 Inducibility of CD19Cre*PR in vivo. 
(A) CD19Cre*PR mice and CD19-cre mice were intercrossed with RRDR mice. Southern blot analysis of EcoRI digested 
DNA reveals the 16 kb wild type ROSA26 allele (WT), the 7.2 kb loxP-flanked RRDR-DsRed, and the 5.7 kb excised 
RRDR-eGFP alleles using probe A.  
(B) CD19Cre*PR; RRDR mice were i.p. injected with 2.5 mg RU486 daily for 5 days. Splenic (sp) T cells and B cells were 
separated by FACS sorting. Pro/pre B cells from bone marrow (bm) were isolated by FACS sorting as B220+, IgM- cells. 
The same cell fractions from non-injected CD19Cre*PR; RRDR mice and CD19-cre; RRDR mice served as controls. 
Deletion efficiencies were quantified using the Fuji Bias reader and are indicated as percent.     
RRDR-DsRed (7.2 kb) and the excised RRDR-eGFP (5.7 kb) alleles by Southern blot 
analysis (Fig. 38A, B). No RU486 inducible recombination mediated by Cre*PR was 
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observed in this experiment. The RRDR-eGFP allele was only detectable in 
approximately 90% of splenic B cells and 73% of pro/pre B cells from control CD19-
cre-/+; RRDR-DsRed/+ mice. 
 
3.6 An attempt to generate a tet-inducible system controlling Cre activity 
Tet-inducible systems are elegant tools to regulate gene expression inducibly in a 
quantitative fashion.  
I attempted to generate a general tet-inducible system by construction of the 
pEXchange vector, in which all elements necessary for the tet-on system are 
included. This system has the advantage that the promoter, which drives the 
expression of the reverse tet-transactivator rtTA-M2, can be exchanged in order to 
obtain cell type restricted expression of the rtTA-M2. The pEXchange construct was 
designed in such a manner that one additional cloning step results in the generation 
of a HPRT targeting vector. The HPRT locus was chosen for these experiments, 
since the HPRT gene is a housekeeping gene. Therefore, expression of transgenes 
driven by any inserted promoter is presumably not restricted by unfavourable 
chromatin configurations. In addition, the HPRT locus is known to be far away from 
any enhancer activity of adjacent genes (Cvetkovic et al., 2000; Su et al., 2002).  
The basic construct and the principle of the system are depicted in Fig. 39. A cell 
type specific or ubiquitous promoter drives the expression of the improved rtTA-M2 
(Urlinger et al., 2000), that is separated from the tet-responsive Cre cassette by two 
SV40 pA and a WSS to prevent transcriptional read-through. The WSS was inserted 
in front of the tet-responsive cassette such that any transcription occurring from 5’ will 
be spliced from the strong splice donor of the WSS to the splice acceptor in front of 
the Cre ORF and a wrong start codon will result in out of frame translation of Cre. To 
drive the doxycycline inducible expression of Cre, the tetO7 promoter was used 
which consists of seven tet-responsive elements and the CMV minimal promoter 
combined with a synthetic intron (kindly provided by F.Schwenk and J.Seibler, 
Artemis Pharmaceuticals, Cologne, Germany). In order to achieve ubiquitous 
expression of rtTA-M2, the EF1α and the CAGGS promoters were cloned into the 
pEXchange construct, respectively (Fig. 40A).This allows testing the tet-on system in 
ES cells. The HPRT targeting vectors were generated as described in Fig. 8 and 
transfected into RRDR ES cells which contain the DsRed/eGFP indicator into the 
ROSA26 locus (Fig. 40B). Transfection of 106 ES cells with 3 µg of each targeting 
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Fig. 39 Priniple of the tet-on system for Cre. 
All elements of the tet-on system are combined in the construct. The promoter (P) drives expression of rtTA-M2 and can be 
exchanged by a PmeI digest. The rtTA-M2 is separated from the tet-responsive cassette by two SV40 pA and the WSS to 
prevent transcriptional read-through. The tetO7 promoter consists of seven tet-responsive elements and the CMV minimal 
promoter. After doxycycline administration, the rtTA binds to tetO7 and activates expression of Cre. The whole construct 
can be cut out from the plasmid by AscI digestion and can be cloned into the HPRT targeting vector pMP10.    
vector resulted in HAT resistant colonies, i.e. two for the EF1α construct and three for 
the CAGGS construct. Correct homologous recombination was confirmed by 
Southern blot analysis of StuI digested DNA using a Cre probe (data not shown).  
 
Initial experiments, in which expression of Cre was induced by doxycycline 
administration revealed a high extent of deletion of the DsRed/eGFP indicator in both 
the EF1α and the CAGGS systems also in the absence of the inducer (data not 
shown). In order to select for clones that still retained the loxP-flanked DsRed-stop 
cassette including the neomycin resistance gene, ES cell clones were treated with 
300 µg/ml G418 for 14 days. Subsequent Southern blot analysis revealed absence of 
cells of the RRDR-eGFP genotype lacking the DsRed-stop cassette (data not 
shown). After two days without G418, 2x105 ES cells containing knock-ins of the 
EF1α and CAGGS tet-systems for Cre were plated on a well of a 6 well-plate and 
were induced with 1 µg/ml doxycycline for 9 days. Control cells that were not treated 
with doxycyline were harvested at the end of the experiment on day 9. Southern blot 
analysis to distinguish between the RRDR-DsRed and the RRDR-eGFP alleles of the 
Cre-indicator showed no recombination without doxycycline in case of the EF1α tet-
system, whereas the CAGGS tet-system exhibited background activity in the 
absence of doxycycline.  
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Fig. 40 Tet-on systems for Cre in RRDR ES cells.  
(A) The two different tet-systems for Cre are shown which were inserted into the HPRT locus of RRDR ES cells.  
(B) RRDR ES cells contain the DsRed/eGFP indicator for Cre activity into ROSA26 locus. The screening strategy to detect 
the loxP-flanked RRDR-DsRed and the excised RRDR-eGFP alleles by Southern blot is shown. 
(C) Western blotting to detect inducible Cre expression in ES cell lysates of twice targeted ES cells (RRDR and CAGGS 
tet-on or EF1α tet-on). Cells were kept in culture for 4 days.   
(D) Southern blot of twice targeted ES cells with RRDR and EF1α tet-on or CAGGS tet-on which were incubated in the 
presence of 1 µg/ml doxycycline (dox) for the indicated days. 
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Deletion of the loxP-flanked DsRed-stop cassette of the indicator was achieved in the 
EF1α tet-system ranging from 10% on day 1 to 35% on day 9 (Fig. 40D). With the 
CAGGS tet-system, however, nearly complete excision of the DsRed-stop cassette 
was obtained after 1 day of doxycycline treatment (92%), which was not further 
increased by prolonged incubation in the presence of doxycycline (Fig. 40D). 
Western blot of cell lysates of the EF1α and CAGGS tet-systems revealed that Cre 
expression was dependent on the addition of doxycycline (Fig. 40C). Cell lysates 
from ES cells transgenic for the CAGGS tet-system knock-in revealed a strong band 
at 38 kDa when ES cells were induced with doxycycline (Fig. 40C). A weak, but 
distinct band in non-induced samples of the CAGGS tet-system was observed only 
after longer exposure of the X-ray films (data not shown). In cell lysates from ES cells 
containing the EF1α tet-system, a weak band specific for Cre appeared only when 
the ES cells had been induced with doxycycline, whereas no band appeared without 
doxycycline treatment (Fig. 40C).  
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4. DISCUSSION 
 
Conditional gene targeting using the Cre/loxP system is a widely used technique to 
analyze gene function in vivo. At present, efforts are undertaken to improve the 
control of the Cre recombinase by inducible systems. The aim of this study was to 
control Cre activity by a posttranslational and by a transcriptional inducible system in 
mice. Hence, I developed and tested inducible systems for Cre in vitro controllable by 
RU486 and doxycycline. Subsequently, the most promising constructs were further 
analyzed in transgenic mice. Specifically, a strategy was developed, which allowed to 
test the systems quantitatively in transiently transfected fibroblasts, then in ES cells, 
and finally in chimeric mice. In order to quantify the inducibility of the Cre constructs, 
a novel reporter for Cre activity had been established.  
 
4.1 RRDR as a new indicator for Cre activity  
Many different mouse indicator strains are available at present which are used to 
characterize the expression pattern of Cre transgenic mouse strains (Tsien et al., 
1996; Lobe et al., 1999). A common feature is the activation of an indicator gene 
after Cre-mediated excision of a transcriptional stop sequence. Subsequently, the 
promoter which drives the indicator gene will come into close proximity to the ORF of 
the reporter gene, thus initiating transcription followed by protein synthesis, which 
can then be monitored. This approach implicates a constitutive transcriptional activity 
of the promoter after excision of the loxP-flanked stop sequence to express the 
reporter gene in any cell at any time. A much better indicator system would be a 
binary indicator construct which couples the Cre-mediated shut down of one indicator 
gene with the activation of a second indicator gene. This would allow discriminating 
between those cells in which Cre-mediated recombination took place, and those cells 
which had not undergone Cre-mediated recombination.  
 
In the present study, I have tried to combine the DsRed and eGFP genes in a binary 
shut down/activation coupled construct for Cre activity. The DsRed gene encodes an 
autofluorescent protein originally identified in Discosoma sp. (Baird et al., 2000) and 
the eGFP gene the autofluorescent protein of Aequorea victoria (for review, see e. g. 
Hadjantonakis & Nagy, 2001). The emission spectrum of DsRed does not overlap 
with that of the eGFP making it an excellent candidate for double fluorescent labelling 
in vivo (Gross et al., 2000; Heikal et al., 2000). 
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I constructed the pTE RFP/GFP plasmid such that the CAGGS promoter drives the 
expression of a slightly modified DsRed gene. The latter is part of a loxP-flanked 
cassette that additionally contains a FRT flanked neo and the WSS (Lakso et al., 
1992). Downstream of the DsRed-stop cassette, the promoterless eGFP gene is 
located. Excision of the DsRed-stop cassette should result in shut down of DsRed 
expression and activation of eGFP, which can be monitored as a switch from red to 
green fluorescence. In addition, the DsRed gene was modified with a NLS sequence 
to restrict it to the nucleus, whereas the eGFP gene is expressed in the cytoplasm. 
Indeed, I could show that the pTE RFP/GFP system worked as anticipated in 
transiently transfected CV1-5B fibroblasts. Transfected cells revealed DsRed-derived 
red fluorescence in nuclei and cytoplasmic eGFP-derived green fluorescence only 
after excision of the DsRed-stop cassette by a cotransfected Cre coding plasmid. 
Since the DsRed/eGFP indicator worked properly in transiently transfected 
fibroblasts, I attempted to extend its usage to ES cells. To this end, the indicator 
construct was targeted into the ROSA26 locus of HM-1 ES cells. 
 
At that time, the ROSA26 locus appeared to be the only convenient option for this 
approach, since it was shown to be expressed in all cells of the adult mouse 
(Wunderlich & Rajewsky, unpublished results). Indeed, the ROSA26 locus was 
widely used for the ubiquitous expression of transgenes, e.g. for CreERT (Vooijs et 
al., 2001), CreERT2 (Seibler et al., 2003), indicators for Cre in combination with lacZ 
(Soriano, 1999), eGFP (Mao et al., 2001), eYFP, eCFP (Srinivas et al., 2001), and a 
conditional allele for LMP2a (Casola & Rajewsky, unpublished results). However, a 
few abnormalities of the ROSA26 locus have been noted during that time. First, the 
ROSA26 mutant allele is not inherited according to Mendelian segregation in 
intercrosses between heterozygotes mutants. In contrast, homozygous mutants do 
not show any obvious phenotype (Zambrowicz et al., 1997; personal observation). 
The only phenotypic effect described so far is, that ApcMin/+ mice carrying in addition 
the ROSA26 insertion are resistant to ethylnitrosourea (ENU)-induced mammary 
tumor development, whereas ApcMin/+ mice without the ROSA mutant allele are 
susceptible to ENU-induced mammary tumors (Kohlhepp et al., 2000; Kohlhepp et 
al., 2001). Second, the expression pattern of some ROSA26 driven transgenes was 
abnormal. For instance, Jonkers and coworkers could not detect any β−galactosidase 
activity from a ROSA26 expressed lacZ transgene when analyzing old mice, whereas 
younger mice displayed the overall expression of ROSA26 (J. Jonkers, personal 
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communication). Third, transgenes driven from the ROSA26 locus seem to be 
expressed at low levels. For instance, Mao et al. (2001) inserted an indicator 
transgene for Cre activity into the ROSA26 locus that activates eGFP expression 
after Cre-mediated recombination, but achieved only minimal eGFP expression.  
 
To obtain a higher expression from the ROSA26 locus, I modified the targeting vector 
pROSA26-1 such that a putative start codon in the first exon of ROSA transcripts 1 
and 2 was mutated. Therefore, I elongated the short arm of homology of the targeting 
vector and inserted two cytosines into the start codon. With this modified targeting 
vector, I expected the first AUG of the downstream ORFs of DsRed and eGFP to be 
used as start codons, thus causing higher expression levels. However, I could not 
detect any red or green fluorescence with this construct in vivo. Although the reason 
for this failure is not clear, I can exclude some possible explanations. First, the 
design of the pTE RFP/GFP plasmid appears to be successful, since S. Casola and 
T. Buch used this plasmid to generate mice with conditional alleles in the ROSA26 
locus for LMP2a and the diphtheria toxin receptor, respectively (personal 
communication). Second, the expressed transgenic mRNAs from the ROSA26 locus 
are not instable. The properly spliced transcripts of DsRed and eGFP were detected 
in RT-PCR experiments and sequencing of the corresponding PCR products 
revealed that the first AUG codons in the mRNAs were those which were introduced 
with the Kozak consensus sequence for DsRed and eGFP, respectively. In addition, 
splenocytes, in which the DsRed-stop cassette - and therefore the DsRed gene - had 
been excised by HTNC treatment, revealed significant amounts of the DsRed mRNA 
after three days, thus indicating the stability of the corresponding mRNA. Thus, 
translation of the mRNA into protein appears to be impaired, since mRNAs of DsRed 
and eGFP are still expressed without any detectable protein fluorescence. In 
accordance, Western blot analysis did not reveal any significant amount of expressed 
eGFP protein in lysates from all major organs of RRDR-eGFP/+ mice, which had the 
loxP-flanked DsRed-stop cassette excised in the germ line, though this method is 
sensitive enough to detect eGFP in the positive control. At the present state of 
experiments, I can only speculate about the fact that, in the newly generated RRDR 
indicator mouse strain, transcription and processing of mRNAs of the introduced 
transgenes take place, but translation is inhibited for unknown reasons. I used a very 
similar targeting strategy as Srinivas et al. (2001) and Mao et al. (2001), which 
showed protein synthesis of fluorescent proteins from ROSA26. A major difference in 
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my strategy was the disruption of the endogenous start codon of ROSA26. It is 
therefore conceivable that cis acting elements in the 5’UTR of ROSA26 have been 
destroyed by introducing the two cytosine nucleotides into the AUG. This view is 
supported by the fact that posttranscriptional regulation of protein expression has 
been shown for nNOS and those genes, which are involved in iron metabolism (for 
review, see e. g. Kaempfer, 2003; Henderson et al., 1996). In case of nNOS, an 
alternatively spliced non-coding exon in the 5’UTR caused a drastic repression of 
protein synthesis, although mRNA levels were not altered (Newton et al., 2003). This 
non-coding exon has been proposed to form a stem loop motif at the mRNA, which 
serves as binding site for inhibitory molecules that interfere with translation.  
 
Such a hypothesis could also reasonably explain my results: the mRNAs of DsRed 
and eGFP are expressed from the ROSA26 locus, but are not translated into protein 
due to inhibitory accessory proteins. In order to test a possible stem loop formation of 
the ROSA26 5’UTR, a computer aided analysis was performed. The 5’UTR consists 
of highly repetitive G-rich sequences which are capable of forming a stem loop 
structure at the RNA level, as shown in Fig. 41. The two cytosine nucleotides were 
inserted at the tip of the putative loop, which possibly disrupted the secondary 
structure or essential protein binding sites. In this context, it is noteworthy that 
several stem loop like motifs in the 5’UTR of cellular mRNAs were shown to act as 
internal ribosome entry site (IRES) (Kim et al., 2001; Rubtsova et al., 2003; Jopling et 
al., 2004) as that from the EMCV virus (for review, see e. g. Martinez Salas, 1999). 
Incidentally, IRES do not require any 5’CAP of the mRNA to initiate translation 
(Bonnal et al., 2003). The EMCV IRES recruits the ribosome by its secondary 
structure through RNA-RNA interactions and RNA-protein interactions specifically to 
AUG number eleven in the viral mRNA to promote translation of the respective 
protein (Jang & Wimmer, 1990, Davies & Kaufman, 1992). The conserved loop motifs 
of the IRES as the GNRA loop and the RAAA loop (where N is any nucleotide and R 
is a purine) serve as binding sites for proteins and do not tolerate many changes in 
their sequence context, as these changes often lead to disruption of the IRES 
function (for review, see e. g. Sachs et al., 1997). Provided the 5’UTR of the ROSA26 
transcripts functions in a similar way, the insertion of the two cytosine nucleotides 
into the AUG could destroy the putative cellular IRES function. I am currently in the 
process of testing this hypothesis. In one approach, I have already constructed a 
modified targeting vector in which the U of the AUG was mutated to a C. Since this is
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Fig.41 Predicted RNA secondary structure of 
the 5’UTR of ROSA26. 
The computer program RNA2 prediction at 
http://www.genebee.msu.su/cgi-bin/nph-rna2.pl predicted 
this secondary structure for the 5’UTR of ROSA26. The 
endogenous putative start codon is boxed and the insertion 
site of the two cytosines is indicated by an arrow. Note that 
nucleotides marked prominent in the predicted loops are 
equal. The last two G nucleotides of this sequence do still 
belong to the first ROSA26 exon, whereas the intronic 
sequences are not shown. 
 
a pyrimidine to pyrimidine exchange and no additional nucleotide is inserted, this 
could keep the predicted stem loop structure intact and, in addition, destroys the first 
AUG in the mRNA. In another approach, a complete expression cassette including 
the RRDR indicator is introduced into the ROSA26 locus. The RRDR indicator can be 
cut out from the pTE RFP/GFP plasmid together with the CAGGS promoter and 
inserted in the targeting vector of ROSA26. This would result in independent 
transcription and translation of RRDR from ROSA26 and would reflect the expression 
pattern of the CAGGS promoter. Transgenes driven by the CAGGS promoter were 
shown to be ubiquitously expressed (Ikawa et al., 1995; Okabe et al., 1997). A third 
approach to generate a strongly ubiquitously expressed transgene from the ROSA26 
locus would be to exchange the complete 5’UTR to a well characterized example as 
the 5’UTR from the β-globin gene (Strong et al., 1997). This might combine the 
widespread expression from the ROSA26 promoter together with the translational 
properties of the β-globin gene.  
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4.2 The inducibility of Cre*PR in fibroblasts 
Cre activity of CrePR fusion proteins has been shown to be dependent on the 
presence of the synthetic steroid RU486 (Kellendonk et al., 1996; Kellendonk et al., 
1999). However, there exist two major obstacles in the CrePR1 system used to date. 
First, the CrePR fusion proteins still exhibited a residual activity in the absence of 
inducer (Psarras et al., 2004). Second, the mutation introduced in the LBD of the PR 
to induce unresponsiveness to progesterone also leads to a decreased affinity to 
RU486. In this thesis, I have established a CrePR system without any detectable 
background activity and with increased affinity to RU486 (Wunderlich et al., 2001). 
 
In order to improve the affinity of CrePR fusion proteins to RU486, I have examined 
different lengths of the PR-LBD in CrePR fusion proteins. The two previously used C-
terminal truncations PR891 and PR914 were not responsive to progesterone, but still 
were responsive to RU486 (Vegeto et al., 1992; Xu et al., 1996). The variants ending 
with amino acid 914 displayed a significant higher affinity to RU486 than the variants 
ending with amino acid 891. Extension of the C-terminus of the PR-LBD was likely to 
result in an enhanced response to the synthetic ligand, since elongation from amino 
acid 891 to 914 increased the activation potential (Wang et al., 1997b). In 
accordance, I showed that the elongated Cre19PR676-914 reached half maximum 
activation at a 100-fold lower concentration of RU486 than the shorter Cre19PR676-
891. The improvements I have obtained in vitro are also expected to hold true in in 
vivo applications, as similar results have been obtained with an improved version of a 
fusion protein between Cre and the LBD of the estrogen receptor (Indra et al., 1999).  
 
In order to increase expression of CrePR fusion proteins, I deleted the first 18 amino 
acids of Cre, which were considered non-essential for the recombinase activity (Guo 
et al., 1997). Indeed, it turned out that the truncated Cre fusion protein exhibited 
definitively higher activity as compared to full length constructs. This result was more 
recently confirmed in a rapamycin-inducible Cre system (Jullien et al., 2003).  
 
However, these novel CrePR fusion proteins still exhibited a substantial residual 
activity in the absence of inducer, varying between three and five percent, which may 
result from proteolytic cleavage and/or aberrant splicing. Both events could lead to C-
terminally truncated forms of CrePR, thus exhibiting uncontrolled recombinase 
activity. Indeed, aberrant splicing using two cryptic splice sites within CrePR mRNA 
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are functional in eukaryotic cells (Wunderlich, 1999). Even if this supposed event 
may result in less then 1% aberrantly spliced mRNAs, this could serve as an 
explanation for a background activity of a few percent.  
 
In order to reduce the risk of aberrant splicing, a distinct cryptic splice donor at the 3’ 
end of the Cre gene was destroyed, the only one which was still present in the 
optimized hCre gene. The mutation also introduces a conservative amino acid 
substitution at this position, namely V336A. This mutated form of hCre, designated 
Cre*, when fused to any PR-LBD, exhibits negligible background activity, whereas 
maximum activity is not affected and still reaches more than 40% of authentic Cre. 
The resulting range of inducibility is more than 200-fold, whereas previously 
published constructs displayed factors of not more than 40-fold (Kellendonk et al., 
1996; Kellendonk et al., 1999). A side by side comparison of the new Cre*PR system 
with the previously described CrePR1 system under identical assay conditions 
revealed a more than 50-fold reduction in residual activity of Cre*PR leading to a 
dramatically expanded range of inducibility (Wunderlich et al., 2001).  
 
4.3 The Cre*PR system in ES cells 
To test the Cre*PR system in ES cells, the Cre*PR transgene was inserted into the 
HPRT locus and into the ROSA26 locus by knock-in. The targetings were performed 
in ES cells which already contained a loxP-flanked construct at the ROSA26 locus or 
the HPRT locus, thus allowing to test quantitatively the Cre*PR system first in ES 
cells and subsequently in chimeric mice.  
 
In a first approach for a knock-in into the HPRT locus, I used an ES cell line which 
contained RRDR as an indicator for Cre activity in the ROSA26 locus. The promoters 
EF1α and CAGGS were used to drive the ubiquitous expression of Cre*PR as a 
single copy gene from the HPRT locus of RRDR ES cells. Since both promoters are 
ubiquitously active in mice, transgenes should also be expressed in ES cells 
(Hanaoka et al., 1991; Sato et al., 2001). However, I was unable to achieve Cre-
mediated inducible recombination of the DsRed-stop cassette in EF1αCre*PR 
clones. Indeed, no protein synthesis of Cre*PR was detectable by Western blot. This 
is consistent with the previous observation that the EF1α promoter is active in ES 
cells only at a very low level (Hanaoka et al., 1991).  
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Though controversially discussed, the EF1α gene is subjected to translational 
downregulation mediated by a cis acting element in the 5’UTR of its mRNA (Zhu et 
al., 2001). This cis acting element is an oligopyrimidine rich tract (TOP) close to the 
CAP site of mRNAs of many translational initiation factors and elongation factors, 
which is bound by inhibitory proteins such as La (Cardinali et al., 2003) in cells that 
are growth-arrested (Avni et al., 1997; Biberman et al., 1997; reviewed in Wilkie et 
al., 2003). Since ES cells are dividing continuously, the EF1α gene product should 
not be downregulated. However, an EF1α CAT transgene was downregulated in 
undifferentiated ES cells, but was expressed in ES cell derived neuronal precursors 
(Hanaoka et al., 1991).  
 
Remarkably, when these ES cells were used to generate mice, the CAT transgene 
was expressed in most tissues of the mice. Therefore, I tried to differentiate the ES 
cells into neuronal precursors in vitro, in order to investigate the properties of 
EF1αCre*PR (Strickland et al., 1980; Coleman et al., 1996). Again, I did not detect 
protein expression of Cre*PR in the potential neuronal precursors, and hence no 
induction of Cre activity.  
 
There are two alternative explanations for the latter observation. First, the HPRT 
locus in EF1αCre*PR ES cells is always present as a single copy gene, whereas the 
ES cells used in Hanaoka et al. (1991) contained multiple copies of the EF1αCAT 
transgene. Second, it is possible that the neuronal precursor cells were not 
differentiated to the neuronal lineage. In the neuronal differentiation protocol 
according to Strickland et al. (1980), the ES cell-derived neuronal precursors were 
identified by morphological criteria which was also applied by Hanaoka et al. (1991) 
and also in my experiment. Later on, Okabe and coworkers (1996) proved the 
neuronal differentiation of ES cells by control stainings against the nestin gene 
product. However, the evidence for nestin expression in these cells is of limited 
usage for distinguishing between neuronal precursor cells and ES cells, since nestin 
is also expressed in ES cells (Lenka et al., 2002). At present, it is attempted to 
identify differentiated neuronal precursors derived from ES cells by coupling the 
morphology of the cells with the downregulation of an Oct-4 EGFP transgene stably 
integrated into the genome of ES cells, indicating their differentiation since Oct-4 is 
only expressed in non-differentiated ES cells.  
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In contrast to the EF1αCre*PR approach, I succeeded to achieve ligand inducible 
recombination of the RRDR indicator in the absence of background recombination 
when Cre*PR in the HPRT locus was driven by the CAGGS promoter. However, the 
inducibility of Cre*PR by the ligand RU486 is odd in so far as it is not dependent on 
the dose of ligand and, even at a given concentration of ligand, maximal Cre-
mediated deletion in 81% of the ES cells can only be achieved upon daily 
administration of fresh ligand for 22 days. The latter observation cannot be 
satisfactorily explained in terms of the well known short half life of RU486 in medium 
(Deraedt et al., 1985a). One possibility for the delayed activation of Cre*PR is that 
Cre-mediated recombination is dependent on the cell cycle (Loonstra et al., 2001; Jo 
et al., 2003). Regular trypsinization keeps ES cells in an undifferentiated stage and 
synchronizes their cell cycle (Held et al., 1989). However, trypsinized and non-
trypsinized cells did not reveal any significant difference in Cre-mediated deletion 
efficiencies of the DsRed-stop cassette of the RRDR indicator. A second possibility is 
an impaired availability of RU486. Indeed, it is known that, in man, RU486 is bound in 
the serum to α-1-acid-glycoprotein, thus limiting its tissue bio-availability. Since the 
RU486-induced Cre-mediated recombination in ES cells was performed in the 
presence of 15% FCS, it is reasonable to assume such a binding of RU486 to 
unknown serum components. This possibility is currently being tested by using serum 
free medium to induce Cre*PR activity in targeted ES cells.  
 
In a third approach, Cre*PR was targeted into the ROSA26 locus. An ES cell clone 
from U.Strobel was used which contained a conditional allele for an artifical LMP1-
CD40 fusion protein in the HPRT locus. Administration of the ligand RU486 to 
activate Cre*PR did not reveal any excision of the loxP-flanked stop cassette of the 
LMP1-CD40 allele. Moreover, treatment with 2 µM HTNC was not able to induce any 
deletion of the conditional LMP1-CD40 allele, although deletion efficiencies of up to 
97% are normally achieved with HTNC in ES cells (Peitz et al., 2002). The 
observation that neither ROSACre*PR nor HTNC could excise the loxP-flanked 
sequence in the HPRT locus is not yet understood. A possible defect in the Cre*PR 
was not the reason for the negative outcome, since the Cre*PR was verified by 
sequencing after PCR amplification of the construct from ES cells and the Cre*PR 
was expressed from the ROSA26 locus, as revealed by Western blot analysis. 
Therefore, it is possible that there was a defect in the LMP1-CD40 construct. For 
instance, one of the loxP sites can be mutated or the restriction digest used to detect 
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the excised allele is not indicative to distinguish between loxP-flanked allele and the 
excised allele. Another possibility is that the loxP sites of conditional alleles in the 
HPRT locus may not be accessible for Cre, since the loxP sites may be incorporated 
into unfavourable chromatin environment. Indeed, such a situation was recently 
described to occur, when inducible Cre systems were used to delete loxP-flanked 
targets inserted into the ROSA26 locus (Vooijs et al., 2001).  
 
4.4 The Cre*PR system in mice 
Several chimeric mice derived from CAGGS Cre*PR; RRDR ES cells were used to 
perform preliminary in vivo experiments, in which the DsRed-stop cassette of RRDR 
was inducibly excised by Cre*PR after administration of RU486 in a broad range of 
the organs, as detected by a PCR based analysis. In particular, it is worth mentioning 
that this system did not reveal any significant background activity of Cre*PR.  
 
The CAGGS Cre*PR transgene is linked to the HPRT locus on the X chromosome. 
For the in vivo analysis of CAGGS Cre*PR, male mice were generated that carry 
both the CAGGS Cre*PR and the loxP-flanked target gene. The RAGE-EG reporter, 
which indicates Cre-mediated recombination by eGFP expression (Constien et al., 
2001), was used to analyze the inducibility of the CAGGS Cre*PR. No background 
recombination was detected in untreated mice indicating the tightness of the Cre*PR 
system. However, when four week old mice were injected with RU486, excision of the 
RAGE conditional allele was achieved only in liver, kidney and brain with an 
efficiency of approximately 13% quantified by Southern blot. In Org31710 injected 
mice, CAGGS Cre*PR could mediate recombination only in liver. The restriction of 
inducible recombination to a few organs and the low deletion efficiencies in these 
organs were unexpected, as deletion occurred in most organs of the CAGGS 
Cre*PR/RRDR chimeras upon administration of RU486. 
No RU486 inducible activation of Cre*PR was detected in ROSACre*PR mice 
intercrossed with several different loxP-flanked alleles such as the loxP-flanked gene 
segment of the DNA polymerase-β (Gu et al., 1994), the RAGE-EG reporter 
(Constien et al., 2001), and the RRDR indicator.  
 
Why is Cre*PR activity not inducible in the ROSACre*PR strain and only at low levels 
in the CAGGS Cre*PR strain? There are three possible explanations and two of them 
I can exclude experimentally.  
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One possibility is that the inducer RU486 is not available at sufficient concentrations 
in vivo. The metabolism of RU486 in organisms is not yet well understood (Deraedt et 
al., 1985b; Babij et al., 2003; for review, see e. g. Sakar, 2002). In humans, it was 
reported that RU486 reached a maximal concentration in the serum 1-2 hours after 
oral application (Leminen et al., 2003), and this did not progressively increase upon 
application of increasing amounts of RU486 (Heikinheimo & Kekkonen, 1993; 
Heikinheimo et al., 2003). In the serum, RU486 exists in a bound and an unbound 
state. In the bound state, RU486 is stabilized by interaction with the α-1-acid 
glycoprotein, the concentration of which is limited. The unbound RU486 is quickly 
metabolized in the liver by a two step process, i.e. demethylation and hydroxylation, 
with its metabolites detectable in plasma about 1 hour after oral application. 
Metabolites bind to the PR with an affinity of only 10 to 20% as compared with the 
parent RU486. In order to determine the bio-availability of RU486 in the serum of 
mice, mice were injected with RU486 and sera were isolated after various periods of 
time. Subsequently, sera were applied to twice targeted ES cells (CAGGS Cre*PR; 
RRDR) to test the RU486 activity. Sera taken after 1 hour and 4 hours induced high 
Cre*PR activity as indicated by excision of the DsRed-stop cassette of RRDR-
DsRed, thus demonstrating that RU486 is active in serum when applied by i.p. 
injection.  
 
The second possibility is that Cre*PR becomes posttranslationally modified 
preventing the protein to fulfil its function. This view is supported by the fact that the 
endogenous PR, for example, can be hyper-phosphorylated in vivo at special 
residues, which has been shown to influence the translocation of the PR from 
cytoplasm to nucleus (Chauchereau et al., 1992). In order to test this possibility for 
the Cre*PR, I performed experiments with embryonic fibroblasts (MEFs). These 
MEFs contain the Cre*PR on one allele of ROSA26 and the RRDR indicator on the 
other allele. Cytoplasmic fractions were separated from the nuclear extracts of 
RU486 induced and non-induced MEFs and analyzed by Western blot. In the 
cytoplasmic fraction of non-induced MEFs, Cre*PR was abundant, whereas almost 
no Cre*PR protein was detectable in the cytosol of induced MEFs. To exclude a 
possible degradation of the Cre*PR after ligand binding, controls were included in 
this experiment, in which the complete cell lysates of induced and non-induced MEFs 
were loaded on the Western. In both controls, the Cre*PR protein was present in 
equal amounts. This experimental approach indicates that the Cre*PR protein 
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translocates to the nucleus upon RU486 binding in MEFs, but failed to recombine the 
DsRed-stop cassette of RRDR-DsRed for unknown reasons. The possibility that 
Cre*PR is not imported in the nucleus, but is retained at the nuclear pore complexes 
and therefore cannot excise the DsRed-stop cassette seems to be rather unlikely. 
Since the non-ionic detergent NP-40 used for isolation of the cytosolic fraction is 
known to solubilize the nuclear envelope (Wunderlich et al., 1976), the cytosol should 
contain that Cre*PR which possibly sticks to the nuclear pore complexes. However, 
this is not consistent with my findings. Therefore, I conclude from this experiment that 
Cre*PR can indeed translocate to the nucleus upon RU486 binding, but, 
recombination of the DsRed-stop cassette did not take place, presumably due to the 
low expression level of Cre*PR.   
 
The third possible explanation is that the Cre*PR protein is not expressed at 
sufficient levels to induce Cre-mediated recombination. In order to examine this 
possibility, Western blot analysis of lysates from all major organs of CAGGS Cre*PR 
mice was performed which all displayed a specific band of Cre*PR. The highest 
expression levels were detected in liver being one of the three organs in which 
deletion of the loxP-flanked region of the RAGE-EG reporter occurred after 
administration of RU486 and Org31710. These data suggest that high levels of 
Cre*PR have to accumulate in cells to achieve RU486 inducible recombination.  
 
Experimental conditions to induce high levels of Cre*PR activity have to be still 
further investigated. However, the fact that even under experimental conditions of 
high protein levels, the Cre*PR system does not exhibit any significant background 
activity is of major relevance for other experimental approaches. For instance, a 
stringently controllable Cre system without any background activity is required for 
Cre-mediated activation of cancer promoting genes (Lakso et al., 1992; Meuwissen 
et al., 2001; Politi et al., 2003). In such experiments, background activity will result in 
immortalization and proliferation of cancer cells and, thus, in undesired tumor 
formation.  
 
4.5 B cell specific inducible Cre systems 
In order to insert Cre*PR into the mCD19 locus, which is specifically expressed in B 
cells, a new CD19 targeting vector was generated, in which insertion of any 
transgene can be performed by a single cloning step. This new vector is similar to the 
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original CD19-cre targeting vector from Rickert et al. (1995), but it contains an 
elongated short arm of homology, which makes a cointegration event of the disrupted 
endogenous CD19 start codon more likely. With this vector, I succeeded to generate 
a correctly targeted ES cell clone in the CD19Cre*PR targeting, which additionally 
carried the restriction site introduced instead of the start AUG. I expected higher 
expression levels of the Cre*PR in B cells than in the original CD19-cre mouse strain. 
High expression of Cre is achieved in the latter mouse strain, despite the fact that the 
endogenous CD19 start codon is still retained in the first exon and the inserted Cre in 
the second exon is not in frame to that codon. This might be due to the introduction 
of a Kozak consensus sequence (Kozak, 1987) at the start codon of the Cre gene, 
which optimizes the initiation of translation (J. Roes, personal communication). The 
CD19Cre*PR transgene also contains the Kozak consensus sequence and the first 
AUG of the mRNA is that from the Cre*PR. Indeed, I could verify the B cell specific 
expression of Cre*PR at the RNA level by RT-PCR and at the protein level by 
Western blot. Correct integration of Cre*PR into the mCD19 locus was confirmed by 
flow cytometry. These data demonstrate that the CD19Cre*PR mouse strain reflects 
the expression pattern of the CD19-cre mouse and, thus, a B cell restricted 
expression of Cre*PR.  
 
Though Cre*PR was expressed at reasonable levels, I was not successful to induce 
Cre*PR activity in vivo by RU486 administration in mice carrying the CD19Cre*PR 
and the RRDR indicator. Possible explanations for that were already discussed 
above and the analysis of the CD19Cre*PR mouse strain is still ongoing. In 
particular, I currently try to inducibly excise the loxP-flanked gene segment of the 
insulin receptor (Brüning et al., 1998) in B cells using the CD19Cre*PR strain, since 
this loxP-flanked gene appears to be well accessible for inducible Cre-mediated 
recombination as revealed by high excision efficiency using the ROSACreERT2 
mouse strain (Seibler et al., 2003; L. Koch & J. Brüning, personal communication). 
  
A new B cell specific inducible Cre system is urgently required. To this end, I am 
currently performing the knock-in of the CreERT2 fusion protein into the CD19 locus. 
This approach may achieve highly B cell specific tamoxifen inducible Cre activity in 
the subsequently generated CD19CreERT2 mouse strain with tolerable background 
activity. The expectation to obtain B cell specific expression of CreERT2 from the 
CD19 locus is supported by the fact that Cre*PR expression is restricted to B 
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lymphocytes in the novel CD19Cre*PR mouse strain and that the same targeting 
strategy will be used to insert the CreERT2 into the second exon of the CD19 gene. 
Moreover, tamoxifen inducible Cre-mediated recombination in B cells can be 
achieved either with the EDCre strain (Schwenk et al., 1998) or with the 
ROSACreERT2 strain (Seibler et al., 2003), indicating that the CreERT2 system has 
the potential to work in B cells.  
 
4.6 Doxycycline inducible systems 
The tet-on systems presently used consist of the doxycycline regulatable rtTA 
transgene and the tet-responsive cassette driving the transgene of interest. A major 
disadvantage of this system is that mouse strains carrying these two transgenes 
have to be intercrossed. A still higher breeding effort has to be undertaken with 
respect to a doxycycline-controllable Cre, since four different alleles have to be 
combined in one mouse. In order to reduce the number of breeding steps, I 
constructed a tet-inducible system for Cre, in which both elements of the tet-on 
system are combined in one allele. In this system, the improved rtTA-M2 
transactivator (Urlinger et al., 2000) is driven by either the CAGGS promoter or the 
EF1α promoter and these two transgenes were inserted separately into the HPRT 
locus of RRDR ES cells.  
 
n order to test these systems first in vitro, I did not perform transient transfections, but 
stably integrated the transgenes. The reason for this is that transient transfections of 
tet-systems result in spontaneous activation of the CMV minimal promoter, which is 
part of the tetO7 promoter (Baron et al., 1995) and which initiates the non-inducible 
transcription of the gene of interest, when many copies of the transgene are present 
in the cell. In my targeting experiments, I noticed that electroporation of the HPRT 
tet-on targeting vectors in RRDR ES cells resulted also in a transient expression 
phase. Administration of doxycycline to ES cells targeted with the CAGGS tet-on 
system resulted in inducible expression of Cre and, thus, in high levels of Cre-
mediated excision of the DsRed-stop cassette of RRDR-DsRed. However, ES cells 
cultured without doxycycline displayed a significant background activity.  
 
This background activity can be explained in two ways. First, the expression level of 
the rtTA driven by the CAGGS promoter could be too high, thus causing the ‘leaky’ 
expression of the Cre from tetO7. Though this possibility cannot be excluded, 
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another explanation seems to be more likely. This possibility specifically concerns the 
CAGGS promoter which consists of the chicken β-actin promoter coupled to the CMV 
enhancer (Niwa et al., 1991). Since enhancers are acting over long distances 
(reviewed in Ogata et al., 2003) and both elements, i.e. the CMV enhancer and the 
CMV minimal promoter of the tetO7 are located in the same construct in close 
vicinity, it is possible that these two elements can act together and activate the ‘leaky’ 
Cre transcription. This view is supported by the finding that the tet-responsive 
cassette has to be integrated into a site of the genome that is distant from any 
enhancer activity to avoid the spontaneous activation of the tetO7 promoter (Schönig 
et al., 2003). Indeed, an integration site with this feature is the HPRT locus I have 
used (Melton et al., 1984). 
 
In contrast to the CAGGS tet-on system, the EF1α tet-on system displayed no 
significant background activity. After doxycycline administration, however, Cre-
mediated excision of the DsRed-stop cassette of RRDR-DsRed was incomplete and 
only low levels of Cre protein were detected by Western blot. This can be explained 
by the low level activity of the EF1α promoter in ES cells, as already discussed 
before. However, this low level activity appeared to be sufficient to express the rtTA-
M2, which after doxycycline binding activated expression of Cre from the tetO7 
promoter, at least in some ES cells. The results obtained with the EF1α tet-on 
system in vitro are promising enough to investigate the performance of this system in 
vivo. This work is in progress.   
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5.1 SUMMARY 
 
Inducible gene targeting based on the Cre/loxP system is a novel technique allowing 
conditional gene modification in mice. Precondition of this method is the regulation of 
Cre activity by inducible genetic switches. This study aimed at improving inducible 
systems for the regulation of Cre activity at both the transcriptional and the 
posttranslational level, which should be tested first in vitro and subsequently in newly 
generated transgenic mice. In order to detect Cre activity, a special double indicator 
containing DsRed and eGFP was constructed and targeted into the ROSA26 locus of 
HM-1 ES cells. This indicator should constitutively express the DsRed gene flanked 
by loxP sites. Cre-mediated recombination excises the DsRed gene and turns on the 
eGFP gene, as evidenced by a change in fluorescence from red to green. Though 
the double indicator worked properly in transiently transfected fibroblasts, the 
targeting strategy used for the integration of the indicator into the ROSA26 locus 
presumably disrupted a putative stem loop motif of the 5’UTR resulting in a silencing 
of the indicator at the protein level. However, the ES cell line with the integrated 
double indicator is suited for targetings of inducible Cre constructs into the HPRT 
locus, since inducibilities are detectable by Southern blot analysis. The Cre*PR 
system was one inducible system I have established. In contrast to the classical 
CrePR1 system, the background activity of Cre*PR was almost abolished by 
introducing a point mutation into the 3’end of the Cre part, thus preventing aberrant 
splicing of the Cre*PR encoding mRNA. Also, the PR-LBD of the Cre*PR system was 
improved, compared to the CrePR1, to obtain a higher affinity towards the inducer 
RU486. The Cre*PR system, driven by either the EF1α promoter or the CAGGS 
promoter, was then targeted into the HPRT locus. The CAGGS Cre*PR worked in ES 
cells as expected. These targeted ES cells were subsequently used to generate 
transgenic mice. In these mice, high protein levels of Cre*PR have to be obtained in 
order to achieve inducible Cre-mediated excision of loxP-flanked gene segments. In 
addition, I generated a novel B cell specific Cre*PR mouse strain by targeting 
Cre*PR into the mCD19 locus. In another approach to inducibly regulate Cre, a tet-on 
system was established consisting of the rtTA-M2 transactivator and the tet-
responsive Cre cassette, which was targeted into the HPRT locus of the double 
indicator ES cell line. This system revealed a tight regulation of Cre expression in a 
doxycycline dependent manner.    
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5.2 ZUSAMMENFASSUNG 
 
Induzierbare gezielte Mutagenese basierend auf dem Cre/loxP System ist eine neue 
Methode, die es erlaubt Gene konditional in Mäusen zu verändern. Vorraussetzung 
dafür ist die Regulierung von Cre durch induzierbare genetische Schalter. Diese 
Arbeit zielte darauf ab die Schalter für die Regulation von Cre auf transkriptionellem 
und posttranslationalem Niveau zu verbessern, diese zuerst in vitro  zu testen und 
dann in transgenen Mäusen. Um die Cre Aktivität zu detektieren, wurde ein 
spezielles, doppeltes Reporterkonstrukt für Cre mit DsRed und eGFP konstruiert und 
in den ROSA26 Locus von HM-1 ES Zellen eingebracht. Dieser Reporter sollte 
konstitutiv das von loxP Sequenzen flankierte DsRed Gen exprimieren. Cre 
vermittelte Rekombination schneidet das DsRed Gen aus und stellt das eGFP Gen 
an, was durch einen Fluoreszenzwechsel von rot zu grün sichtbar wird. Obwohl der 
Doppel-Reporter in transient transfizierten Fibroblasten funktionierte, zerstörte das 
gezielte Einbringen des Reporters in den ROSA26 Locus vermutlich ein bisher 
unbekanntes, mögliches Stamm-Loop-Motiv der 5’ untranslatierten Region der 
ROSA26 mRNA, was zu einem Verlust der Translation führte. Die Reporter ES Zell-
Linie wurde jedoch weiterhin genutzt, um induzierbare Cre Konstrukte in den HPRT 
Locus einzubringen, da man deren Induzierbarkeit über Southern blot nachweisen 
kann. Das Cre*PR System war eines der induzierbaren Systeme, die ich etabliert 
habe. Gegenüber dem klassischen CrePR1 System wurde die Hintergrundaktivität 
des Cre*PR Systems durch Einführen einer Mutation am 3’ Ende vom Cre-Anteil fast 
abgestellt, welche kryptische Spleißereignisse der Cre*PR kodierenden mRNA 
verhindert. Auch die PR-LBD des Cre*PR Systems wurde gegenüber dem CrePR1 
System verbessert, um eine höhere Affinität zum Induktor RU486 zu erreichen. Das 
Cre*PR System wurde gezielt in den HPRT Locus eingebracht und dann entweder 
vom CAGGS oder dem EF1α Promoter exprimiert. Das CAGGS Cre*PR Konstrukt 
zeigte in ES Zellen eine stringent regulierbare Cre-Aktivität und die ES Zellen wurden 
somit genutzt, um transgene Mäuse herzustellen. In diesen Mäusen mussten hohe 
Cre*PR Proteinkonzentrationen erreicht werden, um induzierbare Cre vermittelte 
Rekombination zu erreichen. Ein neuer B Zell spezifischer Cre*PR Maus Stamm 
wurde durch das gezielte Einbringen des Cre*PR in den mCD19 Locus hergestellt. In 
einem weiteren Ansatz, Cre induzierbar zu regulieren, wurde ein tet-on System 
etabliert, welches aus dem rtTA-M2 Transaktivator und der tet-ansprechenden 
Expressionskassette für Cre besteht, welches weiterhin in den HPRT Locus der 
Doppelreporter ES Zell-Linie eingebracht wurde. Experimente in ES Zellen zeigten 
eine stringente Doxyzyklin abhängige Regulation der Cre Expression.  
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